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1. INTRODUCTION 
1.1 Phase-Transfer Catalysis 
 
In the great realm of organic synthesis, phase-transfer catalysis (PTC) is a 
well recognized methodology which plays a key role both in industry and academia 
research. This process involves reactions that take place between reagents which 
are located in different phases, for example an inorganic water-soluble reagent and 
a substrate soluble in the organic phase.1 Different industrial applications in the 
field of pharmaceuticals, agrochemicals, fragrances, polymers are possible and 
many reactions can be realized, using this methodology, even for large-scale 
synthesis (alkylations, epoxidations, nucleophilic additions, oxidations).2,3 These 
reactions generally present numerous advantages: mild conditions and simple 
operations, high reaction rates and selectivities, the use of inexpensive and 
environmentally safe reagents and solvents. Most PTC reactions involve 
displacement of an anionic species from an aqueous phase (liquid-liquid system) 
or solid phase (solid-liquid system) to an organic phase.4 For this reason the main 
catalysts involved in phase-transfer catalysis are cations, for example ammonium 
or phosphonium salts, or macrocyclic complexant agents of inorganic cations such 
as crown ethers and cryptands. The term “phase-transfer catalysis” was 
introduced by Starks in 1971 to explain the critical role of a catalyst, such as a 
tetraalkylammonium or phosphonium salt, in the reactions between two 
substances located in different immiscible phases.5 The reaction of 1-chlorooctane 
with sodium cyanide (scheme 1.1) was accelerated by the presence of a catalytic 
amount of quaternary phosphonium salt. This salt was able to extract the cyanide 
from the aqueous phase, making it more reactive. A great number of parameters 
are known to influence the kinetics of the phase-transfer catalyzed reactions: the 
nature of the catalyst and its lipophilicity, the stirring rate, the temperature, the 
interaction between anion and cation in the ion-pair, the number of water 
                                                          
1. F. Montanari, D. Landini, F. Rolla, Topics in Current Chemistry, 1982, 101,147-200. 
2. J.Tan, N. Yasuda, Org. Process Res. Dev., 2015, 19, 1731−1746. 
3. D. C. M. Albanese, F. Foschi, M. Penso, Org. Process Res. Dev., 2016, 20, 129−139. 
4. M. Fedorynski, M. Jezierska-Zieba, B. Kakol, Drug Research, 2008, 65, 647-654. 
5. C. M. Starks, J. Am. Chem. Soc., 1971, 93, 195-199. 
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molecules associated with the anion, the dielectric constant of the organic solvent. 
Although the phase-transfer catalysis continues to expand, there is a scarce 
investigation into understanding how the catalyst system can affect the rate and 
the selectivity of process. 
 
 
Scheme 1.1 Reaction of chlorooctane with sodium cyanide 
 
However, it is possible to classify the phase-transfer reactions into two main 
categories:  
-an extraction mechanism (scheme 1.2) 
-an interfacial mechanism (scheme 1.3) 
The first mechanism, proposed by Starks,6 concerns a liquid-liquid system and it 
assumes that the species Q+Y- (catalyst) is partitionated between the two 
immiscible phases. First, the catalyst exchanges, in aqueous phase, the X- anion of 
the inorganic salt, denominated MX, generating the catalytically active species Q+X-, 
which moves into the organic phase accelerating the reaction. Once produced, the 





Scheme 1.2 Starks extraction mechanism 
 
The second mechanism proposed by Makosza7 should be considered for reactions 
in which the anion is generated from a slightly acid substrate by the aid of a water-
soluble strong base. This is the case of an interfacial mechanism in which the anion 
is generated from the slightly acid substrate (SH) by the use of a strong base 
(MOH). Subsequently, the catalytically active species Q+S-, produced at the 
                                                          
6. G. Pozzi, S. Quici, R. H. Fish, Journal of Fluorine Chemistry, 2008, 129, 920-929. 
7. M. Makosza, Pure Appl. Chem., 1975, 43, 439–462. 
Organic phase 
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interface by ion-exhange, migrates into the organic phase where it reacts with the 
substrate. However, the reported mechanisms are not completely general because 
the catalytically active species, actually involved in the reaction, can be different 
















Scheme 1.3 Makosza interfacial mechanism  
 
As the Coulomb interaction between the anion and the cation decrease, the anion 
become more reactive. As a result of weak interactions with voluminous counter-
ions, such as a quaternary onium salt or metal cation "trapped" within a neutral 
ligand, Y- behaves like a "naked" anion. The most used catalysts for this kind of 
reactions are quaternary onium salts (e.g. 1, 2), or neutral ligands such as crown 
ethers (e.g. 3, 4, 5, 6), cryptands (e.g. 7), polypodands (e.g. 8, 9) (Figure 1.1). The 
use of quaternary cations with a long alkyl chain ensures the lipophilicity of the 
salt, making a very reactive ion pair and accelerating the next reaction. Pedersen's 
discovery of crown ethers, cyclic polyethers, had led innovation in chemistry in 
recent years: complexation of a specific metal cation within the macrocycle 
facilitates the solubility of the salt in a slightly polar solvent and provides very 
reactive non-solvated anions. Among those most used are 15-crown-5 (3), 18-
crown-6 (4), dicyclohexyl-18-crown-6 (5), dibenzo-18-crown-6 (6). The advantage 
of using these catalysts is substantially represented by the favorable partitioning of 
the crown ethers complexes in the organic phase rather than the aqueous phase 
and the high complexation constants between the cation and the neutral ligand. 
The cryptands are the three-dimensional analogues of crown ethers that are 
 Organic phase  R-Y       S-R 
 
 
S-H Q+S- Q+Y 
 
                       
Interfacial region                         Q+S-      Q+Y-        
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particularly interesting for the anionic activation; in fact, the cation is incorporated 
within the three-dimensional structure to form an inclusion compound which 
provides a "naked anion"; therefore the cryptands are neutral ligands that 
maximize the cation-anion separation. The podands and polypodands, open-chain 
polyethers, are able to complex alkali and alkaline-earth metal cations, but the 
complexation constants are generally lower if compared to that of crown ethers, 
owing to the so-called macrocycle effect; however, they form stable complexes 
with alkali and alkaline-earth metals when the polyoxyethylene chains are long 
and with electron-withdrawing substituents.7,8 
Figure 1.1 Phase transfer catalysts 
1.2 Asymmetric Phase-Transfer Catalysis 
 
The growing demand for enantiomerically enriched compounds by industry 
enforces research towards the development of new synthetic asymmetric 
methodologies. The asymmetric phase-transfer catalysis involves the use of non-
racemic, chiral catalysts, and it is employed in several types of reactions. The 
pioneering study conducted in 1984 by a research group from Merck is recognized 
as the first application of asymmetric phase-transfer catalysis (scheme 1.4). A 
chiral quaternary ammonium salt derived from cinchonine was used as catalyst, 
for the enantioselective methylation of a 2-phenyl-1-indanone. The asymmetric 
induction was attributed to the π-π stacking and the hydrogen bond interactions of 
the resulting enolate with the catalyst (figure 1.2). Subsequently O'Donnell’s group 
                                                          
8. P.E. Stott,  J. S. Bradshaw, W. W. Parish, J. Am. Chem. Soc. 1980, 102, 4810-4815. 
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conducted an enantioselective alkylation, using as a substrate a prochiral 
derivative of protected glycine, providing a valid method for the preparation of 
both natural and non-natural amino acids (scheme 1.5). 
 
Scheme 1.4 Asymmetric synthesis by PTC of indanone derivative 
 
Figure 1.2 Ion pair intermediate 
 
 
Scheme 1.5 Asymmetric PTC alkylation by O’Donnel and coworkers  
 
In this pioneering study the chiral catalysts used were quaternary ammonium salts 
derived from Cinchona alkaloids. The use of a Cinchonine-derived catalyst (a), gave 
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the amino acid (R), while using a cinchonidine-derived catalyst (b) amino acid with 
opposite configuration (S) was recovered (scheme 1.5). The synthetic scheme 
primarily envisages an enantioselective alkylation step of N-
(diphenylmethylene)glycine t-butyl ester and the subsequent hydrolysis, which 
produces the corresponding amino acid with high yields and moderate 
enantiomeric excesses (scheme 1.5).9 The origin of stereoselectivity is ascribed to 
the different arrangement assumed by the structural elements around the 
quaternary nitrogen atom in the catalyst: the ammonium ion can be equated to a 
tetrahedron whose surface is characterized by the four faces F1, F2, F3, and F4 
(figure 1.3). The enolate that is generated during the reaction is coordinated to the 
open face F4 that allows a contact with the positive charge of the cation. The 
preference for the tetrahedron’s F4 face is determined both by conformational 
effects and steric effects. F1 face is cluttered by the presence of 
quinuclidinyl  moiety and F2 by the presence of -OR group. F3 face is encumbered 
by the benzyl ring. Therefore, the enolate coordination is prevented on these three 
faces; face F4 is less hindered and the coordination is stabilized by the attractive 
interaction between the negative charge on the oxygen atom of the enolate and the 
positive charge of nitrogen atom of the catalyst.10 Since their first application in 
1989, the Cinchona alkaloid-derived quaternary ammonium salts have been 
received growing attention in the field of asymmetric phase-transfer catalysis and 
the design of new well-defined chiral catalysts has become a topic of scientific 
interest. Most of the recent contributions are related to the design and application 
of ammonium salts catalysts based on Cinchona alkaloids or different stuctural 
scaffolds.11  
In literature, the Cinchona quaternary ammonium salts have been largely 
employed in asymmetric PTC, as derived structure of the pioneering catalysts (e.g. 
10, 11),12 or as bifunctional PTC in which there are amide or (thio)urea moieties 
                                                          
9. M. J. O'Donnell, W. D. Bennett, S. Wu, J. Am. Chem. Soc. 1989, 111, 2353-2355. 
10 S. Jew, H. Park, Chem. Comm. 2009, 7090-7103. 
11 S. Kaneko, Y. Kumatabara, S. Shirakawa, Org.Biomol.Chem., 2016, 14, 5367-5376. 
12. For examples see:  a) E. J. Corey, F. Xu, M. C. Noe,  J. Am. Chem. Soc. 1997, 119, 
12414−12415; b) B. Lygo, B. J. Andrews, J. Crosby, J. A. Peterson, Tetrahedron Lett. 2002, 43, 
8015−8018; c) H. Park, B. Jeong, J. Lee, M. Park, Y. Lee, M.  Kim, S.  Jew, Angew. Chem., Int. Ed. 
2002, 41, 3036−3038; d) M. Yoo, B.  Jeong, J. Lee, H, Park, S. Jew, Org. Lett. 2005, 7, 
1129−1131; e) S. Jew, M. Yoo, B. Jeong, I. Y. Park, H. Park, Org. Lett. 2002, 4, 4245−4248. 
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(e.g. 12, 13).13 More recently biaryl-based quaternary ammonium salts have been 
introduced by Maruoka and coworkers (14, 15)14 and used in a wide variety of 
asymmetric transformations. Recent derivatives of former Maruoka’s catalysts are 
phosphonium salt (16)15 and bifunctional catalyst (17).16 Other onium salts are: 
tartaric acid derivatives (e.g. 18, 19 and 20),17 C2-symmetric chiral cyclic guanidine 
compounds (e.g. 21),18 cyclic ammonium ion (e.g. 22)19 (figure 1.4).  
 
Figure 1.3 Origin of stereoselectivity in cinchona PTCs 
                                                          
13. For examples see: a) K. M. Johnson, M. S. Rattley, F. Sladojevich, D. M. Barber, M. G. Nuῆez, 
A. M. Goldys, D. J. Dixon, Org. Lett., 2012, 14, 2492–2495; b) P. Bernal, R. Fernández, J. M. 
Lassaletta, Chem. Eur. J., 2010, 16, 7714 – 7718; c) M. Li, P. A. Woods, M. D. Smith, Chem. Sci., 
2013, 4, 2907-2911. 
14. For examples see: a)T. Ooi, M. Kameda, K. Maruoka, J. Am. Chem. Soc., 1999, 121, 6519–
6520; b) T. Ooi, Y. Uematsu, M. Kameda, K. Maruoka, Angew. Chem. Int. Ed. 2002, 41, 1551–
1554; c) M. Kitamura, S. Shirakawa, K. Maruoka, Angew. Chem. Int. Ed. 2005, 44, 1549–1551; 
d) T. Ooi, M. Takeuchi, M. Kameda, K. Maruoka, J. Am. Chem. Soc. 2000, 122, 5228-5229; e) T. 
Ooi, M. Kameda, M. Taniguchi, K. Maruoka, J. Am. Chem. Soc. 2004, 126, 9685-9694; f) M. 
Kitamura, Y. Arimura, S. Shirakawa, K. Maruoka, Tetrahedron Letters, 2008, 49, 2026–2030. 
15. For examples see: a) R. He, X. Wang, T. Hashimoto, K. Maruoka, Angew. Chem. Int. Ed. 
2008, 47, 9466 –9468; b) R. He, C. Ding, K. Maruoka, Angew. Chem. Int. Ed. 2009, 48, 4559 –
4561; c) C. Zhu, F. Zhang, W. Meng, J. Nie, D. Cahard, J. Ma, Angew. Chem. Int. Ed. 2011, 50, 
5869 –5872. 
16. For examples see: a) T. Ooi, D. Ohara, M. Tamura, K. Maruoka, J. Am. Chem. Soc. 2004, 126, 
6844-6845; b) T. Ooi, D. Ohara, K. Fukumoto, K. Maruoka, Org. Lett., 2005, 7, 3195–3197; c) 
Xisheng Wang, Quan Lan, Seiji Shirakawa and Keiji Maruoka, Chem. Commun., 2013, 15, 321-
323. 
17. For examples see: a) T. Shibuguchi, Y. Fukuta, Y. Akachi, A. Sekine, T. Ohshima, M. 
Shibasaki, Tetrahedron Letters, 2002, 43, 9539–9543; b) T. Ohshima, T. Shibuguchi, Y. 
Fukuta, M. Shibasaki, Tetrahedron, 2004, 60, 7743–7754; c) M. Waser, K. Gratzer, R. Herchl, 
N. Müller, Org.Biomol.Chem.,2010, 10, 251-254; d)S. Arai, R. Tsuji, A. Nishida, Tetrahedron 
Lett., 2002, 43, 9535-9537. 
18. T. Kita, A. Georgieva, Y. Hashimoto, T. Nakata, K. Nagasawa, Angew. Chem. Int. Ed., 2002, 
41, 2832-2834. 
19. S. E. Denmark, N. D. G., L. M. Wolf, J. Org. Chem, 2011, 76, 4260-4336. 
 
No coordination: steric hindrance 
on F1 face of the quinuclidinic ring 
No coordination: steric hindrance 
of the -OR group on F2 face  
No coordination: steric hindrance 
of the benzyl group on F3 face  Coordination on F4 face 
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Other onium salts 
 
Figure 1.4 Representative chiral phase-transfer catalysts 
 
1.3 Macrocyclic systems  
 
In the early 1960s, at Du Pont, C. J. Pedersen isolated a very small amount of a 
compound that later was called dibenzo-18-crown-6. The choice to spend efforts to 
characterize this new, serendipitously discovered, product paved the way to the 
development of macrocyclic chemistry, one of the most promising research area of 
chemical science. Since this pioneering work, in the ensuing decades an increasing 
number of scientists have devoted time and effort to the design, synthesis and 
characterization of novel macrocyclic chemical structures, getting sometimes 
inspiration by the amazing macrocyclic compounds, isolated by natural sources.
Macrocycles may be applied in a wide range of research fields, including organic 
and inorganic synthesis, biochemistry, ion transport in membranes, phase-transfer 
catalysis and structure analysis. Moreover macrocyclic chemistry underpins 
supramolecular chemistry: in fact the Izatt-Christensen Award is one of the most 
                                                          
20. (a) L. Cascales, D. J. Craik, Org. Biomol. Chem. 2010, 8, 5035–5047. (b) S. E. Gibson, C. 
Lecci, Angew. Chem. Int.Ed. 2006, 45, 1364–1377. (c) L. A.Wessjohann, E.Ruijter, Top. Curr. 
Chem. 2005, 243, 137–184. 
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prestigious in chemistry which recognizes excellence in the developing both fields 
of macrocyclic and supramolecular chemistry. Three winners, Professor Jean-
Pierre Sauvage, Professor Bernard Lucas Feringa and Sir J. Fraser Stoddart were 
awarded the Nobel Prize in Chemistry very recently.20a In addition the interest in 
the synthesis of macrocycles is increased with the growing demand of new 
therapeutic agents, and naturally occurring bioactive macrocyles and their 
analogues have been synthetized: in fact, generally, cyclization enhances the 
selective binding, uptake, potency and stability of linear precursors, inducing 
constrains in a flexible oligomeric system, and preorganizing the structure in a 
well-defined active conformation. In particular the drug discovery field have 
received a lot of contributions by the synthesis of cyclic peptides and 
peptidomimetics.20b Having a well-defined macrocyclic structure is possible to 
investigate the relationship between structure and function. 
From a synthetic point of view the major challenge in macrocycles’ synthesis is to 
minimize the probability of oligomerization or polymerization instead of  
cyclization. This issue is overcome with high diluition techniques or solid-phase 
synthesis.21  
Figure 1.5 Macrocylization techniques for peptides 
 
For example in the case of a peptide there are four different strategy: head-to-tail 
(C-terminus to N-terminus), head-to-side chain, side chain-to-tail or side-chain-to-
side-chain (figure 1.5). Macrocyclization is a way to “freeze” the motifs of linear 
precursors in order to perform conformational analysis and structure/function 
relationship studies. There are some powerful techniques employed by chemists to 
study macrocyclic systems.22 For instance, in the conformational analysis of 
                                                          
21. C. J. White, A. K. Yudin, Nat. Chem., 2011, 3, 509-524. 
22. A. K. Yudin, Chem. Sci., 2015, 6, 30-49. 
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macrocycles leading methods are: X-ray crystallography, Circular Dichroism, 
indispensable in the comprehension of secondary structure of proteins, and NMR 
spectroscopic evaluation (figura 1.6). The conformational aspects of macrocycles 
can influence the reactivity and the knowledge of the three-dimensional structure 
can direct the design of new scaffolds employed for instance in catalytic 
processes.23 The role covered by macrocycles upon interaction with protein target 
is really crucial in the growing field of drug discovery. The macrocycle is able to 
adopt different conformations that are responsable of precise interactions which 
control a wide range of signals inside the cell. 24  
Figure 1.6 Measurement to assessing the properties of macrocycles 
 
1.3.1 Macrocyclic systems in PTC: crown ethers 
 
Pedersen’s discovery of crown ethers,25 represented a big innovation in organic 
chemistry: thanks to their strong ability to bind metals they have been developed 
in host-guest chemistry and supramolecular field. Crown ethers act as remarkable 
host towards alkali and alkaline earth metals based on the molecular organization 
of the electron-donating oxygen atoms in the macrocycle. They have been 
investigated in the metal-ion recognition and it is possible to identify a relationship 
between the cavity of the macrocycle and the cation diameter (figure 1.7).  
                                                          
23. L. Zheng, A. Marcozzi, J.Y. Gerasimov, A. Herrmann, Angew. Chem. Int. Ed., 2014, 53, 7599-
7603. 
24. J. Gavenonis, B. A. Sheneman, T. R. Siegert, M. R. Eshelman, J. A. Kritzer, Nat. Chem. Biol., 
2014, 10, 716-722. 
25. C. J. Pedersen, Angew. Chem. Int. Ed. Engl., 1988, 27, 1021-1027. 
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Figure 1.7 Crown ethers and alkali metals complexation 
These unique complexation properties have led the crown ethers to be applied in 
phase-transfer catalysis field. In principles the ammonium salts are able to extract 
the cation from the aqueous layer while the crown ethers are able to complex the 
cation with high association constants. The crown ethers in comparison with 
ammonium salts are more expensive but there are some parameters such as metal-
host complexation and lipophilicity of the macrocycle that can radically influence 
and improve the phase-transfer catalytic process.7, 8  From decades to nowadays, 
crown ethers have been used in PTC especially in solid-liquid processes.26 
Macrocyclic polyethers have received importance for applications in PTC reactions 
taking advantages from their ability to complex metal cations. For example in 
recent years various fluorous crown ethers derivatives were synthetized.6 The 
interest towards this type of molecules is linked to an easy recycle of the catalytic 
systems. In particular the catalyst 23 is almost insoluble in common organic 
solvents but totally soluble in perfluorocarbons; this allows the recovery and reuse 
of the catalytic species. For instance, these systems find application in PTC 
nucleophilic substitution and oxidation reactions (scheme 1.6).  
  
Scheme 1.6 Fluorous crown ethers in PTC 
                                                          
26. For examples see: a) A. C. Knipe, J.Chem.Educ. 1976, 53, 618-622; b) G. W. Gokel, H. D. 
Durst, Synthesis, 1976, 168-184; c) A. Maia, D. Landini, S. Petricci, Supramolecular Chemistry, 
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1.3.2 Macrocyclic systems in PTC: calixarenes 
 
Calixarenes are macrocycles derived from an hydroxyalkylation of a phenol with 
an aldehyde. Calixarenes are another leading class of macrocycles able to complex 
metal ions. The ability of the calixarenes in complexing metal ions has been widely 
investigated. In particular, for example, a calix[4]arene functionalized at the lower 
rim with ethyl ester groups shows a high affinity towards the sodium 
cation.27(figure 1.8). Although the ability of calixarenes to complex alkali metals 
has been well-established, and these macrocycles have been largely employed in 
metal-based catalysis, applications in phase-transfer catalysis remain elusive.28 In 
literature is possible to find few examples of reactions in which calixarenes act as 
phase-transfer catalysts. They have been used in nucleophilic substitution, Darzen 
condensation, alkylation, esterification, oxidation reactions. It is possible to make a 
classification of different typologies of calixarenes: “octopus type calixarene”,29 
water soluble calixarenes in which the macrocycle act as an inverse phase-transfer 
catalyst,30 calixarenes with a lower rim functionalization31 and calixarenes with an 
upper rim functionalization.32 For instance, Yilmaz and co-workers reported the 
design of functionalized calixarenes, bearing alkyl amino groups on their upper rim 
                                                          
27. C. D. Gutsche; Calixarenes, Monographs in Supramolecular Chemistry, ed. J. F. Stoddart, The 
Royal Society of Chemistry, UK, 1992, 158-164. 
28. D. M. Homden; C. Redshaw, Chem. Rev., 2008, 108, 5086–5130. 
29. For examples see: a) E. Nomura, H.Taniguchi, K. Kawaguchi, Y. Otsuji, Chem. Lett. 1991, 
2167-2170; b) H. Taniguchi, E. Nomura, Chem. Lett. 1988, 1773–1776; c) H. Taniguchi, Y. 
Otsuji, E. Nomura, Bull. Chem. Soc. Jpn. 1995, 68, 3563–3567; d) E. Nomura, H. Taniguchi, K. 
Kawaguchi, Y. Otsuji, J. Org. Chem. 1993, 58, 4709–4715; e) E. Nomura, H. Taniguchi, Y. 
Otsuji, Bull. Chem. Soc. Jpn. 1994, 67, 792–799; f) E. Nomura, H. Taniguchi, Y. Otsuji, Bull. 
Chem. Soc. Jpn. 1994, 67, 309–311; g) Y. Okada, Y. Sugitani, Y. Kasai, J.  Nishimura, Bull. Chem. 
Soc. Jpn. 1994, 67, 586–588; h) K. Araki,; A. Yanagi, S. Shinkai, Tetrahedron 1993, 49, 6763–
6772. 
30. For examples see: a) S. Shimizu, K. Kito, Y. Sasaki, C. Hirai,  J. Chem. Soc., Chem.Commun. 
1997, 1629–1630; b) S. Shimizu, T. Suzuki, S. Shirakawa, Y. Sasaki, C. Hirai, AdV. Synth. Catal. 
2002, 344, 370–378; c) P. Srivastava, R. Srivastava, Tetrahedron Letters, 2007, 4489–4493; 
d) C. D. Gutsche, I. Alam, Tetrahedron 1988, 44, 4689–4694; e) S. Shinkai, S.Mori, H.Koreishi, 
T. Tsubaki, O. Manabe, J. Am. Chem. Soc. 1986, 108, 2409–2416. 
31. For examples see: a)F. Yang, Y. Wang, H. Guo, J. Xie, Z. Liu, Can. J. Chem. 2010, 88, 622–
627; b) S. J. Harris, A. M. Kinahan, M. J. Meegan, R. C. Prendergast, J. Chem. Res. 1994, 342–
343. 
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for the esterification reaction of p-nitrobenzyl bromide and sodium butyrate or 
sodium caprylate.32 
     
 




Figure 1.9 Effect of PTC on the formation of p-nitrobenzyl butyrate 
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The catalytic activity of calixarenes 24, 25, 26 were examinated for the 
esterification reactions. First of all, the uncatalyzed reaction did not occur 
indicating that 24, 25 and 26 serve as catalysts. From this study the calixarene 24 
proved to be the best performing catalyst in terms of reaction time, conversion and 
yield (figure 1.9 and figure 1.10).  
1.3.3 Macrocyclic systems in PTC: cyclopeptoids 
 
Cyclopeptoids are macrocycles derived from the cyclization of linear peptoids 
(figure 1.11). Peptoids are oligomers of N-substituted glycines. These compounds 
are peptidomimetic that could mimic the biological function of peptides. Peptoids 
can be described as mimics of α-peptides in which the side chain is attached to the 
backbone amide nitrogen instead of the α-carbon. Peptoids lack conformation 
rigidity in comparison to α-peptides; in fact amide bonds are tertiary and can 
isomerize between trans and cis conformations far more readily than the 
secondary amides in α-peptides; further without the presence of amide protons, 
secondary structure can not be stabilized by backbone hydrogen bonds in the 
same manner as in peptides.33 These oligomers are an actractive scaffold for a wide 
range of applications because they can be generated using a modular synthesis, 
based on solid-phase approach, that allows the incorporation of a wide variety of 
functionalities. Macrocyclic constrains are often employed to rigidify the 
conformation of these flexible systems.  
 
Figure 1.11 Peptoid versus α-peptide  
In 2007 Kirshenbaum and co-workers reported the first cyclopeptoid hetero 
oligomers prepared through an head-to-tail cyclization reaction. It is important to 
underline that, in the crystal structure, aromatic and alkyl side chains were 
segregated to opposite faces of the macrocycle. This result in partitioning of 
hydrofobic and polar side chain groups on either face of the macrocycle. 
                                                          
33. S. A. Fowler, H. E. Blackwell, Org. Biomol. Chem. 2009, 7, 1508-1524. 
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Furthermore analysis of peptoid macrocycle crystal structure revealed a 
remarkable similarity of the backbone to protein β-turn (figure 1.12).34, 35  
 
  
Figure 1.12 First cyclopeptoid hetero oligomers 
Subsequently cyclopeptoids proved to have interesting ability in complexing metal 
ions. For instance, the investigation of N-benzyloxyethyl cyclic α-peptoids showed 
the attitude to complex first group alkali metals and ammonium ion. These 
complexing properties were revealed with NMR techniques, conformational 
studies and correlated with Cram’s method investigation (figure 1.13). 36,37 The 
cyclopeptodid 27 showed a good affinity for the smaller cations, in particular for 
Na+. The use of spectroscopy 1H-NMR revealed for compound 27 a complex 
mixture of rotamers which interconvert faster than NMR time scale (figure 1.13, a). 
Addition of sodium picrate (0.5 eq.) revealed the presence of a new species (figure 
1.13, b); interestingly an increasing amount of sodium picrate (1.0 eq.) led to the 
formation of a predominant species with an high symmetry (figure 1.13, c). A 
conformational search on this cyclopeptoid as sodium complex suggested the 
presence of a S6-symmetry axis passing through the intracavity sodium cation. 
Finally a crystal structure was obtained as a 2:3 complex with strontium picrate. 
The structure showed a unique all-trans peptoid bond configuration with the 
carbonyl groups alternately pointing toward the strontium cations and forcing the 
N-linked side chains to assume an alternate pseudo-equatorial arrangement.  
                                                          
34. S. B. Y. Shin, B. Yoo, L. J. Todaro, K. Kirshenbaum, J. Am. Chem. Soc. 2007, 129, 3218-3225. 
35. B. Yoo, S. Bin, Y. Shin, M. L. Huang, K. Kirshenbaum, Chem. Eur. J. 2010, 16, 5528-5537. 
36. N. Maulucci, I. Izzo, G. Bifulco, A. Aliberti, C. De Cola, D. Comegna, C. Gaeta, A. Napolitano, 
C. Pizza, C. Tedesco, D. Flot, F. De Riccardis, Chem. Commun., 2008, 3927–3929. 
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In 2013 the design and synthesis of chiral cyclopeptoids has been reported. The 
choice to introduce L-Proline residues was ascribed to the ability of this natural 
amino acid to induce conformational features on secondary structures of peptides 
and protein. Hexameric cyclic peptoids containing L-Proline and N-methoxyethyl 
glycine showed interesting complexation properties towards first group metal 
cations, and in particular compound 28 showed a unique crystal structure. The 
arrangement of this cyclic α-peptoid is rather intriguing and intricate. In the solid 
state structure three cyclopeptoid rings, four Na+ ions, and one acetonitrile 
molecule form a triple-decker salt sandwich metal complex with a crystallographic 
3-fold rotation symmetry.38  
 
Figure 1.13 N-benzyloxyethyl cyclic α-peptoid and complexation 
More recently, starting from these well-defined complexation properties, 
cyclopeptoids have been tested in phase-transfer catalysis.39 In this contribution 
some differently substituted cyclohexapeptoids were tested in a benchmark phase-
transfer reaction, the nucleophilic substitution of p-nitrobenzyl bromide with 
                                                          
38. I. Izzo, G. Ianniello, C. De Cola, B. Nardone, L. Erra, G. Vaughan, C. Tedesco, F. De Riccardis, 
Organic Letters. 2013, 598-601. 
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sodium or potassium thiocyanate. The most active cyclopeptoids 29, 30 and 31 
have showed catalytic activities comparable with those exhibited by crown ethers; 
furthermore the macrocycle 32, promoted the reaction with NaSCN, with reaction 
time and conversion comparable to 2.2.2- cryptand (7), one of the best macrocyclic 
polyether catalyst tested; (table 1.1).  
 
Figure 1.14 Crystal structure and crystal packing of chiral cyclohexapeptoid 
  
Figure 1.15 Comparison of cyclopeptods and some commercially available PTC 
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This contribution represents the first application of cyclopeptoids in phase-
transfer catalysis. 




1.4 Application of macrocyclic systems in asymmetric PTC 
 
The continuing search for new chiral catalysts for the synthesis of enantio-
enriched molecules, have in some way also exploited the design of novel chiral 
macrocyclic systems. Compared to the extensively developed above mentioned 
ammonium salts and Maruoka’s catalysts, the macrocyclic systems have been less 
investigated although they look to be intriguing alternative to the onium salts.40, 41 
First of all, it must be considered the different reaction mechanism for the two 
main classes of catalytic systems. The reaction mechanism for onium salts 
envisages the formation of an intimate ion pair between the quaternary 
ammonium salt and the anion of the substrate generated by deprotonation 
(scheme 1.7). On the other hand, the mechanism for neutral macrocyclic systems 
                                                          
40. T. Ooi, Keiji Maruoka, Angew. Chem. Int. Ed. 2007, 46, 4222 – 4266. 









 catalyst Time (h) Conversion(%) Time (h) Conversion(%) 
      
1 - 24 10 24 5 
2 29 24 95 13 >99 
3 30 4.5 >99 24 53 
4 31 8 >99 24 91 
5 32 2.5 >99 7.5 >99 
6 33 12 >99 24 71 
7 1 4.5 >99 4.5 >99 
8 3 8 >99 1 >99 
9 4 24 >99 7.5 >99 
10 5 6.5 >99 3 >99 
11 7 2 >99 1 >99 
12 8 24 81 24 85 
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involves the formation of a metal-macrocycle complex, and then the generation of 
the intimate ion pair between the host-guest complex and the anion of the 
substrate (scheme 1.7). The application of different neutral macrocyclic systems 
will be discussed in the next paragraphs, especially focused on chiral crown ethers 
and calixarenes. 
 
Scheme 1.7 Reaction mechanism of phase transfer processes promoted by onium salts or 
neutral macrocycles 
 
1.4.1 Crown ethers in asymmetric PTC 
 
Chiral crown ethers have been used for asymmetric phase-transfer catalysis. The 
first successfull application involved binaphtyl-modified crown ethers (figure 1.16) 
in Michael reactions between methyl vinyl ketone and 2-methoxycarbonyl-1-
indanone or between methyl 2-phenylpropionate and methyl acrylate. The 
resulting enantioselectivities were good.42  
 
 
 Figure 1.16 Chiral binaphtyl-modified crown ethers 
 
                                                          
42. D. J. Cram, G. D. Y. Sogah,  J. Chem. Soc., Chem. Commun. 1981, 625−628. 
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The addition of methyl phenylacetate to methyl acrylate was also investigated with 
different chiral crown ethers by other research groups.43 For example, the Michael 
addition of differently substituted phenylacetates with methyl acrylate was carried 
out with various chiral crown ethers (36-44) (figure 1.17). It has been found that 
simple chiral C2-symmetric chiral crown ethers (36-42), in the presence of KOtBu, 
catalyze the Michael addition with moderate to good enantiomeric excesses (Table 
1.2, entries 1-10), while the crown ethers 43 and 44 afforded disappointing results 
(Table 1.2, entries 11, 12). 
 
 Figure 1.17 Asymmetric Michael addition with chiral crown ethers 
 
Subsequently some chiral azacrown ethers (45-48) derived from D-glucose were 
synthetized and applied in Michael reaction of nitropropane to trans-chalcone.44 
The same catalysts were used also in the Darzens condensation. Moreover, these 
catalysts (45) have been used in asymmetric epoxidation of chalcones. For instance 
                                                          
43. For examples see: a) M. Alonso-López, M. Martí́n-Lomas, S. Penadés, Tetrahedron Lett., 
1986, 27, 3551−3554; b) S. Aoki, S. Sasaki, K. Koga, Tetrahedron Lett., 1989, 30, 7229−7230; 
c) E. Brunet, A. M. Poveda, D. Rabasco, E. Oreja, L. M. Font, M. S. Batra, J. C. Rodrígues-Ubis, 
Tetrahedron: Asymmetry, 1994, 5, 935−948.; d) L. Tõke, P. Bakó, G. M. Keserű, M. Albert, L. 
Fenichel, Tetrahedron, 1998, 54, 213−222. 
44. For examples see: a) M. Alonso-López, M. Martí́n-Lomas, S. Penadés, Tetrahedron Lett., 
1986, 27, 3551−3554; b) S. Aoki, S. Sasaki, K. Koga, Tetrahedron Lett., 1989, 30, 7229−7230; 
c) E. Brunet, A. M. Poveda, D. Rabasco, E. Oreja, L. M. Font, M. S. Batra, J. C. Rodrígues-Ubis, 
Tetrahedron: Asymmetry, 1994, 5, 935−948.; d) L. Tõke, P. Bakó, G. M. Keserű, M. Albert, L. 
Fenichel, Tetrahedron, 1998, 54, 213−222. 
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the chiral catalyst 45, with R = (CH2)3OH, is able to catalyze the asymmetric 
epoxidation of α,β-enones (Table 1.3). 45b 
 
Table 1.2 Asymmetric Michael addition with chiral crown ethersa 
 
Entry Catalyst R Time(h) Yield(%) eeb(%) 
1 36 H 3 95 79 (S) 
2 36 OMe 2.5 66 81 –b 
 3a 36 NO2 48 73 60 – b 
4 36 Me 2 80 79 - b 
5 37 H 3 97 48 (S) 
6 38 H 3 98 74 (S) 
7 39 H 3 99 70 (S) 
8 40 H 1 72 63 (S) 
9 41 H 3 89 56 (R) 
10 42 H 3 91 56 (R) 
11 43 H 3 79 1(R) 
12 44 H 3 96 2 (R) 
aCarried out at -45°C. bNot yet determinated.  
 
Table 1.3 Asymmetric epoxidation with the chiral monosaccharide-based crown ether 46 
 
Entry Ar1 Ar2 Time(h) Yield(%) ee(%) 
1 Ph Ph 1 82 94 
2 CH3 Ph 20 - - 
3 tBu Ph 16 86 90 
4 1-Naphthyl Ph 10 64 67 
5 2-Naphthyl Ph 3 30 87 
6 Ph CH3 6 60 55 
7 Ph tBu 18 53 34 
8 Ph 1-Naphthyl 9 68 83 
9 Ph 2-Naphthyl 6 33 66 
10 tBu 1-Naphthyl 12 60 85 
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Chiral crown ethers were also employed in the enantioselective oxidation of 
aromatic ketones,45 asymmetric alkylation of glycine derivatives with moderate 
enantioselectivity,46 and conjugated addition of glycine imine with several Michael 
acceptors (figure 1.18).47 
 
  
Figure 1.18 Chiral crown ethers tested in asymmetric phase-transfer catalysis 
 
 
1.4.2 Calixarenes in asymmetric PTC 
The use of calixarenes in asymmetric phase transfer catalysis has been rarely 
investigated and very few examples are reported in literature. To the best of our 
knowledge there are just two articles in which calixarenes are employed in this 
field. However, in both examples the calixarene is used as a scaffold to anchor 
ammonium salts. In the Sirit’s group contribution, a cinchonidine-derived chiral 
calix[4]arene (49) has been synthetized and used in the alkylation reaction of the 
glycine derivatives with moderate enantioselectivity.48 The calixarene 49 was used 
to carried out the asymmetric phase-transfer alkylation of N-
(diphenylmethylene)glycine ethyl ester with benzyl bromide (Table 1.4). 
                                                          
45. a) E. F.J. de Vries, L. Ploeg, M. Colao, J. Brussee, A. Van der Gen, Tetrahedron: Asymmetry 
1995, 6, 1123−1132; b) T. Bakò, Pèter Bakò, G. Keglevich, P. Bombicz, M. Kubinyi, 
K. Pàl, S. Bodor, A. Makò, L. Tòke, Tetrahedron: Asymmetry, 2004, 15, 1589-1595. 
46. K. Yonezawa, M. L. Patil, S.Takizawa, H. Sasai, Heterocycles, 2005, 66, 639-644. 
47. T. Akiyama, M. Hara, K. Fuchibe, S. Sakamoto, K. Yamaguchi, Chem.Commun., 2003, 14, 
1734-1735. 
48. S. Bozkurt, M. Durmaz, M. Yilmaz, A. Sirit, Tetrahedron: Asymmetry 2008, 19, 618-623. 
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Figure 1.19 Calixarene-based chiral phase-transfer catalysts 
 
Table 1.4 Asymmetric alkylation of N-(diphenylmethylene)glycine ethyl ester catalyzed by 
cinchonidine-derived calix[4]arene 49  
 
Entry Solvent T (°C) Base Yielda (%) eeb (%) 
1 Toluene/CHCl3 7/3 -20 KOH 87 25 (S) 
2 Toluene/CHCl3 7/3 -20 NaOH 89 46 (S) 
3 Toluene/CHCl3 7/3 0 NaOH 95 57 (S) 
4 Toluene/CHCl3 7/3 rt NaOH 92 52 (S) 
aIsolated yields. bEnantiomeric excess was determined by HPLC analysis using a chiral column 
(DAICEL Chiralcel OD-H) using hexane/isopropanol (99:1) as an eluent. 
 
The best level of enantioselectivity was accomplished with an aqueous solution of 
NaOH at 0°C (Table 1.4, entry 3). The enantioselectivity was sensitive to the cation 
of the base: in fact, with an aqueous solution of KOH, (Table 1.4, entry 1) a low ee 
was achieved. The temperature also affected the outcome of this reaction with a 
lower ee value at -20°C (Table 1.4, entries 2,3). In 2010, Shimuzu’s group reported 
the synthesis of inherently chiral calix[4]arenes 50 containing a quaternary 
ammonium moiety, which were applied in the asymmetric alkylation reaction of 
glycine derivatives. Although the enantioselectivity was very low, this represents 
the first application of inherently chiral calix[4]arene as a chiral phase-transfer 
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catalyst.49 Although the calixarenes are involved in PTC processes these two 
contributions did not exploit the ability of macrocycles in complexing metal ions. 
 
1.4.3 Cyclopeptoids in asymmetric PTC 
 
Despite the wide use of peptides and synthetic analogues in asymmetric catalysis, 
to the best of our knowledge, up to the date, peptoids, peptide analogues, have 
been scarcely explored for applications in this field: in fact despite the wide use of 
peptide systems in catalysis, in literature is reported a single example in which a 
linear peptoidic system is employed as enantioselective catalyst.50  The study, 
reported by Kirshenbaum, focuses on the use of linear peptoidic oligomers in the 
enantioselective catalysis.51  
 
Scheme 1.8 Catalytic oxidation of 1-phenylethanol by peptoids 
 
Figure 1.20 Peptoid sequences evaluated for catalysis 
The approach involves the synthesis of hexapeptoids containing different TEMPO 
(2,2,6,6-tetramethylpiperidine-1-oxyl) residues into peptoidic backbone. These 
catalysts were effectively used for the oxidative kinetic resolution of 1-
phenylethanol (scheme 1.8). The peptoid (51) is characterized by right-handed 
                                                          
49. S. Shirakawa, S. Shimizu, New J. Chem. 2010, 34, 1217-1222. 
50. R. P. Megens, G. Roelfes, Chem. Eur. J., 2011, 17, 8514-8523. 
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helical configuration and the TEMPO group is covalently attached at the N 
terminus; this compound was able to perform the kinetic resolution; the same 
behaviour was revealed by the linear oligomer (52) presenting left-handed helical 
configuration. When the TEMPO was attached on internal positions of the oligomer 
(53 or 54), on the other hand, no enantioselectivity (Table 1.5) was observed. 
 
Table 1.5 Oxidative kinetic resolution reaction with peptoids 
 
Catalyst Conversion % Time (min) ee% 
51 84 120 >99(R) 
52 85 120 >99(S) 
53 26 30 - 
54 25 30 - 
  
The challenge of using macrocyclic peptoid in asymmetric phase-transfer catalysis 
started few years ago in our laboratories where the first application of chiral 
cyclopeptoids was succesfully performed. The efficiency of this novel class of 
macrocycle catalysts was tested in the benzylation of N-
(diphenylmethylene)glycine t-butyl ester (scheme 1.9).52 The investigation was 
performed with a liquid-liquid biphasic system of toluene and 50% NaOH aqueous 
solution. All reactions were conducted with a catalyst loading of 5 mol%.  
 
Scheme 1.9 Benzylation of N-(diphenylmethylene)glycine t-butyl ester 
 
Preliminary studies showed a partial decomposition of the starting material 
performing the alkylation under aerobic conditions. The degradation process was 
revealed by the presence of benzophenone, observed by 1H-NMR. Similar 
secondary reactions have been reported for imines derivatives of glycine, under 
phase-transfer catalysis.53 This problem has been overcome, by the Maruoka’s 
group, by conducting the reactions under inert atmosphere. Also in this 
                                                          
52. R. Schettini, B. Nardone, F. De Riccardis, G. Della Sala, I. Izzo, Eur. J. Org. Chem., 2014, 
7793−7797. 
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cyclopeptoid catalyzed process, the use of inert atmosphere, after deoxygenation 
of the two phases, totally suppressed the decomposition of the substrate. This 
result confirmes that the decomposition of the substrate was favored by the 
presence of oxygen in the reaction medium. After an exhaustive screening of 
different catalysts and reaction conditions, this investigation showed that the 
cyclopeptpoid 57, consisting of alternating residues of L-Proline and N-benzyl 
glycine, is able to catalyze the reaction of asymmetric alkylation with 67% ee. The 
(R) absolute configurations of 56a-h was determined by comparison of the HPLC 
retention times reported in the literature: R enantiomer was obtained. 
Table 1.6 Enantioselective benzylation of 55 with alkylating agents, catalyzed by 57a,b 
 
Entry RBr Product Time (h) Yield (%) ee (%)c,d 
1 Benzyl bromide 56a 20 64 67 (R) 
2 4-Nitrobenzyl bromide 56b 5 86 57 (R) 
3 4-Fluorobenzyl bromide 56c 24 62 60 (R) 
4 4-Cyanobenzyl bromide 56d 45 62 45 (R) 
5 4-Methylbenzyl bromide 56e 24 66 73 (R) 
6 3,5-Dimethylbenzyl bromide 56f 18 60 60 (R) 
7 4-(t-Butyl)benzyl bromide 56g 24 53 47 (R) 
8e Allyl bromide 56h 23 55 55 (R) 
aAll reactions were carried out in liquid-liquid system for 20 h, at 0.08 mmol scale using 55 (1.0 
eq.), benzyl bromide (1.2 eq.) and catalyst (5 mol%) in toluene (0.8 mL), with 50% aq. NaOH (0.5 
mL), unless otherwise stated. bAll reactions were performed under an inert atmosphere by 
deoxygenating the two phases. cDetermined by HPLC using a Chiralcel OD-H chiral stationary phase. 
dThe absolute configurations of products 56a–e, 56g, and 56h were determined by comparison of 
the HPLC retention times and optical rotations with literature values12a, 53and for 56f by analogy 
with known products. eAllyl bromide (1.5 equiv.). 
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To expand the scope of the reaction different alkylating agents were tested 
using catalyst 57 under optimized reaction conditions. As can be seen, in 
Table 1.6, all the alkylating agents afforded enantioselectivities and yields 
comparable to those obtained with benzyl bromide. The reaction carried out 
in presence of 4-methylbenzyl bromide gave the best enantioselectivity (73% ee).  
 
1.5 Aims of the work 
 
Considering the well-defined advantages of asymmetric phase-transfer catalysis as 
a powerful method for organic synthesis, the aim of this research project is to 
introduce novel macrocycle systems as new and efficient catalysts in this field. 
 First of all, considering the advantages of the easy synthetic process for the 
preparation of cyclopeptoids, their well-explored complexation properties and the 
preliminary study on the application as phase-transfer catalysts,52 the idea is to 
deeply investigate their use in PTC. The advantages of the solid phase synthesis, 
such as the easy purification of the intermediates and the modular nature of the 
products, make cyclopeptoids ideal candidates for the discovery of new catalytic 
systems, as it is possible to incorporate a wide variety of functionalities inside the 
backbone of the macrocycle in an expeditious way.  As a consequence, a library of 
peptoid-based chiral macrocycles of different size, decorated with alternating 
residues of L-Proline and different aromatic side chains, will be prepared and used 
for enantioselective alkylation reactions.  
 The scope of this project extends also to the investigation of novel chiral 
calixarenes. However, in this case, the idea is to exploit the ability of calixarenes to 
form host-guest complexes with alkali cations. The study is also devoted to further 
explore the potential of crown ethers in new catalytic processes. The second 
chapter focus first on the synthesis of novel chiral cyclopeptoids and then on their 
application in asymmetric phase-transfer alkylations, in particular for the 
enantioselective synthesis of α-amino acids.  Afterwards the application of new 
designed calixarenes for the same alkylation reaction is described. Finally the 
application of cyclopeptoidic systems in the enantioselective alkylation of 2-aryl-
oxazoline-4 carboxylic acid esters is discussed. The third chapter describes the 
application of crown ethers in phase-transfer processes. For this purpose a 
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diasteroselective methodology for the synthesis of γ-substituted butenolides by a 
direct vinylogous Mukayama-Michael reaction has been developed.   




Scheme 1.10 Summary of reactions in every chapter 
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2. ALKYLATION REACTIONS 
 
2.1 Introduction  
 
Since its first application, the asymmetric alkylation of glycine derivatives, 
introduced by O'Donnell’s group, has proved to be a valid method for the 
preparation of α-amino acids and their analogues with high enantioselectivity. 
Nowadays the alkylation of N-(diphenylmethylene)glycine t-butyl ester is 
generally used as benchmark reaction in order to investigate the performances of 
new catalytic systems in phase-transfer reactions. An important aspect of the 
reaction is the selective formation of the mono-alkylated product without the 
undesired dialkylated byproduct. This result has been attributed to the lower 
acidity of the α proton in the product compared to the acidity of protons in the 
reagent. This is crucial for the configurational stability of chiral center generated in 
the course of the reaction (figure 2.1).54, 55 
 
 
Figure 2.1 Blockage of the second alkylation on the benzophenone imine derivative 
 
The mechanistic aspects of the reaction have been studied. The substrate, soluble 
in the organic phase, is distributed by diffusion in the interfacial region where, in 
the presence of a base, is deprotonated in α position, leading to the formation of a 
metallic enolate; the use of a chiral phase-transfer catalyst enables the exchange of 
the cationic species and consequently generates a chiral enolate, characterized by 
two π enantiotopic faces. This enolate is more soluble in the organic phase where it 
reacts with the alkylating agent (scheme 2.1). It is important to underline that the 
generation of the chiral enolate must be fast to prevent any stereoselective 
alkylation reactions; it is also important that the chiral enolate is characterized by 
an intimate ion pair, so that the chiral species can be actively engaged in the 
asymmetric induction of the next alkylation reaction. 
                                                          
54. M. J. O’Donnell, Acc. Chem. Res., 2004, 37, 506-517. 
55. M. J. O’Donnell, J. Am. Chem. Soc., 1988, 110, 8520-8525. 
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Scheme 2.1 Asymmetric PTC mechanism of benzofenone imine derivative    
  
The increasing development of this enantioselective reaction has led to a large 
number of new catalysts. In figure 2.2 are reported the most common catalysts, 
used in this reaction, featuring the most significant structural modifications 
introduced, thanks to the understanding of different aspects of this reaction. For 
example Corey’s12a and Lygo’s groups56, developed a modified Cinchona alkaloid-
derived quaternary ammonium catalysts with a N-anthracenylmethyl group.  
These catalysts showed an increased enantioselectivity in the asymmetric 
alkylation of a benzophenone-derived glycine-imine. A recent systematic study on 
structure/activity relationship revealed that the Corey/Lygo catalysts gave the 
higher values of enantioselectivity because the N-anthracenylmethyl group was 
able to direct the enolate molecular recognition.57 The synthesis of dimeric and 
trimeric quaternary ammonium salts58 offers the possibility to investigate different 
aspects of this reaction such as the counter-anion effect or electronic features. The 
counter-anion generally affected the final enantioselectivity, for instance, the 
hexafluorophosphate salt 64 and its analogue tetrafluoroborate salt anions gave 
                                                          
56. B. Lygo, P. G. Wainwright, Tetrahedron, 1997, 38, 8595-8597. 
57. S. E. Denmark, N. D. Gould, L. M. Wolf, J. Org. Chem. 2011, 76, 4337–4357. 
58. a) H. Park, B. Jeong, M. Yoo, J. Lee, B. Park, M. G. Kim, S. Jew, Tetrahedron Letters 2003, 44, 
3497–3500; b) R. Chinchilla, P. Mazόn, C. Nájera, F.  J. Ortega, Tetrahedron: Asymmetry 2004, 
15, 2603–2607. 
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higher ee in comparison with chloride or bromide. The increased 
enantioselectivity was attributed to the formation of a less tight ion pairs between 
tetrafluoroborate or hexafluorophosphate anions and the quaternary ammonium 
cation. Moreover, various functional groups with different electronic properties 
were introduced on the catalyst’ structure to improve their performances. In some 
cases, the presence of fluorine atoms allowed higher enantioselectivity. Another 
leading class of catalysts successfully used in the same reaction are the Maruoka’s 
catalysts.  The first synthesis of Maruoka's spirobinaphtyl quaternary ammonium 
salts, reported in 1999, was realized starting from commercially available (S)- or 
(R)-1,1’-bi-2-naphtol (figure 2.3).14a These new C2-symmetric phase-transfer 
catalysts were successfully applied in the alkylation reaction with high levels of 
enantioselectivity. In summary Cinchona alkaloids and Maruoka’s catalysts are 
extensively involved in this reaction, while catalysts based on different chiral 
scaffolds are less common. As described in the first chapter there are several 
efficient binaphtyl-derived quaternary ammonium salts based on Maruoka’s 
scaffold while catalysts based on different chiral scaffold are less common (chapter 
1, figure 1.4).  The interest in developing new phase-transfer catalysts for this type 
of reaction also lies in the opportunity to realize the synthesis of biologically active 
compounds or drugs on large scale preparation. Some examples are: the synthesis 
of (S)-N-acetylindoline-2-carboxylic acid t-butyl ester (66), a key intermediate in 
the synthesis of the angiotensin converting enzyme (ACE) inhibitor, or L-Dopa t-
butyl ester (67).59 This methodology was applied for the first asymmetric 
synthesis of levobupivacaine (68) a long-acting local anaesthetic drug.60  The use of 
N-(diphenylmethylene)glycine t-butyl ester in the total synthesis of (-)-antofine 
(69) is an important application in the antitumor discovery field.61 The growing 
interest towards cancer chemotherapy drives the reserch of new agents for 
examples bengamide derivatives are ideal candidates in this area (70).62 
                                                          
59. T. Ooi, M. Kameda, K. Maruoka, J. Am. Chem. Soc., 2003, 125, 5139-5151. 
60. S. Kumar, U. Ramachandran, Tetrahedron Letters, 2005, 46, 19–21. 
61. S. Kim, J. Lee, T. Lee, H. Park, D. Kim, Org. Lett. 2003, 5, 2703–2706. 
62. R. K. Boeckman, T. J. Clark, B. C. Shook, Org. Lett., 2002, 4, 2109–2112. 
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Figure 2.2 Representative examples of Cinchona Alkaloid Derived Catalysts 
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Figure 2.4 Representative examples of N-(diphenylmethylene)glycine t-butyl ester derived 
drug candidates  
 
2.2 New insights on the asymmetric alkylation reaction of N-
(diphenylmethylene)glycine derivatives 
 
The purpose of the research study has been the synthesis and application of new 
cyclopeptoid scaffolds in phase-transfer catalysis. Considering the complexation 
abilities, the metal ion affinities, the similarities with the well know crown ethers 
and the promising results observed with a catalyst decorated with N-benzyl groups 
alternating with residues of L-Proline,52 the design and the synthesis of new 
cyclopeptoids, containing differently substituted aromatic side chains, was 
planned.  
The first target has been the preparation of a library of cyclohexapeptoids 
and cyclotetrapeptoids in order to study not only the influence of the side chain 
but also of cavity size on the catalytic efficiency (figure 2.5). Moreover, considering 
the promising results obtained with the first application of the chiral cyclopeptoids  
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in the alkylation of N-(diphenylmethylene)glycine t-butyl ester (55, figure 2.5)52 
we decided to investigate more deeply this reaction, considering new parameters, 
such as the structure of the substrate, in order to improve the enantiomeric 
excesses and to obtain results comparable to the best catalysts reported in 
literature. 
 
Figure 2.5 General structures of cyclotetrapeptoids and cyclohexapeptoids 
 
2.2.1 Synthesis of Chiral Cyclohexapeptoids 
 
Taking advantage of a mixed sub-monomeric/monomeric approach, nine chiral C3-
symmetric cyclohexapeptoids (80-88) were prepared, containing alternating 
residues of N-arylmethylglycine and L-Proline. The modular synthesis is based on a 
solid-phase process, potentially automated, characterized by quick preparation 
and easy workup/purification. The first step is the loading of bromoacetic acid on a 
chlorotrityl resin; this step is followed by a nucleofilic substitution with a primary 
amine to build the first monomer. Then there is a coupling reaction with a chiral 
monomer, in this case L-Proline, in presence of a coupling reagent such as HATU 
followed by a deprotection step. The repetition of the steps described above 
affords a linear peptoid oligomer, attached on the resin. Cleavage reaction, in mild 
acidic conditions, affords the free linear hexapeptoid (scheme 2.2). No purification 
steps are required and by-products are eliminated by easy filtration. The next step 
is a cyclization reaction that involves an head-to-tail connection in high dilution 
conditions (scheme 2.3). By this way, compounds 80-88 were prepared in a good 
yield and purity as confirmed by NMR and HPLC analysis. 
 
2.2.2 Synthesis of Chiral Cyclotetrapeptoids 
 
Subsequently, in order to investigate the role of the macrocycle’s cavity 
size in the catalytic process, the synthesis of a small library of cyclotetrapeptoids, 
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containing aromatic chains, was performed, using the same sub-
monomeric/monomeric approach (Scheme2.4).  
 
Reagents and conditions: a) bromoacetic acid, DIPEA; b) RNH2; c) N-Fmoc-L-Proline, HATU; d) 20% 
piperidine/DMF; e) bromoacetic acid, DIC; f) HFIP/CH2Cl2 (1:4). DIPEA = N,N diisopropylethylamine; 
DIC = N,N’-diisopropyl carbodiimide. HATU = 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-
b]pyridinium 3-oxid hexafluorophosphate. 
 
Scheme 2.2 Solid phase synthesis of linear hexapeptoids 
 
Yields: 80 49%, 81 18%, 82 23%, 83 22%, 84 57%, 85 43%, 86 20%, 87 10%, 88 53%. 
 
Scheme 2.3 Head-to-tail cyclization of hexapeptoids  
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Reagents and conditions: a) bromoacetic acid, DIPEA; b) RNH2; c) N-Fmoc-L-Proline, HATU; d) 20% 
piperidine/DMF; e) bromoacetic acid, DIC; f) HFIP/CH2Cl2 (1:4). DIPEA = N,N diisopropylethylamine; 
DIC = N,N’-diisopropyl carbodiimide. HATU= 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-
b]pyridinium 3-oxid hexafluorophosphate. 
 
 
Scheme 2.4 Solid phase synthesis of linear tetrapeptoids  
 
Yields: 94 19%, 95 11% 96 62%, 97 13%, 98 27%. 
Scheme 2.5 Head-to-tail cyclization of tetrapeptoids 
 
Cyclic tetrapeptoids, unlike the cyclohexapeptoids, present a rigid conformation 
and non prolinated cyclotetrapeptoids, previously described in literature, adopt a 
cis−trans−cis−trans peptoid sequence.36,63,64 To the best of our knowledge only one 
example of a bis-prolinated analogue is reported in literature.65,66  The cyclo(L-Pro-
Sar)2, prepared by Shimizu and co-workers, showed a rigid all-cis peptoid bond 
conformation, as revealed by X-ray analysis (figure 2.6, a). In our case this C2-
                                                          
63. C. Tedesco, L. Erra, I. Izzo, F. De Riccardis, CrystEngComm, 2014, 16, 3667−3687. 
64. (a) A. S. Culf, M. Čuperlović-Culf, D. A. Léger, A. Decken, Org. Lett. 2014, 16, 2780−2783.  
(b) P. Groth, Acta Chem. Scand. 1970, 24, 780−790. (c) J. Dale, K. Titlestad, J. Chem. Soc. 
1970, 1403− 1404. 
65. T. Shimizu, Y. Tanaka, K. Tsuda, Biopolymers 1983, 22, 617− 632 
66. K. Ueno, T. Shimizu, Biopolymers 1983, 22, 633−641. 
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symmetric structure was confirmed by a ROESY experiment performed on 
cyclotetrapeptoid 98.67 The key cross peak between the Pro-Hα (d, 5.52 ppm) and 
the Gly-H (d, 4.67 ppm) corroborated a cis peptoid bond junction for the Pro-
N(alkyl)-Gly sequence (figure 2.6, b). Starting from the X-rays analysis reported in 
literature by Shimuzu a computational study by DFT calculations was performed. 
This study confirmed the proximity of Pro-Hα and Gly-H. 
 a. b. 
ROE effect
 
Figure 2.6 a. X-ray structure for the all-cis cyclo(L-Pro-Sar)2 reported by Shimizu; b. 
predicted lowest energy conformation for the cyclotetrapeptoid 98 by DFT calculations 
(atom type: C gray, N blue, O red, H white; hydrogen atoms omitted for clarity). The ROE 
effect is depicted by the red arrow. Gaussian 08 Software Package.  
 
2.2.3 Evaluation of complexation ability of cyclotetra and cyclohexapeptoids 
 
Considering the influence of the complexation ability towards cations on the 
efficiency of phase-transfer catalysis, the association constants with alkali metal 
for cyclotetra and cyclohexapeptoids containing L-Proline residues was evaluated 
for the first time.  
For this reason the complexing abilities of the simplest members of the two cyclic 
peptoid series (the N-benzyl- substituted compounds 80 and 94), the association 
constants (Ka), −ΔG° and RCHCl3,
68 in the presence of Na+ and K+, were calculated 
                                                          
67. A. Bax, D. G. Davis, J. Magn. Reson. 1985, 63, 207. 
68. RCHCl3 = [M]CHCl3 / [Hi ]CHCl3 = [Guest]/[Host] in CHCl3 layer at equilibrium. 
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following the Cram’s method37 and reported in table 2.1. 
To our delight we observed that the association constant between sodium cation 
and 80 was one order magnitude higher than the association constant determined 
for the well-known sodium complexing agent 15-crown-5.38 Interestingly the 
association constant of cyclotetrapeptoid was higher than that determined for the 
non prolinated cyclohexapeptoids36 which, however, performed as good phase-
transfer catalyst too.39 
 




a Ka×10-4/M-1 -ΔG°/Kcal/mol 
1 94 Na+ 0.38 530 9.1 
2 K+ 0.34 206 8.5 
3 80 Na+ 0.73 10000 10.8 
4 K+ 0.62 2000 9.9 
a[Guest]/[Host] in CHCl3 layer at equilibrium obtained by direct measurement, or 
calculated by difference from measurement made on aqueous phase at 25 °C (figures 
within ±10% in multiple experiments). Guest : host stoichiometry for extractions was 
assumed as 1 : 1.  
 
 
2.2.4 Chiral cyclotetrapeptoids in the enantioselective benzylation of N-
(diphenylmethylene) glycine t-butyl ester 
 
Taking into account the complexation ability observed for the prolinated 
cyclotetrapeptoid, the small library of these macrocyclic compounds was studied 
in the asymmetric alkylation of N-(diphenylmethylene) glycine t-butyl ester which 
was previously investigated only for the larger cyclohexapeptoids.52 
Cyclotetrapeptoids proved to be able to catalyze the benzylation reaction 
(Table 2.2), even though with lower ee values than those with 
cyclohexapeptoids. Also in this case the macrocycles contaning N-benzylic 
and 3,5-dimethylbenzylic side chains (94 and 98) proved to be the best, 
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Table 2.2 Enantioselective benzylation with chiral cyclotetrapeptoids 94-98a,b 
 
 
Entry Catalyst Yield (%) ee (%)c,d 
1 94 67 36 (R) 
2 95 39 31 (R) 
3 96 64 10 (R) 
4 97 75 4 (R) 
5 98 54 41 (R) 
aAll reactions were carried out in liquid-liquid system for 20 
h, at 0.08 mmol scale using 55 (1.0 eq.), benzyl bromide (1.2 
eq.) and catalyst (5 mol%) in toluene (0.8 mL), with 50% aq. 
NaOH (0.5 mL), unless otherwise stated. bAll reactions were 
performed under an inert atmosphere by deoxygenating the 
two phases. cDetermined by HPLC using a Chiralcel OD-H 
chiral stationary phase. dThe absolute configurations of 
product was determined by comparison of the HPLC 
retention times and optical rotations with literature 
values.12a,53   
 
 
2.2.5 Further developments in the application of chiral cyclohexapeptoids in 
the enantioselective alkylation of N-(diphenylmethylene)glycine derivatives: 
the role of ester functionality 
 
As told before, the promising results in the enantioselective monoalkylation of N-
(diphenylmethylene)glycine t-butyl ester in the presence of chiral cyclopeptoids, 
prompted us to thoroughly explore different aspects of the enantioselective 
alkylation in order to improve yields and ee’s of the reaction products.69  First of all 
we decided to investigate the influence of the substrate’s ester group on the 
outcome of the alkylation reaction. Therefore the synthesis of different N-
(diphenylmethylene)glycine esters (table 2.3) was realized and the 
enantioselective benzylation was tested using catalyst 80 under the best reaction 
conditions.  
 
                                                          
69. R. Schettini, F. De Riccardis, G. Della Sala, I. Izzo, J. Org. Chem., 2016, 81, 2494–2505. 
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Entry R Product Time (h) Yield (%)b ee (%)c,d 
1 t-Bu (55) 56a 20 91 75 
2 Et (99a) 100a 4 88 41 
3 Bn (99b) 100b 4 89 49 
4 Ph(Me)2C (99c) 100c 20 74 81 
5 Ph2CH (99d) 100d 3 70 18 
aAll reactions were performed in a liquid-liquid system with 0.08 mmol of 95, benzyl 
bromide (1.2 equiv.), and catalyst 80 (5 mol %) in toluene (0.8 mL) and NaOH 50% aq 
(0.5 mL). bIsolated yields. cDetermined by HPLC using a Chiralcel OD-H chiral stationary 
phase. dThe absolute configuration of the products was determined by comparison of 
the HPLC retention time and optical rotation with literature values12a,53,48,56,70 
 
In order to assess the actual effect of macrocyclic system, the same alkylation 
reaction was performed using an acyclic peptoid. Although the reaction procedeed 
with high yields, the enantiomeric excess was low (scheme 2.6). This result 
confirmed that the conformational restrictions imposed by the macrocycle are 




Scheme 2.6 Enantioselective benzylation catalyzed by acyclic peptoid 
 
 
The presence of ethyl or benzyl group gave moderate ee in comparison with the t-
butyl ester residue (Table 2.3, entries 2, 3) while the presence of two aromatic 
rings, as in benzydryl group, gave a decrease of ee (Table 2.3, entry 5). Finally, to 
our delight, a significant increase of ee was obtained with cumyl ester 99c (Table 
2.3, entry 4).  
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2.2.5 Enantioselective alkylation of N-(diphenylmethylene)glycine cumyl 
ester 
 
With the best substrate in our hands, the N-(diphenylmethylene)glycine cumyl 
ester 99c, the asymmetric benzylation was realized in the presence of different 
cyclopeptoids as macrocyclic chiral catalysts. The best results were obtained with 
the cyclohexapeptoid 80 (Table 2.4, entry 1). The presence of substituents in meta 
and para positions on the aromatic ring gave a slight decrease in terms of 
enantioselectivity (Table 2.4, entries 2, 3, 5 and 6). 3,4-Dimethoxybenzyl group 
(Table 2.4, entry 7) and the -naphtyl group 3,4-dichloro derivative (Table 2.4, 
entry 4) afforded moderate ee’s and yields. Very low levels of enantioselectivity 
were observed with ortho substitution (Table 2.4, entry 8) and with 3,4-dichloro 
derivative (Table 2.4, entry 9). 
 
Table 2.4 Screening of catalysts in phase-transfer benzylation of 99ca  
 
 
Entry Catalyst Yield (%)b ee (%)c,d 
1 80 74 81 
2 81 71 65 
3 82 89 77 
4 83 61 48 
5 84 86 77 
6 85 92 77 
7 86 54 45 
8 87 60 12 
9 88 50 5 
10 94 55 52 
11 95 55 46 
12 96 54 46 
13 97 54 10 
14 98 55 rac 
aAll reactions were performed in a liquid-liquid system with 0.08 
mmol of 99c, benzyl bromide (1.2 equiv.), and catalyst (5 mol %) in 
toluene (0.8 mL) and NaOH 50% aq (0.5 mL). bIsolated yields. 
cDetermined by HPLC using a Chiralcel OD-H chiral stationary phase. 
dThe absolute configuration of 100c was determined by comparison 
of the HPLC retention time and optical rotation with literature 
values.70  
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The previous trend, changing the cavity dimension, was observed during the 
investigation with cyclotetrapeptoids. In fact, although they were able to catalyze 
the asymmetric alkylation, the catalytic efficiency and the enantioselectivity were 
lower in comparison with the corresponding cyclohexapeptoids (compare entry 1 
and 10, 6 and 14, 7 and 12, 8 and 13, 9 and 11). Subsequently, an extensive study 
was performed on various parameters of the reaction using the best catalyst 80 
and substrate 99c. First, the screening of solvents revealed that toluene as the best 
solvent for this process (Table 2.5, entries 1-5). 
 
Table 2.5 Screening of catalyst loading, solvents and bases promoted by 80a  
 










1 toluene NaOH 50% aq. 5 0 74 81 
2 Et2O NaOH 50% aq. 5 0 63 49 
3 p-xylene NaOH 50% aq. 5 0 72 62 
4 toluene/CHCl3 9:1 NaOH 50% aq. 5 0 72 17 
5 toluene/CH2Cl2 9:1 NaOH 50% aq. 5 0 69 78 
6 toluenee NaOH 50% aq. 5 0 73 75 
7 toluene NaOH 50% aq. 10 0 70 73 
8 toluene NaOH 50% aq. 2.5 0 75 86 
9 toluene NaOH 50% aq. 1 0 68 46 
10 toluene NaOH 50% aq. 5 –20 71 82 
11 toluene NaOH 50% aq. 2.5 –20 50 74 
12 toluene KOH 50% aq. 5 0 71 78 
13 toluene KOH 50% aq. 5 –20 70 87 
14 toluene KOH 50% aq. 2.5 –20 75 93 
15 toluene KOH 50% aq. 1 –20 76 92 
16 toluene CsOH 66% aq. 5 0 65 78 
17 toluene CsOH 66% aq. 5 –20 77 18 
18 toluene CsOH·H2O (s)f 5 0 69 rac 
aAll reactions were performed in a liquid-liquid system with 0.08 mmol of 93c, benzyl bromide 
(1.2 equiv.), and catalyst 80 in the appropriate solvent (0.8 mL) and aqueous base (0.5 mL). 
bIsolated yields. cDetermined by HPLC using a Chiralcel OD-H chiral stationary phase. dThe 
absolute configuration of 100c was determined by comparison of the HPLC retention time and 
optical rotation with literature values.70 e1.6 mL of toluene were used. f5.0 equiv. of solid base 
were used. 
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More diluted condition afforded a small decrease in enantioselectivity (Table 2.5, 
entry 6). The screening about the catalyst loading showed an important aspect: 
amazingly, we could appreciate an improvement of ee with a lower amount of 
catalyst (2.5 mol %, Table 2.5, entry 8). At lower temperature (-20°C) a slight 
decrease of the enantioselectivity was observed in (Table 2.5, entries 10, 11). Then, 
we evaluated the effect of the base. With 5 mol % of catalyst and aqueous KOH 
50% at 0°C the ee value was comparable to NaOH at 0°C (Table 2.5, entry 12). 
Interestingly, a lower temperature with aqueous KOH 50% gave the best results: 
we obtained 87% ee with 5 mol % of catalyst (Table 2.5, entry 13), 93% ee with 2.5 
mol % of catalyst (Table 2.5, entry 14), and, with our surprise, 92% ee, a very slight 
drop, with 1 mol % of catalyst (Table 2.5, entry 15). On the other hand, 
disappointing results were obtained with CsOH as the base (Table 2.5, entry 16-
18). 
To summarize, careful studies on the influence of substrate structure, solvent and 
nature of base allowed us to select the best conditions to obtain enantiomeric 
excesses comparable with the best reported to date in literature for this type of 
reaction. The N-(diphenylmethylene)glycine cumyl ester proved to be the 
substrate of choice, in presence of the chiral cyclohexapeptoid 80 as catalyst and 
employing toluene and an aqueous solution of KOH 50% at -20°C. Notably, only 2.5 
mol% of catalyst (Table 2.5, entry 14) was necessary to reach the best ee, but even 
using a very low  catalyst loading (1 mol%) the enantioselectivity was still 
remarkable (Table 2.5, entry 15). This is a remarkable achievement considering 
that normally higher loading (10%) are required with the most used chiral 
ammonium salts. 
With the optimized conditions in our hands we decided to extend the scope of 
reaction with different alkylating agents. Very good yields and ee values with 
benzyl, allyl, alkyl bromides and iodides (83-96%) were achieved. The presence of 
an ortho methyl group in the alkylating agent allowed an ee up to 96% (Table 2.6, 
100c). The introduction of para substituents gave high enantioselectivities (Table 
2.6, 102d-i). Comparable enantioselectivities were achieved with allyl, propargyl, 
t-butoxycarbonylmethyl and ethyl substrates (Table 2.6, 102j-n). 
Moreover, to the best of our knowledge only one example of asymmetric alkylation 
of N-(diphenylmethylene)glycine cumyl ester is reported in literature, by 
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Kodanko’s group, which described the phase-transfer process catalyzed by O-allyl-
N-(9- antracenylmethyl)-cinchonidinium bromide (10 mol% of catalyst loading).70 
The cumyl ester group is useful in transformation of the glycine derivatives to free 
amino acids, as can be cleaved by hydrogenolysis without affecting acid-labile 
groups in the scaffold molecule; for this reason it represents a valide alternative to 
a t-butyl group. 
 
2.4 Calixarenes in asymmetric alkylation 
Taking into account our successful results and experience in the enantioselective 
alkylation of N-(diphenylmethylene)glycine derivatives we decided to investigate 
the potential of new macrocyclic compounds in phase-transfer catalysis.  
 
Table 2.6 Scope of phase-transfer alkylation of 99c promoted by 80 a-d 
 
                                                          
70. T. Respondek, E. Cueny, J. J. Kodanko, Org. Lett., 2012, 14, 1, 150-153 
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aReactions were performed in a liquid-liquid system on a 0.5 mmol scale by using 99c, alkyl bromide 
(1.2 equiv.), and catalyst 80 in toluene (5.0 mL) and KOH 50% aq (3.0 mL), unless otherwise noted. 
bThe yields are referred to the isolated products. cThe ee values are determined by HPLC using a 
Chiralcel OD-H chiral stationary phase.dThe absolute configurations of products 102c, 102j, 102l 
and 102m were assigned by comparison of the HPLC retention times and optical rotations with 
literature values.70 For the other products the same (R) absolute configuration was assumed. e1.5 
equiv. of alkyl bromide were used. f3.0 equiv. of alkyl bromide were used. gEthyl iodide was used as 
alkylating agent. 
 
As previously anticipated, calixarenes have been largely employed in 
metal-based catalysis but applications in phase-transfer processes remain 
elusive.28 The few examples of calixarenes applied in PTC reported to date are 
limited to macrocycles functionalized with chiral quaternary ammonium 
moieties.26a,49 In collaboration with Neri’s group at the Department of Chemistry 
and Biology “A. Zambelli” of the University of Salerno the design and the synthesis 
of novel chiral calixarenes was performed and their ability as PTC catalysts was 
tested during this PhD project. The first attempts in the enantioselective 
benzylation of N-(diphenylmethylene)glycine t-butyl ester were performed with 
calixarenes 103 and 104 (figure 2.8), containing free -OH groups at lower rim and 
chiral residues of α-methyl benzylamine. As described in the first chapter, the 
ability of the calixarenes in complexing metal ions has been widely investigated. 
For instance, a calix[4]arene functionalized at the lower rim with ethyl ester 
groups shows a high affinity towards the sodium cation (figure 2.7).27  
Based on these proprierties, initially some calixarene analogues were syntetized 
with the lower rim decorated with chiral amide groups. The introduction of 
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chirality was achieved with (S)-(-)-α-methyl benzylamine groups. The chiral amine 
is commercially available. Although these compounds were able to catalyze the 
alkylation reaction of N-(diphenylmethylene)glycine t-butyl ester with benzyl 
bromide in toluene and an aqueous solution of NaOH 50% with high reaction rate 
(total conversion after 4h was observed) the enantiomeric excesses observed were 
very low (5% and 7% respectively) (Table 2.6, entries 1, 2) . We wondered if the 
presence of free -OH groups could be detrimental for the catalytic activity and 
enantioselectivity. For this reason a small library of chiral calixarenes containing 
methoxy groups instead of free –OH was prepared (105-107 figure 2.8). 
     
Figure 2.7 Calixarene and affinity towards sodium cation  
The novel macrocycles were tested using 5 mol% of catalyst loading and a 50% 
aqueous NaOH/toluene biphasic system. All compounds were able to catalyze the 
reaction and in particular compound 107, containing three chiral side chains at 
lower rim, afforded the alkylated compound with 26% of ee (Table 2.7, entry 5). 
Subsequently, with the best catalyst 107 the influence of different bases was 
investigated (table 2.8). All the basic systems afforded lower enantioselectivities in 
comparison to 50% aqueous NaOH solution. Interestingly, inversion of 
configuration was observed with 50% aqueous KOH solution (table 2.8, entry 1). 
Considering the beneficial effect of an appropriate ester moiety, previously 
observed using chiral cyclopeptoids, different glycine ester derivatives were 
examinated. The presence of ethyl or benzyl group gave really low ee in 
comparison with the t-butyl ester residue (Table 2.9, entries 2, 3); in presence of 
two aromatic rings, as with the benzydrilic ester, was observed an inversion of 
enantioselectivity (Table 2.9, entry 5). With cumyl ester (Table 2.9, entry 4) was 
obtained an ee value comparable to t-butyl group. 
2. Alkylation reactions 
 





Figure 2.8 Novel chiral calixarenes 
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Table 2.7 Enantioselective benzylation with chiral calixarenes 103-110a  
 
 
Entry Catalyst Time (h) Yield (%) ee (%)b,c 
1 103 4 53 5(R) 
2 104 4 65 7(R) 
3 105 28 48 rac 
4d 106 4 92 13(R) 
5 107 5 92 26(R) 
6 108 21 66 13(R) 
7 109 19 97 9(R) 
8 110 22 84 rac 
aAll reactions were carried out in liquid-liquid system, at 0.08 mmol 
scale using 55 (1.0 eq.), benzyl bromide (1.2 eq.) and catalyst (5 mol%) 
in toluene (0.8 mL), with 50% aq. NaOH (0.5 mL), unless otherwise 
stated. bAll reactions were performed under an inert atmosphere by 
deoxygenating the two phases. cDetermined by HPLC using a Chiralcel 
OD-H chiral stationary phase. dThe absolute configurations of 56a were 
determined by comparison of the HPLC retention times and optical 
rotation with literature values. 12a,53   
 
 
Table 2.8 Screening of bases in phase-transfer benzylation of 55 promoted by 107a 
 
 
Entry Base T (°C) Time (h) Yield (%) ee (%)b,c 
1 KOH 50% aq. 0 48 80 5(S) 
2d CsOH 66% aq. 0 72 84 5(R) 
3 CsOH·H2O (s) 0 28 72 7(R) 
4 NaOH 50% aq. -20 72 12 14(R) 
aAll reactions were carried out in liquid-liquid system, at 0.08 mmol scale using 55 (1.0 
eq.), benzyl bromide (1.2 eq.) and catalyst (5 mol%) in toluene (0.8 mL), with 50% aq. 
NaOH (0.5 mL), unless otherwise stated. bAll reactions were performed under an inert 
atmosphere by deoxygenating the two phases. cDetermined by HPLC using a Chiralcel OD-
H chiral stationary phase. dThe absolute configurations of 56a were determined by 
comparison of the HPLC retention times and optical rotation with literature values.  12a,53 
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1 t-Bu (55) 56a 5 89 28 
2 Et (99a) 100a 3 77 4 
3 Bn (99b) 100b 7 60 rac 
4 Ph(Me)2C (99c) 100c 6 84 24 
5 Ph2CH (99d) 100d 5 74 6(S) 
aAll reactions were performed in a liquid-liquid system with 0.08 mmol of 99, benzyl 
bromide (1.2 equiv.), and catalyst 107 (5 mol %) in toluene (0.8 mL) and NaOH 50% 
aq (0.5 mL). bIsolated yields. cDetermined by HPLC using a Chiralcel OD-H chiral 
stationary phase. dThe absolute configuration of the products was determined by 
comparison of the HPLC retention time and optical rotation with literature values.  
12a,53,48,56,70 
 
Finally the nature of solvent and the catalyst loading were investigated (Table 
2.10). Taking into account the ameliorative results obtained using mesitylene 
(35% ee, Table 2.10, entry 8), the influence of catalyst loading and some different 
basic system were evaluated using this solvent. 10 mol% of catalyst gave a slight 
decrease of enantioselectivity (Table 2.10, entry 10) while a dramatic effect was 
observed with 2.5 mol% (Table 2.10, entry 11). In addition, using a solid-liquid 
system (NaOH (s)/mesitylene) an inversion of the enantioselectivity (Table 2.10, 
entry 12) was observed, as previously revealed in presence of 50% aqueous NaOH 
solution. This results seems to suggest that the catalytic process is sensitive to the 
cation (Table 2.10, entries 13-15), which may play a key role in the transition state. 
Finally, to extend the scope of the reaction, we tested different alkylating agents 
(Table 2.11). The presence of a 4-methyl or t-butyl groups in the aromatic ring of 
the alkylating agent led to 44% ee (Table 2.11, entries 2, 3); the introduction of 
electron withdrawing groups afforded a decrease of ee (Table 2.11, entries 5, 8, 9). 
The presence of an ortho methyl group resulted in a decrease of ee (Table 2.11, 
entry 6). Low enantioselectivities were also observed with allyl, propargyl and t-
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butoxymethyl bromides. In conclusion this is the first example based on the use of 
chiral calixarenes in asymmetric phase-transfer catalysis.  
 
Table 2.10 Screening of catalyst loading, solvents in the alkylation promoted by 107a 
 









1 toluene NaOH 50% aq. 5 5 84 24 
2 CH2Cl2 NaOH 50% aq. 7 5 83 6 
3 Et2O NaOH 50% aq. 5 5 87 4 
4 p-xylene NaOH 50% aq. 7 5 84 rac 
5 m-xylene NaOH 50% aq. 28 5 82 3 
6 o-xylene NaOH 50% aq. 5 5 88 17 
7 chlorobenzene NaOH 50% aq. 5 5 90 rac 
8 mesitylene NaOH 50% aq. 7 5 86 35 
9 mesitylene/ 
CH2Cl2 9/1 
NaOH 50% aq. 7 5 89 26 
10 mesitylene NaOH 50% aq. 18 10 73 28 
11 mesitylene NaOH 50% aq. 18 2.5 73 13 
12 mesitylene NaOH (s) f 96 5 55 4(S) 
13 mesitylene KOH 50% aq. 96 5 66 10(S) 
14 mesitylene KOH (s) f 47 5 69 15(S) 
15 toluene CsOH·H2O (s)f 48 5 72 11(S) 
aAll reactions were performed in a liquid-liquid system with 0.08 mmol of 99c, benzyl bromide 
(1.2 equiv.), and catalyst 107 in the appropriate solvent (0.8 mL) and aqueous base (0.5 mL) at 
0°C. bIsolated yields. cDetermined by HPLC using a Chiralcel OD-H chiral stationary phase. dThe 
absolute configuration of 100c was determined by comparison of the HPLC retention time and 
optical rotation with literature values.70 e1.6 mL of toluene were used. f5.0 equiv. of solid base 
were used. 
 
In conclusion this is the first example based on the use of chiral calixarenes in 
asymmetric phase-transfer catalysis, where the complexation ability was 
exploited. Using the N-(diphenylmethylene)glycine t-butyl ester as substrate and 
the 4-methyl or t-butylbenzyl bromides as alkylating agents a moderate 
enantioselectivity (44% ee) was obtained (Table 2.11, entries 2 and 3). Despite the 
levels of enantioselectivity were moderate or low, these results pave the way to 
deeper investigations: indeed some interesting insights have emerged. The cation 
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seems to be crucial in the formation of the specific transition state so that an 
inversion of the enantioselectivity has been registered. Moreover, the structure 
substrate also influenced the configuration of the product, suggesting the 
opportunity to finely tune the enantioselective outcome of the reaction. 
 
Table 2.11 Enantioselective alkylation of 55 in presence of catalyst 107 with different 
alkylating agentsa,b 
 







1 Benzyl bromide 56a 7 86 35(R) 
2 4-Methylbenzyl bromide 56e 7 76 44(R) 
3 4-(t-Butyl)benzyl bromide 56g 15 79 44(R) 
4e Allyl bromide 56h 24 67 15(R) 
5 4-Chlorobenzyl bromide 56i 7 75 rac 
6 2-Methylbenzyl bromide 56l 7 72 15(R) 
7 2-(bromomethyl)naphtalene 56m 7 76 3(R) 
8 4-Fluorobenzyl bromide 56n 20 72 11(R) 
9 4-Nitrobenzyl bromide 56o 3 69 7(R) 
10 3,5-Dimethylbenzyl bromide 56p 20 75 rac 
11e Propargyl bromide  56q 5 88 4(R) 
12e t-Butylbromoacetate 56r 5 78 9(R) 
aAll reactions were carried out in liquid-liquid system for 20 h, at 0.08 mmol scale using 55 
(1.0 eq.), benzyl bromide (1.2 eq.) and catalyst (5 mol%) in toluene (0.8 mL), with 50% aq. 
NaOH (0.5 mL), unless otherwise stated. bAll reactions were performed under an inert 
atmosphere by deoxygenating the two phases. cDetermined by HPLC using a Chiralcel OD-H 
chiral stationary phase. dThe absolute configurations of products 56a–e, 56g and 56h were 
determined by comparison of the HPLC retention times and optical rotations with literature 
values 12a,53  and for 56f by analogy with known products. eAllyl bromide (1.5 equiv.). 
 
 
2.5 Asymmetric alkylation of 2-aryl-oxazoline-4-carboxylic acid esters 
 
The efficient formation of quaternary stereocenters is a fundamental task 
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in organic synthesis.71 In this context the catalytic asymmetric preparation of Cα-
tetrasubstituted α-amino acids has gained considerable attention in the recent 
years, because these building blocks are widely present in drugs and biologically 
and pharmaceutically active compounds. Since the pioneering work of O’Donnell in 
1992,72 phase transfer catalysis proved to be an efficient methodology for the 
preparation of non proteogenic, chiral α,α-dialkyl-α–amino acid, through 
asymmetric alkylation of Schiff bases derivatives of α-amino acids. The 
construction of Cα-tetrasubstituted α-amino acids represents a challenge in organic 
synthesis and various phase-transfer catalysts have been designed for this 
purpose. The most common catalysts are Cinchona alkaloids-derived and 
binaphthyl-derived quaternary ammonium salts and very few examples are based 
on different alternative chiral scaffolds.17,73 In particular macrocyclic systems are 
scarsely investigated.46,74 Generally, chiral crown ethers afford moderate 
enantioselectivities in this process. 
α–Alkyl serines or, more generally, β-hydroxy-α-amino acids, are widespread in 
peptidomimetics and bioactive natural products: some examples are conagenin,75, 
myriocin76, mycestericins77 (figure 2.9). The conagenin is a low molecular weight 
immunomodulator produced by Streptomyces roseosporus. Myriocin possesses a 
more potent immunosuppressant activity than ciclosporin. Mycestericins are a 
family of potent immunosuppressants as well. 
                                                          
71 (a) H. Vogt, S. Bräse, Org. Biomol. Chem., 2007, 5, 406-430. (b) S. Cabrera, E. Reyes, J. 
Alemán, A. Milelli, S. Kobbelgaard, K. A. Jørgensen,  J. Am. Chem. Soc. 2008, 130, 12031-
12037. (c) J. Zhou, Organic Chem. Curr. Res. 2014, 3, e136. (d) L. Yiyang, H. Seo-Jung, L. Wen-
Bo, B. M. Stoltz, Acc. Chem. Res. 2015, 48, 740−751. 
72. M. J. O'Donnell, S. Wu, Tetrahedron: Asymmetry 1992, 3, 591-594. 
73. a) Y. N. Belokon, K. A. Kochetkov, T. D. Churkina, N. S. Ikonnikov, A. A. Chesnokov, O. V. 
Larionov, I. Singh, V. S. Parmar, S. Vyskocil, H. B. Kagan,  J. Org. Chem. 2000, 65, 7041-7048; 
(b) Y. N. Belokon, T. D. North, T. D. Churkina, N. S. Ikonnikov, V. I. Maleev, Tetrahedron 2001, 
57, 2491-2498. (c)  B. Lygo, U. Butt, M. Cormack, Org. Biomol. Chem. 2012, 10, 4968-4976. 
74. T. Itoh, S.  Shirakami, Heterocycles 2001, 55, 37-43.  
75. T. Yamashita, M. Iijima, H. Nakamura, K. Issiki, H. Naganawa, S. Hattori, M. Hamada, M. 
Ishizuka, T. Takeuchi, Y. Iitaka,  J. Antibiot. 1991, 44, 557-559. 
76. (a) T. Fujita, K. Inoue, S. Yamamoto, T. Ikumoto, S. Sasaki, R. Toyama, K. Chiba, Y. Hoshino, 
T. Okumoto, J. Antibiot. 1994, 47, 216-224. (b) T. Fujita, K. Inoue, S. Yamamoto, T. Ikumoto, 
S. Sasaki, R. Toyama, K. Chiba, Y. Hoshino, T. Okumoto,. J. Antibiot. 1994, 47, 208-215. (c) C. 
R. Strader, C. J. Pearce, N. H. Oberlies,  J. Nat. Prod. 2011, 74, 900-907. 
77. (a) S. Sasaki, R. Hashimoto, M. Kiuchi, K. Inoue, T. Ikumoto, R. Hirose, K. Chiba, Y. Hoshino, 
T. Okumoto, T. Fujita, J. Antibiot. 1994, 47, 420-433. (b) T. Fujita, N. Hamamichi, M. Kiuchi, T. 
Matsuzaki, Y. Kitao, K. Inoue, R. Hirose, M. Yoneta, S. Sasaki, K. Chiba,  J. Antibiot. 1996, 49, 
846-853.  
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Figure 2.9 α-alkyl serines in biologically active natural products 
Moreover chirality of -alkyl serines proved to be relevant for the binding affinity 
to biological targets.78 The first application of phase-transfer catalysis for the 
asymmetric synthesis of α–alkyl serines was reported in 2004 by Jew and Park,79 
exploiting the alkylation of a carboxyl-activated oxazoline ring. The oxazoline 
moiety enhances the acidity of the α-proton of the ester and acts as a protecting 
group for the amino- and hydroxy- functionalities of the serine. Here too, Cinchona 
alkaloids and Maruoka’s catalysts (figure 2.10) have been applied. In that case 
starting point was the asymmetric alkylatoin of the 2-phenyl-oxazoline-4 
carboxylic acid t-butyl ester (figure 2.11). The following acid hydrolysis affords the 
unprotected α–alkyl serines. In the first report the enantioselective phase-transfer 
catalytic benzylation was performed in the presence of different catalysts (111-
114). The commercially available (S)-binaphthol-derived catalyst 111, disclosed 
by the Maruoka group, afforded the alkylated product with very high 
enantioselectivity (>99% ee). 
 
Figure 2.10 Phase-transfer catalysts for asymmetric alkylation of oxazoline-carboxylic 
esters 
                                                          
78. O. Frązczak, A. Lasota, Leśniak, A. W. Lipkowski, A. Olma, Chem. Biol. Drug Des. 2014, 84, 
199-206. 
79. (a) S. Jew, Y. J. Lee, J.  Lee, M. J. Kang, B. S. Jeong, J. H. Lee, M. S. Yoo, M. Kim, S. Choi,  J. M. 
Ku, H. Park, Angew. Chem. Int. Ed. 2004, 43, 2382-2385; (b) H. Park, J. Lee, M. J. Kang, Y. Lee, 
B. Jeong, J. Lee, M. Yoo, M. Kim, S. Choi, S. Jew, Tetrahedron 2004, 60, 4243–4249. 
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Figure 2.11 Enantioselective benzylation of oxazoline-carboxylic esters 
 
Subsequently Maruoka exploited this method for the preparation of α–methyl 
serines.80 Later on a solid–phase synthetic strategy to obtain α–alkyl serines81 was 
proposed by Park and coworkers: Merrifield resin-supported 2-phenyl-2-
oxazoline-4-carboxylate was exposed to alkylation conditions, showing moderate 
enantioselectivity for the products (figure 2.12). More recently Park and Jew 
investigated the role of 2-aryl oxazoline substituent in the asymmetric alkylation. 
Reaction of o-biphenyl-2-oxazoline-4-carboxylic acid t-butyl ester in presence of 
Cinchona alkaloids-derived catalysts afforded very high enantioselectivity (scheme 
2.7).82 
 
Figure 2.12 Solid-phase synthetic strategy of α-alkylserines 
 
 
Scheme 2.7 Enantioselective catalytic alkylation of o-biphenyl-2-oxazoline-4-carboxylic 
acid t-butyl ester 
 
                                                          
80. K. Nakayama, K. Maruoka, Tetrahedron Letters 2008, 49, 5461–5463. 
81. J. Lee, M. W. Ha, T. Kim, M. Kim, J. Ku, S. Jewa, H. Park, B. Jeong, Tetrahedron, 2009, 65, 
8839–8843. 
82. Y. Lee, J. Lee, M. Kim, T. Kim, H. Park, S. Jew, Organic Letters, 2009, 7, 1557–1560. 
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Considering that neutral chiral macroclycles have never been investigated in this 
synthetically useful enantioselective process, we decided to prove the catalytic 
ability of chiral cyclopeptoids in the asymmetric alkylation of 2-aryl-oxazoline-4-
carboxylic acid esters. 
 
2.5.1 Synthesis of 2-phenyl-2-oxazoline-4-carboxylic acid esters. 
 
In order to evaluate the ability of cyclopeptoids as phase-transfer catalysts in the 
alkylation of 2-aryl-2-oxazoline-4-carboxylic acid esters, the first step was the 
synthesis of the substrates. We began our study investigating the role of ester 
moiety in the oxazoline derivatives, so the synthesis of different 2-phenyl-2-
oxazoline-4-carboxylic acid esters (figure 2.13) was planned and realized. 
Subsequently the role of aryl moiety was investigated and a second set of 
substrates, containing different aryl groups was prepared. 
The synthetic strategy used for the 2-phenyl-2-oxazoline-4-carboxylic acid esters 
was based on the described approach for the known oxazoline 115.81 This route 
required the preparation of the desired serine esters. While the ethyl and benzyl 
esters of serine are commercially available, the t-butyl ester was prepared  by 
reacting Z-Ser-OH (Z = Cbz = carbobenzyloxy) with t-butyl bromide in presence of 
potassium carbonate and benzyltriethyl ammonium chloride (BTEAC),83 followed 
by Pd/C catalyzed hydrogenolysis 84 (scheme 2.8). 
 
Figure 2.13 First generation of 2-aryl-oxazoline-4-carboxylic acid esters 
 
                                                          
83. P. Chevallet, P. Garrouste, B. Malawska, J. Martinez, Tetrahedron Lett., 1994, 34, 46, 7409-
7412. 
84. L. Le Corre, C. Gravier-Pelletier, Y. Merrer, Eur. J. Org. Chem., 2007, 5386–5394. 
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Scheme 2.8 Synthesis of H-Ser-O-t-butyl ester 
Then the synthesis of oxazoline 115-117 was accomplished through the coupling 
reaction between serine esters and ethyl benzimidate hydrochloride with 
trimethylamine (scheme 2.9).  
 
Scheme 2.9 Synthesis of 2-aryl-oxazoline-4-carboxylic acid esters  
On the other hand, the synthesis of oxazolines 118 and 119 started with the 
preparation of 2-phenyl-2-oxazoline-4-carboxylic acid. The coupling reaction 
between ethyl benzimidate hydrochloride and the commercially available H-Ser-O-
methyl ester afforded the corresponding oxazoline methyl ester. The 
saponification with LiOH∙H2O83 gave the desidered carboxilic acid (scheme 2.10). 
The preparation of the oxazoline 118 required the synthesis of the intermediate 1-
methyl-1-phenylethyl 2,2,2-trichloro acetimidate, starting from cumyl alcohol 
(scheme 2.11).72  The synthesis of 119 was instead accomplished through a radical 
reaction between 2-phenyl-oxazoline-4-carboxylic acid and benzophenone 
hydrazone in presence of iodine and diacetoxyiodobenzene (scheme 2.12).85 
  
Scheme 2.10 Synthesis 2-phenyl-2-oxazoline-4-carboxylic acid 
                                                          
85. P. Elsner, L. Bernardi, G. Della Sala, J. Overgaard, K. A. Jørgensen, J. Am. Chem. Soc., 2008, 
130, 4897-4905. 
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 Scheme 2.11 Synthesis of 2-phenyl-2-oxazoline-4-carboxylic acid cumyl ester 
 
 
Scheme 2.12 Synthesis of 2-phenyl-2-oxazoline-4-carboxylic acid benzhydryl ester 
2.5.2 Enantioselective alkylation of 2-phenyl-2-oxazoline-4-carboxylic acid 
esters using cyclopeptoids.  
 
With various substrates in our hands the enantioselective alkylation was 
investigated. The starting point choosen to begin our screening involved the same 
reaction conditions previously described in the enantioselective alkylation of 
glycine ester (using toluene/NaOH 50% at 0°C with 5 mol% of catalyst loading in a 
liquid-liquid biphasic system with the chiral cyclopeptoid 80). 
The use of bulky t-butyl and benzhydryl esters (Table 2.12, entries 1 and 5) 
appeared to be beneficial for the enantiomeric excesses, while benzyl, cumyl and 
the smaller ethyl group led gave from moderate to very low ee (Table 2.12, entries 
2-4). However the best yield was observed again with the t-butyl ester and 
therefore further optimization or reaction conditions (base, catalyst loading, 
solvent, concentration) were performed on compound 115 (Table 2.12). Only with 
solid KOH better enantiomeric excess was obtained albeit with a lower yield (Table 
2.12, entry 10). A reduction in the catalyst loading resulted in a lost of 
enantioselectivity both for NaOH and for KOH (Table 2.12, entries 6,9). More 
diluted conditions did not affect yield and ee (Table 2.12, entry 14). Performing the 
reaction at -20°C caused a turbidity of the NaOH aqueous phase and, consequently, 
a worse catalytic performance (Table 2.12, entry 13). Finally, the use of different 
solvents did not improve the results obtained with toluene (Table 2.12, entries 15-
17). 
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Table 2.12 Investigation of the role of ester groups and of reaction parameters in phase-












1 tBu (115) NaOH 50% aq 5 20 toluene 120 76 62 
2 Et (116) NaOH 50% aq 5 21 toluene 121 61 18 








NaOH 50% aq 5 3 toluene 124 50 61 
6 tBu (115) NaOH 50% aq 2.5 72 toluene 120 74 23 
7 tBu (115) NaOH(s) 5 144 toluene 120 29 c 22 
8 tBu (115) KOH 50% aq 5 46 toluene 120 32 c 62 
9 tBu (115) KOH 50% aq 2.5 72 toluene 120 46 c 54 
10 tBu (115) KOH(s) 5 20 toluene 120 47 61 
11 tBu (115) CsOH(s) 5 46 toluene 120 40 c 34 
12 tBu (115) LiOH(s) 5 144 toluene 120 - - 
13 tBu (115) NaOH 50% aq 5 96 toluene 120 16c 54 
14 tBu (115) NaOH 50% aq 5 22 toluenee 120 74 62 
15 tBu (115) NaOH 50% aq 5 22 Et2O 120 74 57 
16 tBu (115) NaOH 50% aq 5 5 p-xilene 120 75 50 
17 tBu (115) NaOH 50% aq 5 6 toluene/ 
DCM (9/1) 
120 60 61 
aIsolated yields: yields refer to complete conversion, unless otherwise stated. bDetermined by chiral 
HPLC. The absolute configuration was determined by comparison of the HPLC retention times and 
optical rotation with literature values. 79a cConversions were incomplete and reactions were stopped at 
the times reported. dThe reaction was performed at -20°C. e Toluene (1.6 mL) was used. 
 
Also in this case the role of macrocycle cavity size in the asymmetric induction was 
investigated and, for this purpose, the synthesis of a new chiral cyclooctapeptoid 
was performed on solid-phase system (scheme 2.15, 2.16). Moreover the synthesis 
of a cyclohexapeptoid containing two proline residues was done (scheme 2.13, 
2.14) to study the influence of catalyst’s symmetry.  
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Reagents and conditions: a) bromoacetic acid, DIPEA; b) RNH2; c) N-Fmoc-L-Proline, HATU; d) 20% 
piperidine/DMF; e) bromoacetic acid, DIC; f) HFIP/CH2Cl2 (1:4). DIPEA = N,N diisopropylethylamine; 




Scheme 2.13 Solid phase synthesis of linear hexapeptoids with two proline residues 
 
 
 126: 46% yield. 
 




 Reagents and conditions: a) bromoacetic acid, DIPEA; b) RNH2; c) N-Fmoc-L-Proline, HATU; d) 20% 
piperidine/DMF; e) bromoacetic acid, DIC; f) HFIP/CH2Cl2 (1:4). DIPEA = N,N diisopropylethylamine; 
DIC = N,N’-diisopropyl carbodiimide. 
 
Scheme 2.15 Solid phase synthesis of linear octapeptoids 
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 128: 41% yield. 
 
Scheme 2.16 Head-to-tail cyclization generating octapeptoid 
 
The screening was performed testing the cyclotetra, cyclohexa and 
cyclooctapeptoids with benzyl side chains, under the previously developed best 
conditions. In the figure below, are summarized all the cyclopeptoids previously 
synthetized and described, used in this investigation (figure 2.14).  
 
 
Figure 2.14 Chiral cyclopeptoids 
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Entry catalyst Time (h)  Yielda (%) eeb,c (%) 
1 94 24 83 44 
2 126 21 88 47 
3 128 23 67 19 
4d 128 24 30e 62 
aIsolated yiels. bDetermined by chiral HPLC. cThe absolute configuration was 
determined by comparison of the HPLC retention time and optical rotation with 
literature values.79a dThe reaction was performed in presence of solid 
KOH/toluene, 0°.eConversion was incomplete and the reaction was stopped at 
the time reported. 
 
 
Reduction or increase in the macrocyclic cavity size caused a lowering in the 
enantioselectivity (Table 2.13, entries 1,3). The bis-prolinated C2 symmetric 
cyclopeptoids showed a good catalytic activity, but the enantioselectivity was 
lower than the usual C3 symmetric analogue (Table 2.13, entry 2). 
Cyclooctapeptoid 126 was further tested in a biphasic system (solid KOH/toluene), 
considering its presumed ability in complexing larger K+ cation. Enantioselectivity 
was comparable with that exhibited by 80 (Table 2.12, entry 1) but the yield was 
very low. Moreover the catalytic activity of cyclotetrapeptoids, containing different 
aromatic side chains were tested and compared to the results obtained with the 
related cyclohexapeptoids. As previously observed cyclotetra-compounds 
catalyzed efficiently the reaction but affording lower ee (Table 2.14), so we 
decided to continue our investigation on the influence of substituents in the 
benzylic side chains of cyclohexapeptoids. 
The presence of p-substituents on the aromatic side chain of cyclohexapeptoids 
(OMe and CF3) gave comparable values of ee (Table 2.15, entries 2,5), while more 
substituted or more hindered benzyl side groups, as in 86, 87, 82 and 83, resulted 
in  drop of the ee values (Table 2.15, entries 3, 4, 6 and 7). However, a slight 
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improvement of the enantioselectivity was observed with p-CF3-benzylated 
cyclopeptoid 84, this was the catalyst employed with other substrates. 
 
Table 2.14 Screening of the cyclotetrapeptoids 94-98 
 
 
Entry catalyst Time (h)  Yielda (%) eeb,c (%) 
1 94 24 83 44 
2 95 20 64 33 
3 96 20 79 7 
3 97 18 87 10 
4 98 18 62 3 
aIsolated yiels. bDetermined by chiral HPLC. cThe absolute configuration was 
determined by comparison of the HPLC retention time and optical rotation with 
literature values.76a 
 
Table 2.15 Screening of the cyclohexapeptoids in asymmetric benzylation 
 
 
Entry catalyst Time (h) Yielda (%) eeb,c (%) 
1 80 20 76 62 
2 81 18 90 65 
3 82 20 69 47 
4 83 20 74 57 
5 84 18 67 66 
6 86 24 88 56 
7 87 20 69 56 
aIsolated yiels. bDetermined by chiral HPLC. CThe absolute configuration 
was determined by comparison of the HPLC retention time and optical 
rotation with literature values.79a 
 
2.5.3 Synthesis of 2-aryl-2-oxazoline-4-carboxylic acid esters 
 
With the purpose to investigate the steric and electronic effects of the phenyl ring 
in the oxazoline moiety, a small library of 2-aryl-2-oxazoline-4-carboxylic acid t-
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butyl ester was synthetized 129-133 (figure 2.15). 
 
 
Figure 2.15 2-aryl-2-oxazoline-4-carboxylic acid t-butyl esters tested as substrates 
 
The synthesis was realized in two steps: a reaction between HO-Ser-OtBu with aryl 
carboxylic acid, mediated by 1-ethyl-3-(3-dimethylaminopropil)carbodiimide 
(EDC) in presence of hydroxybenzotriazole (HOBt), followed by a cyclization 




Scheme 2.17 Synthesis of 2-aryl-2-oxazolines 129-133 
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2.5.4 Enantioselective alkylation of 2-aryl-2-oxazoline-4-carboxylic acid 
esters using cyclopeptoids.  
 
Once prepared, the different oxazoline t-butyl esters (129-133) were submitted to 
enantioselective alkylation catalyzed by 84 under the previously optimized 
reaction conditions. The best ee value was achieved with o-biphenyl-2-oxazoline-
4-carboxylic acid t-butyl ester like as in the Park’s work84 albeit the yield was 
lower (Table 2.16, entry 5) than those obtained with other substrates. It is 
interesting to observe that the presence of electron withdrawing group on the 
phenyl ring allowed to substantially reach the best ee value obtained with 133, 
ensuring a better yield (Table 2.16, entry 1). Subsequently, with the best substrate 
129 and catalyst 84 we decided to expand the scope of this reaction with different 
alkylating agents. The introduction of methyl groups in ortho or para position 
furnished comparable ee values (Table 2.17, entries 1, 2). The steric hindrance of a 
t-butyl or naphtyl group gave better ee values (Table 2.17, entries 3, 6). The 
presence of electron withdrawing group such as fluoride or chloride groups did 
not affect the enantioselectivities (Table 2.17, entries 4, 5). Lower level of ee was 
instead achieved with allyl bromide (Table 2.17, entry 7).  
α-Alkyl serines can be easily generated through the procedure described by 
Zervosen and coworkers.86 Using this methodology, which envisage the NaBH3CN 
reduction followed by hydrogenolysis of the benzyl amine residue (Scheme 2.19), 
we were able to confirm that 135 had the same (S) absolute configuration of the 
previously reported 120 (determined by comparison of the HPLC retention time 
and optical rotation with literature values): 81a both oxazolines afforded (S)-α-
benzyl serine t-butyl ester 147.  
 
 
Scheme 2.18 Synthesis of (S)- α -benzyl serine t-butyl ester  
 
                                                          
86. (a) T. Denoël, A. Zervosen, C. Lemaire, B. Joris, M. Hervé, D. Blanot, G. Zaragoza, A. Luxena, 
Org. Biomol. Chem. 2014, 12, 9853. (b) T. Denoël, A. Zervosen, C. Lemaire, A. Plenevaux, 
Luxena, Tetrahedron 2014, 70, 4526. 
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Table 2.16 Screening of 2-aryl-oxazoline t-butyl ester substrate promoted by 80 
 
 
Entry oxazoline Time (h)  product  Yielda (%) eeb,c (%) 
1 129 20 135 75 72 
2 130 21 136 67 62 
3 131 21 137 52 46 
4 132 21 138 64 62 
5 133 96 139 44 73 
aIsolated yiels. bDetermined by chiral HPLC.  
 
Table 2.17 Scope of phase-transfer alkylation of 129 promoted by 81 
 



































































19 55 48 
aIsolated yiels. bDetermined by chiral HPLC.  
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In conclusion, this work represents the first application of nonionic macrocycles 
systems in the efficient phase-transfer alkylation of oxazoline carboxylic esters. 
The enantiomeric excesses were moderate to good (67-75%). Anyway, since the 
previous results could be improved, this process can be considered as a new 
benchmark for the design and the application of different cyclopeptoidic phase-
trasfer catalysts.87  
 
2.5.5 A new library of chiral hexapeptoids containing different chiral 
residues. 
 
With the aim of further expand the diversity of this original macrocyclic catalysts, a 
small library of new chiral hexacyclopeptoids, containing different chiral proline 
analogs, was designed (figure 2.16). L-Pipecolic acid (148), L-t-butyl-
hydroxyproline (149), and L-thiazolidine-2-carboxilic acid (150), were used as 
monomers in place of L-Proline. The synthesis was realized following the 
previously described “sub-monomer/monomer solid phase approach” for the 
linear oligomer (scheme 2.2), followed by cyclization in high dilution conditions 
(scheme 2.3). The solid phase synthesis of 148, 149 and 150 was made using 
Fmoc-protected monomers. 
 
Yield: 148 3%, 149 27%, 150 21%. 
Figure 2.16 Novel chiral cyclohexapeptoids 
Preliminary results on their potential catalytic activity have been obtained in the 
enantioselective benzylation of 2-phenyl-2-oxazoline-4-carboxylic acid t-butyl 
                                                          
87. R. Schettini, A. D’Amato, F. De Riccardis, G. Della Sala, I. Izzo, Synthesis, 2016, eFirst, DOI: 
10.1055/s-0036-1588102. 
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ester (115). The reaction carried out with the catalyst 148 gave a racemic mixture 
(Table 2.18, entry 1). More interesting was the catalyst 149, with with L-t-butyl- 
hydroxyproline, which gave an ee comparable to the value achieved with the 
catalyst 80 (Table 2.18, entry 2). Finally, the presence of a sulfur atom in the five-
member ring, as in 150, had a drastic effect in the enantioselectivity of this 
reaction (Table 2.18, entry 3); in this case an inversion of configuration was 
observed. This preliminar screening indicated compound 149 as the most 
promising macrocycle. This structure, among other things, offer the possibility of 
different structural modification by deprotection of the L-t-butyl- hydroxyproline 
residues and subsequent functionalization, paving the way to the synthesis of new 
catalysts. 
Table 2.18 Asymmetric alkylation with new catalysts 
 
entry catalyst Time (h) Yielda (%) eeb,c (%) 
1 148 24 20 rac 
2 149 5 39 63 
3 150 5 68 17(R) 
aIsolated yiels. bDetermined by chiral HPLC. cThe absolute configuration 
was determined by comparison of the HPLC retention time and optical 
rotation with literature values.79a 
 
2.6 Conclusions  
In conclusion, the starting point of this PhD project was the first evidence that 
chiral cyclopeptoids are good phase-transfer catalysts in the alkylation reaction of 
glycine derivatives (figure 2.17).  
 
Figure 2.17 Enantioselective alkylation of N-(diphenyl-methylene)glycine t-butyl esters 
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Further studies in the alkylation reaction allowed to reach higher levels of 
enantioselectivity using N-(diphenylmethylene)glycine cumyl ester as the 
substrate (83-96% ee) and low catalyst loading. This work represents the first 
example of efficient macrocyclic neutral catalysts used in phase-transfer reactions. 
This result  becomes all the more relevant  if we take into account that 
cyclopeptoids can be prepared with a very convenient solid-phase synthesis in a 
modular approach which offers the opportunity to prepare differently decorated 
compounds in a very expeditious way. 
 
Figure 2.18 Enantioselective alkylation of N-(diphenylmethylene)-glycine cumyl ester 
 
Good enantioselectivity were also obtained in the asymmetric alkylation of 2-aryl-
2-oxazoline-4-carboxylic esters, affording synthetic precursors of α-alkyl serines 
(figure 2.19). This additional application confirms the potential of this type of 
compounds in asymmetric phase-transfer catalysis and suggests further uses in 
asymmetric organic synthesis. 
 
Figure 2.19 Enantioselective alkylation of 2-aryl-2-oxazolin-4-carboxylic esters 
 
up to 85 % yield
and 75 ee
(5 % mol), RBr
50% NaOH/toluene, 0  C
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Moreover different macrocycles, based on the calixarene scaffold, were also 
investigated. In collaboration with Neri’s group, the asymmetric alkylation of N-
(diphenyl-methylene)glycine t-butyl esters with chiral calixarenes (figure 2.20) 
was evaluated. Even if the enantiomeric excesses obtained were moderate, this is 
the first example employing metal-complexing calixarenes as asymmetric phase-
transfer catalysts. 
 
Figure 2.20 Enantioselective alkylation of N-(diphenyl-methylene)glycine t-butyl esters 
with chiral calixarene 
 
In summary, during this period, 19 novel chiral cyclopeptoids were synthetized 
and totally characterized with monodimensional and bidimensional spectroscopy.  
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Figure 2.21 Novel chiral cyclopeptoids 
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2.7 Experimental section 
2.7.1 General procedures 
 
Starting materials and reagents purchased from commercial suppliers were 
generally used without purification unless otherwise mentioned. Reaction 
temperatures were measured externally; reactions were monitored by analytical 
thin layer chromatography (TLC) on precoated silica gel plates (0.25 mm) and 
visualized by UV light. Flash chromatography was performed on silica gel 60 
(particle size: 0.040−0.063 mm) and the solvents employed were of analytical 
grade. Cyclopeptoids 94-98, 80-88, 126, 128, 148-150 were purified by reversed-
phase chromatography on C18 bonded silica (particle size 0.040−0.063 mm) and 
the purity grade were checked by HPLC analysis using a C18 reversed-phase 
analytical column (Bondapak, 10 μm, 125 Å, 3.9 mm × 300 mm) run with linear 
gradients of ACN (0.1% TFA) into H2O (0.1% TFA) over 30 min, at a flow rate of 1.0 
mL/min, with an UV detector set at 220 nm. Enantiomeric excesses of products 
56a-r, 100c, 102a-n, 140-146 were determined by chiral HPLC using Chiralcel 
OD-H columns with an UV detector set at 260 nm. All ultraviolet (UV) 
measurements were made at 24−26 °C, using spectrophotometric grade solvents. 
Low-resolution ESI-MS analysis in positive ion mode were performed using a Bio-Q 
triple quadrupole mass spectrometer equipped with an electrospray ion source. 
High resolution mass spectra (HRMS) in positive ion mode were recorded on a 
Fourier transform ion cyclotron resonance mass spectrometer (FTICR-MS) using 
electrospray ionization (ESI). Optical rotation values were measured at λ = 589 nm, 
corresponding to the sodium D line, at the temperatures indicated. 1H NMR and 13C 
spectra were recorded on a 600 MHz, 400 and 300 MHz instruments. Chemical 
shifts (δ) are reported in ppm relative to the residual solvent peak (CHCl3, δ = 7.26; 
13CDCl3, δ = 77.0; 1H-DMSO-d6, δ = 2.50; 13C-DMSO-d6, δ = 39.5) and the multiplicity 
of each signal is designated by the following abbreviations: s, singlet; d, doublet; t, 
triplet; m, multiplet; bs, broad singlet; bd, broad doublet. Coupling constants (J) are 
quoted in Hertz. COSY and ROESY spectra of compound 98 were measured on a 
600 MHz instrument.  
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2.7.2 Mixed monomer/submonomer solid-phase synthesis of tetra linear 
precursors 
 
Linear peptoids 89-93 were synthesized by alternating submonomer solid-phase 
method using standard manual Fmoc solid-phase peptide synthesis protocols. 
Typically 0.40 g of 2-chlorotrityl chloride resin (2, α-dichlorobenzhydryl-
polystyrene cross-linked with 1% DVB; 100−200 mesh; 1.20 mmol/g) was swelled 
in dry DCM (4 mL) for 45 min and washed twice in dry DCM (3 mL). Bromoacetic 
acid (107 mg, 0.77 mmol) and DIPEA (310 mg, 2.4 mmol) in dry DCM (4 mL) were 
added to the resin and the vessel was stirred on a shaker platform for 40 min at 
room temperature, and then washed with dry DCM (3 × 4 mL) and then with DMF 
(3 × 4 mL). Then the arylmethylamine (4.80 mmol) in dry DMF (4 mL) was added 
to the bromoacetylated resin. The mixture was left on a shaker platform for 40 min 
at room temperature, then the resin was washed with DMF (3 × 4 mL). The resin 
was incubated with a solution of N-Fmoc-L-Proline (486 mg, 1.44 mmol), HATU 
(529 mg, 1.39 mmol) and DIPEA (248 mg, 1.92 mmol) in dry DMF (4 mL) on a 
shaker platform for 1 h, followed by extensive washes with DMF (3 × 4 mL), DCM 
(3 × 4 mL) and DMF (3 × 4 mL). Chloranil test was performed and once the 
coupling was complete the Fmoc group was deprotected by sequential additions of 
two aliquots of 20% piperidine/DMF (v/v, 3 mL), stirring on a shaker platform for 
3 and 7 min respectively, followed by extensive washes with DMF (3 × 3 mL), DCM 
(3 × 3 mL) and DMF (3 × 3 mL). Subsequent bromoacetylation reactions were 
accomplished by reacting the oligomer with a solution of bromoacetic acid (690 
mg, 4.8 mmol) and DIC (666 mg, 5.28 mmol) in DMF (4 mL), stirring on a shaker 
platform for 40 min at room temperature. Then, reaction with arylmethylamine, 
with N-Fmoc-L-Proline, Fmoc deprotection and bromoacetylation steps were 
repeated as described above. Generally, addition of the proline at the fourth 
position required longer reaction time (3 h). The synthesis was stopped for the 
tetramer. The oligomer-resin was cleaved by treatment with three aliquots of a 
solution of 20% HFIP in DCM (v/v; 3 × 4 mL), with stirring each time on a shaker 
platform for 30 min  at room temperature, and filtering the resin away after each 
treatment. The combined filtrates were concentrated in vacuo. The final product 
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was analyzed by ESI mass spectrometry and RP-HPLC and used for the cyclization 
step without further purification. 
2.7.3 Mixed monomer/submonomer solid-phase synthesis of hexa linear 
precursors 
 
Linear peptoids 71-79 were synthesized by alternating submonomer solid-phase 
method using standard manual Fmoc solid-phase peptide synthesis protocols as 
described in section 2.8.1. The synthesis proceeded until the desired hexaoligomer 
was obtained before the cleavage treatment.  
The synthesis of the linear hexapeptoid 125 required a different solid-phase 
scheme. Linear peptoid was synthesized by alternating submonomer solid-phase 
method using standard manual Fmoc solid-phase peptide synthesis protocols. 0.20 
g of 2-chlorotrityl chloride resin (Novabiochem; 2,α-dichlorobenzhydryl-
polystyrene crosslinked with 1% DVB; 100-200 mesh; 1.63 mmol/g) was swelled 
in dry DCM (2 mL) for 45 min and washed twice in dry DCM (2 mL). Bromoacetic 
acid (72 mg, 0.52 mmol) and DIPEA (207 mg, 1.6 mmol) in dry DCM (2 mL) were 
added to the resin and the vessel was stirred on a shaker platform for 40 min at 
room temperature, and then washed with dry DCM (3 × 4 mL) and then with DMF 
(3 × 4 mL). Then the benzylamine (349 mg, 3.26 mmol) in dry DMF (2 mL) was 
added to the bromoacetylated resin. The mixture was left on a shaker platform for 
40 min at room temperature, then the resin was washed with DMF (3 × 2 mL), 
DCM (3 × 2 mL) and then with DMF (3 × 2 mL). The resin was incubated with a 
solution of N-Fmoc-L-Proline (330 mg, 0.98 mmol), HATU (361 mg, 0.95 mmol) 
and DIPEA (168 mg, 1.30 mmol) in dry DMF (2 mL) on a shaker platform for 1 h, 
followed by extensive washes with DMF (3 × 2 mL), DCM (3 × 2 mL) and DMF (3 × 
2 mL). Chloranil test was performed and once the coupling was complete the Fmoc 
group was deprotected by sequential additions of two aliquots of 20% 
piperidine/DMF (v/v, 2 mL), stirring on a shaker platform for 3 and 7 min 
respectively, followed by extensive washes with DMF (3 × 2 mL), DCM (3 × 2 mL) 
and DMF (3 × 2 mL). Subsequent bromoacetylation reactions were accomplished 
by reacting the oligomer with a solution of bromoacetic acid (453 mg, 3.26 mmol) 
and DIC (453 mg, 3.59 mmol) in DMF (2 mL), stirring on a shaker platform for 40 
min at room temperature. Then, reaction with benzylamine, bromoacetylation step 
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and again reaction with benzylamine were repeated, followed by the reaction with 
N-Fmoc-L-Proline and Fmoc deprotection. The addition of this proline residue 
required longer reaction time (3 h). Then bromoacetylation step and reaction with 
benzylamine were repeated as described above. The oligomer-resin was cleaved 
by treatment with three aliquots of a solution of 20% HFIP in DCM (v/v; 3 × 2 mL), 
with stirring each time on a shaker platform for 30 min at room temperature, and 
filtering the resin away after each treatment. The combined filtrates were 
concentrated in vacuo. The final product was analyzed by ESI mass spectrometry 
and RP-HPLC and used for the cyclization step without further purification.  
 
2.7.4 Mixed monomer/submonomer solid-phase synthesis of octa linear 
precursors 
 
Linear peptoid 127 was synthesized by alternating submonomer solid-phase 
method using standard manual Fmoc solid-phase peptide synthesis protocols. 0.20 
g of 2-chlorotrityl chloride resin (Novabiochem; 2,α-dichlorobenzhydryl-
polystyrene crosslinked with 1% DVB; 100-200 mesh; 1.63 mmol/g) was swelled 
in dry DCM (2 mL) for 45 min and washed twice in dry DCM (2 mL). Bromoacetic 
acid (72 mg, 0.52 mmol) and DIPEA (207 mg, 1.6 mmol) in dry DCM (2 mL) were 
added to the resin and the vessel was stirred on a shaker platform for 40 min at 
room temperature, and then washed with dry DCM (3 × 4 mL) and then with DMF 
(3 × 4 mL). Then benzylamine (349 mg, 3.26 mmol) in dry DMF (2 mL) was added 
to the bromoacetylated resin. The mixture was left on a shaker platform for 40 min 
at room temperature, then the resin was washed with DMF (3 × 2 mL), DCM (3 × 2 
mL) and then with DMF (3 × 2 mL). The resin was incubated with a solution of N-
Fmoc-L-Proline (330 mg, 0.98 mmol), HATU (361 mg, 0.95 mmol) and DIPEA (168 
mg, 1.30 mmol) in dry DMF (2 mL) on a shaker platform for 1 h, followed by 
extensive washes with DMF (3 × 2 mL), DCM (3 × 2 mL) and DMF (3 × 2 mL). 
Chloranil test was performed and once the coupling was complete the Fmoc group 
was deprotected by sequential additions of two aliquots of 20% piperidine/DMF 
(v/v, 2 mL), stirring on a shaker platform for 3 and 7 min respectively, followed by 
extensive washes with DMF (3 × 2 mL), DCM (3 × 2 mL) and DMF (3 × 2 mL). 
Subsequent bromoacetylation reactions were accomplished by reacting the 
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oligomer with a solution of bromoacetic acid (453 mg, 3.26 mmol) and DIC (453 
mg, 3.59 mmol) in DMF (2 mL), stirring on a shaker platform for 40 min at room 
temperature. Then, reaction with benzylamine, with N-Fmoc-L-Proline, Fmoc 
deprotection and bromoacetylation steps were repeated twice as described above. 
Subsequently, a further sequence consisting of reaction with benzylamine, with N-
Fmoc-L-Proline and Fmoc deprotection was effected. The addition of the proline at 
the fourth, sixth and eighth positions required longer reaction time (3 h). The 
oligomer-resin was finally cleaved by treatment with three aliquots of a solution of 
20% HFIP in DCM (v/v; 3 × 2 mL), with stirring each time on a shaker platform for 
30 min at room temperature, and filtering the resin away after each treatment. The 
combined filtrates were concentrated in vacuo. The final product was analyzed by 
ESI mass spectrometry and RP-HPLC and used for the cyclization step without 
further purification. 
 
2.7.5 Mixed monomer/submonomer solid-phase synthesis of linear 
precursor 101 
 
0.40 g of 2-chlorotrityl chloride resin (Fluka; 2, α-dichlorobenzhydryl-polystyrene 
cross-linked with 1% DVB; 100−200 mesh; 1.20 mmol/g) was swelled in dry DCM 
(4 mL) for 45 min and washed twice in dry DCM (3 mL). Bromoacetic acid (107 mg, 
0.77 mmol) and DIPEA (310 mg, 2.4 mmol) in dry DCM (4 mL) were added to the 
resin and the vessel was stirred on a shaker platform for 40 min at room 
temperature, and then washed with dry DCM (3 × 4 mL) and then with DMF (3 × 4 
mL). Then benzylamine (514 mg, 4.80 mmol) in dry DMF (4 mL) was added to the 
bromoacetylated resin. The mixture was left on a shaker platform for 40 min at 
room temperature, then the resin was washed with DMF (3 × 4 mL). The resin was 
incubated with a solution of N-Fmoc-L-Proline (485 mg, 1.44 mmol), HATU (529 
mg, 1.39 mmol), DIPEA (248 mg, 1.92 mmol) in dry DMF (4 mL) on a shaker 
platform for 1 h, followed by extensive washes with DMF (3 × 4 mL), DCM (3 × 4 
mL) and DMF (3 × 4 mL). Chloranil test was performed and once the coupling was 
complete the Fmoc group was deprotected by sequential additions of two aliquots 
of 20% piperidine/DMF (v/v, 3 mL), stirring on a shaker platform for 3 and 7 min 
respectively, followed by extensive washes with DMF (3 × 3 mL), DCM (3 × 3 mL) 
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and DMF (3 × 3 mL). Subsequent bromoacetylation reaction was accomplished by 
reacting the oligomer with a solution of bromoacetic acid (690 mg, 4.8 mmol) and 
DIC (666 mg, 5.28 mmol) in DMF (4 mL), stirring on a shaker platform for 40 min 
at room temperature. Then, reaction with benzylamine, with N-Fmoc-L-Proline, 
Fmoc deprotection and bromoacetylation steps were repeated as described above. 
Addition of the proline at the fourth position required longer reaction time (3 h). A 
solution of N-Boc-L-Proline (310 mg, 1.44 mmol), HATU (529 mg, 1.39 mmol) and 
DIPEA (248 mg, 1.92 mmol) in dry DMF (4 mL) was added, stirring on a shaker 
platform for 3 h, followed by extensive washes with DMF (3 × 4 mL), DCM (3 × 4 
mL) and DMF (3 × 4 mL). The oligomer-resin was cleaved by treatment with three 
aliquots of a solution of 20% HFIP in DCM (v/v; 3 × 4 mL), with stirring each time 
on a shaker platform for 30 min at room temperature, and filtering the resin away 
after each treatment. The combined filtrates were concentrated in vacuo. The 
residue (25.3 mg, 0.030 mmol) was dissolved in in DCM (0.9 mL), then EDC (11.5 
mg, 0.060 mmol), HOBt (8.0 mg, 0.060 mmol), DIPEA (7.8 mg, 0.060 mmol) and 
diethylamine (4.4 mg, 0.060 mmol) were added, and the solution was stirred 
overnight. The reaction mixture was diluted with DCM (2 × 4 mL) and water (2 
mL), and the combined organic layers were washed with HCl 1 M (2 mL), dried 
over Na2SO4, filtered, and concentrated in vacuo. The crude residue was purified by 
HPLC semipreparative column (Waters, Bondapak, 10 μm, 125 Å, 7.8 × 300 mm) 
affording peptoid 101. 
 
2.7.6 General procedure for high dilution cyclization 
 
To a stirred solution of HATU (178 mg, 0.47 mmol), DIPEA (93.0 mg, 0.72 mmol) in 
dry DMF (30 mL) at room temperature, a solution of linear precursors (0.12 mmol) 
in dry DMF (10 mL) was added by syringe pump during 6 h. After 18 h the 
resulting mixture was concentrated in vacuo, diluted with DCM (20 mL) and 
washed with 1M HCl (3 × 7 mL). The mixture was extracted with DCM (2 × 10 mL) 
and the combined organic phases were washed three times with water (10 mL), 
dried (MgSO4) and concentrated in vacuo. The crude residues were purified by 
reversedphase chromatography on C18 bonded silica.  
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Linear acyclic peptoid 101 
 
13.5 mg, 67% yield, white amorphous solid; [α]D19 −6.0 (c = 0.8, CHCl3); 
RP-HPLC analysis: Bondapak, 5% B in A → 100% B in 30 min (A: 0.1% TFA in 
water, B: 0.1% TFA in acetonitrile), 1.0 mL/min, 220 nm, tr 15.1 min.; 1H NMR 
(400 MHz, CDCl3, mixture of rotamers) δ 7.46−7.27 (m, 15H), 5.45−3.07 (m, 28H), 
2.40−1.68 (m, 9H), 1.45 (s, 9H), 1.09 (m, 6H); 13C NMR (150 MHz, CDCl3, mixture of 
rotamers, broad signals) δ 174.0, 173.4, 172.3, 169.8, 166.9, 166.7, 160.4, 160.2, 
159.9, 154.6, 154.3, 153.6, 136.8, 136.6, 135.7, 135.4, 129.2, 128.9, 128.8, 128.6, 
127.9, 127.8, 127.4, 116.5, 114.6, 80.1, 79.8, 79.5, 58.2, 57.5, 57.0, 55.9, 51.9, 50.8, 
49.2, 48.1, 47.4, 46.7, 46.1, 41.3, 40.7, 31.6, 31.2, 30.8, 30.4, 29.8, 29.4, 28.5, 28.4, 
25.1, 24.6, 13.9, 12.9; MS (ESI) [M + Na]+ 929.0; HRMS (FTICR) [M + H]+ calcd for 




10.2 mg, 19% yield, white amorphous solid; [α]D25 −113.5 (c = 1.0, CHCl3);  
RP-HPLC analysis: Bondapak, 5% B in A → 100% B in 30 min (A: 0.1% TFA in 
water, B: 0.1% TFA in acetonitrile), 1.0 mL/min, 220 nm, tr 10.3 min.; 1H NMR 
(400 MHz, CDCl3) δ 7.29 (m, 10H), 5.36 (d, J = 15.0 Hz, 2H), 5.06 (d, J = 7.9 Hz, 2H), 
4.36 (d, J = 14.6 Hz, 2H), 3.87 (m, 2H), 3.76 (d, J = 14.6 Hz, 2H), 3.74 (m, 2H), 3.51 
(d, J = 15.0 Hz, 2H), 2.23−1.81 (m, 8H); 13C NMR (100 MHz, CDCl3) δ 169.1 ( × 2), 
165.9 ( × 2), 136.0 ( × 2), 128.9 ( × 4), 128.7 ( × 4), 127.6 ( × 2), 57.1 ( × 2), 50.7 ( × 
2), 47.9 ( × 2), 47.5( × 2), 30.8 ( × 2), 21.7 ( × 2); MS (ESI) [M + H]+ 489.6; HRMS 
(FTICR) [M + H]+ calcd for C28H33N4O4 489.2496, found 489.2501. 
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8.2 mg, 11% yield, white amorphous solid; [α]D20 −211.5 (c = 0.9, CHCl3);  
RP-HPLC analysis: Bondapak, 5% B in A → 100% B in 30 min (A: 0.1% TFA in 
water, B: 0.1% TFA in acetonitrile), 1.0 mL/min, 220 nm, tr 14.3 min.; 1H NMR 
(400 MHz, CDCl3) δ 7.39 (m, 4H), 7.16 (m, 2H), 5.22 (d, J = 15.0 Hz, 2H), 4.97 (d, J = 
8.2 Hz, 2H), 4.32 (d, J = 15.0 Hz, 2H), 3.85 (m, 2H), 3.72 (m, 2H), 3.71 (d, J = 15.0 Hz, 
2H), 3.46 (d, J = 15.0 Hz, 2H), 2.24 (m, 6H), 1.78 (m, 2H); 13C NMR (100 MHz, 
CDCl3) δ 169.2 ( × 2), 165.1 ( × 2), 136.0 ( × 2), 132.7 ( × 2), 132.0 ( × 2), 130.8 ( × 
2), 130.7 ( × 2), 128.5 ( × 2), 57.1 ( × 2), 50.8 ( × 2), 47.8 ( × 2), 46.4 ( × 2), 30.9 ( × 
2), 21.7 ( × 2); MS (ESI) [M + Na]+ 647.4; HRMS (FTICR) [M + H]+ calcd for 





45.3 mg, 62% yield, white amorphous solid; [α]D25 −149.2 (c = 1.0, CHCl3);  
RP-HPLC analysis: Bondapak, 5% B in A → 100% B in 30 min (A: 0.1% TFA in 
water, B: 0.1% TFA in acetonitrile), 1.0 mL/min, 220 nm, tr 11.8 min.; 1H NMR 
(300 MHz, CDCl3) δ 6.44 (m, 4H), 6.34 (m, 2H), 5.27 (d, J = 14.9 Hz, 2H), 5.12 (d, J = 
8.2 Hz, 2H), 4.42 (d, J = 14.8 Hz, 2H), 3.92−3.60 (m, 6 H), 3.73 (m, 12H), 3.42 (d, J = 
14.9 Hz, 2H), 2.26−1.75 (m, 8H); 13C NMR (75 MHz, CDCl3) δ 169.5 ( × 2), 165.9 ( × 
2), 160.8 ( × 4), 138.4 ( × 2), 106.2 ( × 4), 99.9 ( × 2), 57.1 ( × 2), 55.2 ( × 12), 50.7 ( 
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× 2), 47.8 ( × 2), 47.5( × 2), 30.7 ( × 2), 21.6 ( × 2); MS (ESI) [M + H]+ 609.3; HRMS 




8.9 mg, 13% yield, white amorphous solid; [α]D20 −3.1 (c = 0.5, CHCl3);  
RP-HPLC analysis: Bondapak, 5% B in A → 100% B in 30 min (A: 0.1% TFA in 
water, B: 0.1% TFA in acetonitrile), 1.0 mL/min, 220 nm, tr 14.8 min.; 1H NMR 
(600 MHz, DMSO-d6) δ 6.79 (s, 4H), 5.48 (d, J = 9.0 Hz, 2H), 5.20 (d, J = 15.6 Hz, 
2H), 4.50 (d, J = 15.6 Hz, 2H), 3.96 (d, J = 15.6 Hz, 2H), 3.55 (m, 4H), 3.45 (m, 2H), 
3.17 (d, J = 15.6 Hz, 2H), 2.21 (s, 18H), 1.89 (m,4H), 1.78 (m, 2H); 13C NMR (100 
MHz, DMSO-d6) δ 169.2 ( × 2), 166.4 ( × 2), 137.6 ( × 4), 136.1 ( × 2), 128.9 ( × 4), 
128.3 ( × 2), 57.1 ( × 2), 49.9 ( × 2), 47.8 ( × 2), 30.9 ( × 2), 21.8 ( × 2), 20.5 ( × 2), 
19.5 ( × 6); MS (ESI) [M + H]+ 573.7; HRMS (FTICR) [M + H]+ calcd for C34H45N4O4 





17.9 mg, 27% yield, white amorphous solid; [α]D25 −108.6 (c = 1.0, CHCl3);  
RP-HPLC analysis: Bondapak, 5% B in A → 100% B in 30 min (A: 0.1% TFA in 
water, B: 0.1% TFA in acetonitrile), 1.0 mL/min, 220 nm, tr 12.8 min.; 1H NMR (600 
MHz, DMSO-d6) δ: 6.88 (s, 2H), 6.73 (s, 4H), 5.53 (d, J = 9.0 Hz, 2H), 4.96 (d, J = 15.3 
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Hz, 2H), 4.68 (d, J = 15.0 Hz, 2H), 3.56 (m, 4H), 3.45 (d, J = 15.0 Hz, 2H), 3.25 (d, J = 
15.3 Hz, 2H), 2.25 (m, 14H), 1.92 (m, 4H), 1.73 (m, 2H); 13C NMR (150 MHz, DMSO-
d6,) δ 170.1 ( × 2), 165.7 ( × 2), 137.5 ( × 2), 128.0 ( × 2), 127.8 ( × 2), 127.6 ( × 2), 
125.4 ( × 4), 56.2 ( × 2), 50.8 ( × 2), 47.3 ( × 2), 46.3 ( × 2), 30.4 ( × 2), 21.4 ( × 2), 
20.9 ( × 4); MS (ESI) [M + H]+ 545.7, [M + Na]+ 567.7; HRMS (FTICR) [M + H]+ calcd 
for C32H41N4O4 545.3122, found 545.3134. 
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43.0 mg, 49% yield, white amorphous solid; [α]D25 + 25.5 (c = 1.0, CHCl3);  
RP-HPLC analysis: Bondapak, 5% B in A → 100% B in 30 min (A: 0.1% TFA in 
water, B: 0.1% TFA in acetonitrile), 1.0 mL/min, 220 nm, tr 14.8 min.; 1H NMR 
(400 MHz, CDCl3, mixture of rotamers) δ 7.69−6.85 (m, 15H), 5.98−3.04 (m, 21H), 
2.59−1.26 (m, 12H); 13C NMR (100 MHz, CDCl3, mixture of rotamers, broad signals) 
δ 174.0, 173.8, 173.2, 172.7, 172.6, 172.2, 171.9, 170.9, 169.9, 168.9, 168.4, 168.1, 
167.9, 167.7, 167.3, 167.1, 166.8, 166.7, 165.4, 137.0, 136.7, 136.6, 136.5, 136.4, 
136.2, 136.1, 135.7, 129.3, 129.0, 128.7, 128.5, 128.4, 128.3, 128.2, 128.0, 127.8, 
127.7, 127.6, 127.5, 127.3, 127.1, 126.9, 126.7, 126.6, 126.4, 126.2, 58.9, 58.8, 57.9, 
57.8, 57.3, 56.7, 56.5, 56.1, 53.6, 53.3, 53.1, 53.0, 52.3, 51.7, 51.4, 50.8, 50.1, 50.0, 
49.9, 49.8, 49.4, 49.1, 48.8, 48.4, 48.1, 47.8, 47.7, 47.6, 47.4, 47.1, 46.9, 46.8, 46.4, 
46.3, 46.2, 32.2, 32.0, 31. 9, 31.4, 31.3, 29.9, 29.6, 29.4, 29.2, 28.9, 28.6, 28.2, 25.9, 
25.4, 25.2, 25.0, 24.8, 24.6, 22.7, 22.6, 22.0, 21.6 ; MS (ESI) [M + Na]+ 755.2; HRMS 




20.2 mg, 18% yield, white amorphous solid; [α]D25 + 28.6 (c = 1.0, CHCl3);  
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RP-HPLC analysis: Bondapak, 5% B in A → 100% B in 30 min (A: 0.1% TFA in 
water, B: 0.1% TFA in acetonitrile), 1.0 mL/min, 220 nm, tr 17.5 min.; 1H NMR 
(400 MHz, CDCl3, mixture of rotamers) δ 7.78−7.26 (m, 12H), 5.90−2.85 (m, 21H), 
2.35−1.00 (m, 12H); 13C NMR (150 MHz, CDCl3, mixture of rotamers, broad signals) 
δ 174.4, 173.9, 173.8, 173.6, 173.5, 172.9, 172.4, 172.1, 171.9, 171.5, 171.0, 169.9, 
169.8, 169.7, 169.2, 168.8, 168.5, 168.2, 167.7, 167.0, 166.8, 166.6, 166.3, 165.9, 
165.6, 165.3, 141.5, 141.3, 141.1, 140.9, 140.5, 140.1, 139.8, 139.6, 139.1, 130.8, 
130.3, 130.0, 129.7, 129.4, 129.2, 128.5, 128.3, 127.9, 127.7, 127.4, 127.1, 126.9, 
126.7, 126.5, 126.0, 125.6, 125.5, 125.3, 122.5, 59.5, 58.9, 57.7, 57.5, 57.3, 56.6, 
56.5, 56.2, 53.3, 53.2, 52.7, 52.3, 51.8, 51.7, 51.5, 51.0, 50.7, 50.5, 50.6, 50.4, 49.8, 
49.6, 49.3, 49.0, 48.8, 48.4, 48.3, 48.1, 47.8, 47.6, 47.4, 47.2, 46.9, 46.6, 46.5, 46.3, 
37.4, 32.7, 32.1, 31.9, 31.6, 31.4, 30.3, 30.0, 29.3, 28.9, 28.7, 28.3, 27.8, 27.3, 27.1, 
26.3, 25.9, 25.6, 25.4, 25.2, 25.0, 24.8, 23.0, 22.9, 22.6, 22.1, 21.6, 21.1, 19.7; MS 
(ESI) [M + K]+ 975.0; HRMS (FTICR) [M + H]+ calcd for C45H46F9N6O6 937.3329, 





31.4 mg, 23% yield, white amorphous solid; [α]D25 + 22.9 (c = 1.0, CHCl3);  
RP-HPLC analysis: Bondapak, 5% B in A → 100% B in 30 min (A: 0.1% TFA in 
water, B: 0.1% TFA in acetonitrile), 1.0 mL/min, 220 nm, tr 19.0 min.; 1H NMR 
(400 MHz, CDCl3, mixture of rotamers) δ 8.17−7.56 (m, 9H), 5.73−2.79 (m, 21H), 
2.34−1.03 (m, 12H); 13C NMR (150 MHz, CDCl3, mixture of rotamers, broad signals) 
δ 174.4, 173.7, 172.8, 172.4, 169.9, 169.7, 168.4, 168.2, 167.4, 168.2, 167.4, 166.3, 
166.1, 139.6, 139.1, 138.3, 133.0, 132.7, 132.4, 132.1, 131.8, 131.5, 128.5, 128.3, 
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127.5, 127.2, 127.0, 126.5, 124.6, 124.5, 124.3, 122.2, 121.9, 121.6, 121.4, 119.2, 
118.9, 116.6, 113.7, 59.6, 58.0, 57.8, 57.8, 56.6, 56.3, 53.4, 53.1, 52.4, 52.0, 51.9, 
50.7, 50.4, 49.8, 49.2, 48.8, 48.5, 47.6, 46.9, 46.8, 46.6, 37.4, 37.1, 32.7, 31.9, 31.6, 
31.3, 30.0, 29.5, 29.3, 28.5, 27.8, 27.6, 27.3, 27.0, 25.5, 25.4, 25.1, 24.4, 22.8, 22.7, 
20.8, 19.7; MS (ESI) [M + H]+ 1141.0; HRMS (FTICR) [M + H]+ calcd for 
C48H43F18N6O6 1141.2951, found 1141.2972. 
 
 Cyclohexapeptoid 83 
 
 
23.3 mg, 22% yield, white amorphous solid; [α]D25 +8.3 (c = 0.9, CHCl3);  
RP-HPLC analysis: Bondapak, 5% B inA → 100% B in 30 min (A: 0.1% TFA in 
water, B: 0.1% TFA in acetonitrile), 1.0 mL/min, 220 nm, tr 17.4 min.; 1H NMR 
(400 MHz, CDCl3, mixture of rotamers) δ 8.30−6.96 (m, 21H), 6.10−3.10 (m, 21H), 
2.74−1.26 (m, 12H); 13C NMR (100 MHz, CDCl3, mixture of rotamers, broad signals) 
δ 175.5, 174.4, 173.7, 173.4, 173.2, 173.0, 172.2, 172.1, 171.8, 171.4, 169.9, 169.8, 
169.1, 168.9, 168.5, 168.3, 168.0, 167.6, 166.9, 166.1, 166.0, 165.8, 133.8, 133.7, 
133.0, 132.6, 132.5, 132.3, 132.1, 131.9, 131.7, 131.5, 131.3, 131.2, 131.0, 130.9, 
130.8, 130.6, 130.3, 129.2, 129.0, 128.7, 128.4, 128.3, 128.2, 127.8, 127.6, 127.0, 
126.8, 126.6, 126.3, 125.9, 125.6, 125.4, 125.3, 125.2, 124.4, 123.6, 123.5, 123.1, 
122.9, 122.6, 122.5, 122.3, 121.7, 59.0, 58.9, 58.6, 57.9, 57.8, 57.4, 57.3, 56.9, 56.7, 
56.6, 56.1, 55.8, 51.6, 51.5, 51.1, 50.7, 50.5, 50.1, 50.0, 49.3, 48.9, 48.7, 48.5, 47.9, 
47.6, 47.5, 47.3, 47.2, 46.8, 46.6, 46.4, 46.2, 45.6, 32.0, 31.9, 31.6, 31.3, 31.2, 31.1, 
30.0, 29.3, 29.1, 28.7, 28.3, 27.5, 27.3, 27.1, 25.8, 25.4, 25.2, 25.1, 24.8, 23.2, 23.0, 
22.6, 22.1, 21.4, 20.6, 20.1, 19.7; MS (ESI) [M + Na]+ 905.4; HRMS (FTICR) [M + H]+ 
calcd for C54H55N6O6 883.4178, found 883.4152. 
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60.4 mg, 57% yield, white amorphous solid; [α]D25 + 30.8 (c = 1.0, CHCl3); RP-HPLC 
analysis: Bondapak, 5% B in A → 100% B in 30 min (A: 0.1% TFA in water, B: 0.1% 
TFA in acetonitrile), 1.0 mL/min, 220 nm, tr 14.1 min.; 1H NMR (300 MHz, CDCl3, 
mixture of rotamers) δ 7.53−6.59 (m, 12H), 5.26−3.16 (m, 30H), 2.52−1.21 (m, 
12H); 13C NMR (100 MHz, CDCl3, mixture of rotamers, broad signals) δ 173.3, 
173.2, 172.5, 171.9, 171.8, 171.6, 171.0, 169.8, 168.5, 168.3, 168.0, 167.3, 167.1, 
166.9, 166.8, 165.6, 159.4, 159.2, 159.0, 158.7, 129.9, 129.5, 129.2, 129.0, 128.9, 
128.7, 128.4, 128.3, 128.1, 127.9, 127.7, 114.4, 114.3, 114.2, 114.1, 113.9, 113.7, 
58.7, 58.5, 58.2, 57.8, 57.6, 57.3, 57.0, 56.7, 56.2, 56.1, 55.7, 55.3, 55.1, 53.0, 52.6, 
52.5, 52.3, 51.2, 50.8, 50.4, 50.3, 49.5, 49.2, 48.7, 48.4, 47.9, 47.7, 47.5, 47.4, 47.2, 
46.7, 46.5, 46.4, 46.2, 37.4, 37.0, 36.8, 32.7, 32.0, 31.9, 31.6, 31.5, 31.4, 31.2, 30.2, 
30.0, 29.3, 29.2, 28.9, 28.2, 27.7, 27.5, 27.3, 27.0, 25.7, 25.4, 24.9, 24.8, 24.4, 22.9, 
22.6, 22.1, 21.7, 21.3, 21.1, 20.5, 20.3, 19.7; MS (ESI) [M + H]+ 823.4, [M + Na]+ 
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42.1 mg, 43% yield, white amorphous solid; [α]D25 + 9.9 (c = 0.3, CHCl3);  
RP-HPLC analysis: Bondapak, 5% B in A → 100% B in 30 min (A: 0.1% TFA in 
water, B: 0.1% TFA in acetonitrile), 1.0 mL/min, 220 nm, tr 17.2 min.; 1H NMR 
(400 MHz, CDCl3, mixture of rotamers) δ 7.20−6.72 (m, 9H), 5.75−3.22 (m, 21H), 
2.66−0.94 (m, 30H); 13C NMR (100 MHz, CDCl3, mixture of rotamers, broad signals) 
δ 173.9, 173.4, 172.6, 171.9, 171.6, 171.5, 168.5, 168.3, 167.6, 167.4, 166.1, 165.8, 
138.8, 138.7, 138.6, 138.3, 138.1, 137.8, 136.9, 136.8, 135.9, 129.5, 129.3, 129.1, 
128.6, 126.3, 125.9, 125.5, 125.0, 124.5, 124.4, 124.2, 58.4, 58.1, 57.5, 56.8, 56.1, 
53.6, 53.0, 52.8, 52.0, 51.3, 50.5, 50.1, 48.8, 48.1, 47.9, 47.6, 47.1, 46.7, 46.4, 46.2, 
37.4, 37.1, 32.8, 32.2, 31.9, 31.4, 30.0, 29.7, 29.4, 29.2, 28.3, 27.4, 25.0, 24.9, 24.8, 
23.0, 22.7, 22.0, 21.7, 21.4, 20.9, 19.7, 18.3; MS (ESI) [M + H]+ 817.0; HRMS (FTICR) 




21.9 mg, 20% yield, white amorphous solid; [α]D25 + 6.5 (c = 1.0, CHCl3);  
RP-HPLC analysis: Bondapak, 5% B inA → 100% B in 30 min (A: 0.1% TFA in 
water, B: 0.1% TFA inacetonitrile), 1.0 mL/min, 220 nm, tr 13.5 min.; 1H NMR (300 
MHz,CDCl3, mixture of rotamers) δ 6.75−6.10 (m, 9H), 5.31−3.94 (m,9H), 3.63 (bs, 
18H), 3.70−3.20 (m, 12H), 2.01−1.65 (m, 12H); 13CNMR (100 MHz, CDCl3, mixture 
of rotamers, broad signals) δ 173.4,172.3, 171.9, 171.3, 169.8, 168.4, 167.9, 166.9, 
161.2, 160.9, 160.7,139.1, 138.8, 106.2, 105.9, 105.4, 105.0, 104.5, 104.2, 103.5, 
100.2,100.0, 99.6, 99.3, 58.6, 57.6, 56.7, 55.3, 55.1, 54.9, 53.2, 52.8, 52.4,52.1, 51.4, 
50.7, 50.5, 49.1, 47.8, 47.5, 46.9, 46.4, 46.1, 40.4, 40.2, 39.9,39.7, 32.3, 31.8, 31.4, 
29.9, 29.6, 29.3, 28.6, 27.4, 25.8, 25.2, 24.8, 23.0,22.6, 22.2, 21.8, 19.7; MS (ESI) [M 
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+ H]+ 913.7, [M + Na]+ 935.8;HRMS (FTICR) [M + H]+ calcd for C48H61N6O12 




10.3 mg, 10% yield, white amorphous solid; [α]D25 + 9.9 (c = 0.3, CHCl3); 
RP-HPLC analysis: Bondapak, 5% B inA → 100% B in 30 min (A: 0.1% TFA in 
water, B: 0.1% TFA inacetonitrile), 1.0 mL/min, 220 nm, tr 17.1 min.; 1H NMR (400 
MHz,CDCl3, mixture of rotamers) δ 6.89−6.81 (m, 6H), 5.28−4.53 (m,9H), 
3.98−3.17 (m, 12H), 2.31−1.90 (m, 39H); 13C NMR (150MHz, CDCl3, mixture of 
rotamers, broad signals) δ 178.4, 172.9,172.2, 171.6, 170.4, 169.9, 168.2, 140.1, 
139.9, 139.4, 138.3, 138.1,137.8, 136.9, 130.8, 130.5, 130.4, 130.0, 129.4, 59.3, 
57.9, 48.6, 48.3,47.7, 47.0, 46.7, 46.2, 45.6, 45.5, 44.8, 32.9, 32.3, 30.7, 29.3, 28.0, 
26.8,23.6, 23.5, 21.9, 21.0, 20.5; MS (ESI) (M + H)+ 859.6; HRMS(FTICR) (M + H)+ 





2. Alkylation reactions 
 
- 101 - 
 
59.5 mg, 53% yield, white amorphous solid;[α]D20 −2.5 (c = 0.5, CHCl3); RP-HPLC 
analysis: Bondapak, 5% B in A → 100% B in 30 min (A: 0.1% TFA in water, B: 0.1% 
TFA inacetonitrile), 1.0 mL/min, 220 nm, tr 15.5 min.; 1H NMR (600 MHz,CDCl3, 
mixture of rotamers) δ 7.72−6.97 (m, 9H), 5.66−2.88 (m,21H), 2.40−1.00 (m, 12H); 
13C NMR (150 MHz, CDCl3, mixture ofrotamers, broad signals) δ 173.0, 172.4, 
172.1,171.9, 171.3, 171.2,171.05, 170.0, 169.5, 168.7, 168.4, 167.9, 167.5, 166.8, 
166.6, 166.5,165.3, 165.1, 137.6, 137.5, 137.2, 136.7, 136.4, 136.1, 134.8, 
133.7,133.5, 133.3, 132.9, 132.7,132.6, 132.4, 132.2, 132.1, 132.0, 131.5, 131.4, 
131.2, 130.8, 130.7, 130.5, 130.3, 130.0, 129.9, 129.7, 129.6,129.0, 128.6, 128.4, 
127.8, 127.3, 127.2, 127.0, 126.9, 126.7, 62.7, 59.7,58.8, 58.2, 57.9, 57.5, 56.5, 56.2, 
51.0, 50.5, 50.2, 49.7, 49.1, 48.9, 48.2,47.3, 46.6, 31.7, 29.3, 28.7, 27.7, 25.6, 25.2, 
24.8, 23.0, 22.6, 21.9, 21.1;MS (ESI) [M + Na]+ 959.1; HRMS (FTICR) [M + H]+ calcd 





117.0 mg, 46% yield, white amorphous solid; [α]D28: +3.4 (c = 1.0, CHCl3); 
RP-HPLC analysis: Bondapak, 5% B inA → 100% B in 30 min (A: 0.1% TFA in 
water, B: 0.1% TFA inacetonitrile), 1.0 mL/min, 220 nm, tr 12.4 min.; 1H NMR (400 
MHz, CDCl3, mixture of rotamers) δ 7.39−7.10 (m, 20H), 5.43−3.07 (m, 22H), 
2.29−1.93 (m, 8H); 13C NMR (100 MHz, CDCl3, mixture of rotamers, broad signals) δ 
175.2, 172.3, 171.0, 169.9, 167.8, 165.5, 160.3, 160.0, 136.8, 136.6, 136.5, 129.2, 
129.0, 128.7, 128.7, 128.6, 128.6, 128.4, 128.3; 128.0, 127.9, 127.8, 127.6, 127.3, 
127.2, 126.9, 126.6, 119.9, 117.0, 114.1, 58.6, 57.8, 57.6, 57.3, 57.0, 54.7, 53.6, 52.3, 
51.4, 50.0, 49.6, 48.4, 48.0, 47.6, 47.3, 46.7, 46.0, 43.4, 31.9, 31.8, 31.7, 30.2, 30.1, 
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30.0, 29.7, 29.3, 29.1, 28.9, 28.6, 28.3, 27.3, 25.7, 24.3, 22.7, 20.6, 19.6; HRMS 





19 mg, 3% yield, amorphous solid;  
RP-HPLC analysis: Bondapak, 5% B in A → 100% B in 30 min (A: 0.1% TFA v/v in 
water, B: 0.1% TFA v/v in acetonitrile), 1.0 mL/min, 220 nm, tr 13.3 min; 1H NMR 
(400 MHz, CDCl3, mixture of rotamers) δ 7.36−7.20 (m, 15H), 5.08−2.90 (m, 21H), 
2.34−0.83 (m, 18H); 13C NMR (100 MHz, CDCl3, mixture of rotamers, broad signals) 
δ 176.8, 172.9, 171.7, 170.6, 169.9, 166.4, 165.7, 161.2, 160.9,  137.0, 136.8, 136.0, 
134.8, 130.0, 129.7, 129.5, 129.0, 128.8, 128.0, 127.7, 127.5, 127.2, 126.5, 126.3, 
125.8, 124.4, 124.0, 119.0, 117.0, 115.1, 113.2, 111.2, 103.1, 70.5, 62.7, 58.0, 54.7, 
53.4, 53.0, 51.9, 51.5, 51.3, 50.0, 49.3, 47.2, 46.8, 46.3, 46.0, 45.5, 45.1, 44.8, 43.8, 
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95 mg, 27% yield, amorphous yellow solid; [α]D26 + 15.3 (c = 1.0, CHCl3);  
RP-HPLC analysis: Bondapak, 5% B in A → 100% B in 30 min (A: 0.1% TFA v/v in 
water, B: 0.1% TFA v/v in acetonitrile), 1.0 mL/min, 220 nm, tr 13.2  min.; 1H NMR 
(400 MHz, CDCl3, mixture of rotamers) δ 7.63−6.98  (m, 15H), 5.38−3.10 (m, 24H), 
2.32-1.60 (m, 6H), 1.21−1.08 (m, 27H); 13C NMR (100 MHz, CDCl3, mixture of 
rotamers, broad signals) δ 174.0, 173.2, 172.8, 172.5, 172.3, 172.1, 168.7, 168.3, 
168.0, 167.2, 166.1, 165.9, 137.0, 136.6, 136.4, 135.5, 129.1, 128.9, 128.7, 128.6, 
128.5, 128.0, 127.8, 127.7, 127.3, 127.0, 126.7, 126.6, 126.5, 75.2, 74.6, 74.3, 74.1, 
70.8, 70.2, 70.0, 69.7, 68.4, 68.1, 67.6, 57.5, 56.8, 56.4, 55.7, 55.3, 54.8, 54.6, 53.9, 
53.7, 53.3, 52.2, 51.6, 50.7, 49.2, 48.7, 48.6, 48.2, 47.3, 39.1, 37.5, 37.2, 36.5, 28.2, 




61 mg, 21% yield, amorphous solid; [α]27D - 34.1 (c = 1.0, CHCl3);  
RP-HPLC analysis: Bondapak, 5% B in A → 100% B in 30 min (A: 0.1% TFA v/v in 
water, B: 0.1% TFA v/v in acetonitrile), 1.0 mL/min, 220 nm, tr 11.0 min.; 1H NMR 
(400 MHz, CDCl3, mixture of rotamers) δ 7.63-7.20 (m, 15H), 5.34-2.81 (m, 21H), 
1.56-0.83 (m, 6H); 13C NMR (100 MHz, CDCl3, mixture of rotamers, broad signals) δ 
171.9, 170.8, 170.0, 166.8, 165.8, 164.7, 160.6, 136.8, 136.5, 136.3, 135.1, 129.4, 
129.2, 129.0, 128.3, 128.1, 128.0, 127.9, 127.7, 127.6, 126.8, 126.5, 126.4, 126.0, 
125.8, 114.9, 60.2, 59.8, 59.3, 58.6, 53.8, 53.6, 52.9, 52.4, 51.8, 51.4, 51.2, 50.8, 50.5, 
50.2, 49.2, 48.6, 48.4, 47.8, 37.4, 35.4, 33.3, 32.5, 31.8, 30.0, 29.7, 29.3, 27.2, 23.4, 
22.6, 20.6, 20.3 ; MS (ESI) m/z [M + Na]+ 971.1, [M ]+ 948.1. 
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58.0 mg, 41% yield, white amorphous solid; [α]D30: –48.1 (c = 0.7, CHCl3); 
RP-HPLC analysis: Bondapak, 5% B inA → 100% B in 30 min (A: 0.1% TFA in 
water, B: 0.1% TFA inacetonitrile), 1.0 mL/min, 220 nm, tr 12.9 min.; 1H NMR (400 
MHz, CDCl3, mixture of rotamers) δ 7.37-7.13 (m, 20H), 5.62-3.28 (m, 28H), 2.26-
1.42 (m, 16H); 13C NMR (100 MHz, CDCl3, mixture of rotamers, broad signals) δ 
173.7, 171.8, 168.2, 165.8, 165.1, 136.6, 129.0, 128.8, 128.4, 128.3, 127.8, 127.6, 
126.9, 126.8, 57.2, 57.0, 51.5, 50.7, 50.2, 49.7, 47.7, 47.4, 47.1, 46.8, 31.6, 29.8, 28.7, 
27.2, 25.1, 24.6, 22.7, 22.2; HRMS (MALDI) m/z [M + H]+  977.4920 calcd for 
C56H65N8O8+; found 977.4911. 
 
2.7.7 Determination of Binding Affinities for Compounds 80 and 94. 
 
Association constants Ka were calculated from the equation Ka = Ke/ Kd, according 
to methodology reported by Cram and co-workers.37 Kd values, which represent 
the distribution constants of the picrate salts between water and CHCl3, were 
previously determined by Cram,37 while Ke values were calculated following the 
“ultraviolet method” reported by Cram and co-workers.37 All ultraviolet (UV) 
measurements were made at 380 nm at 24−26 °C, using spectrophotometric grade 
solvents. The picrate salts were prepared according to literature procedures,86,88 
and dried under high vacuum before use. 0.0150 M aqueous solutions (250 μL) of 
sodium or potassium picrates were mixed thoroughly with 0.0150 M solution of 
the host in CHCl3 (250 μL) into an Eppendorf vial, using a Vortex mixer, for 5 min 
                                                          
88. Bhatnagar, M.; Awasthy, A.; Sharma, U. Main Group Met. Chem. 2004, 27, 163−168.  
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and then centrifuged (14000 rpm). An aliquot of 50 μL of the aqueous phase was 
diluted with CH3CN up to 5.0 mL. Successively 200 μL of this solution was diluted 
with CH3CN up to 5.0 mL. Successively 200 μL of the latter solution was diluted 
with CH3CN up to 1.0 mL. The absorbance of each sample was then measured 
against the appropriate blank solution at 380 nm at 25 °C. R, Ke, Ka and ΔG° were 
thus calculated in the proper way.37 
 
2.7.8 Computational details for compound 98  
 
Density functional calculations were performed on all the systems with the 
Gaussian09 set of programs.89 BP86 was used as a functional and gradient 
corrections were taken from the works of Becke88,90 and Perdew.89,91 The 
electronic configuration of the molecular systems was described by the split-
valence basis set with polarization functions of Ahlirchs and co-worker (standard 
SVP basis set in Gaussian09), for H, C, N, and O.90,92 Minimum free-energy 
structures were characterized by the presence of zero imaginary frequency. 
Cartesian coordinates of the cyclopeptoid 98 structure 
80 
  O      2.673041    -3.187140    -1.264518 
  O     -0.867981    -1.805740     0.718647 
  O     -2.672681     3.187240    -1.263528 
  O      0.867747     1.805730     0.718424 
  N      1.749164    -0.057603    -0.286051 
  N     -0.478008     2.652486    -1.525094 
                                                          
89. M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. 
Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H. P. 
Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, 
R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. A. 
Montgomery J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. N. Brothers, K. Kudin, V. N. 
Staroverov, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell,  J. C, Burant, S. S. Iyengar, 
J. Tomasi, M. Cossi, N. Rega, J. M. Millam, M. Klene, J. E. Knox, J. B.  Cross, V. Bakken, C. Adamo, 
J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. 
Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, P. Salvador, J. J. 
Dannenberg, S. Dapprich, A. D. Daniels, Ö Farkas, J. B. Foresman, J. V. Ortiz, J. Cioslowski, D. J. 
Fox, Gaussian 09, Revision A.02, Gaussian, Inc., Wallingford, CT, 2009. 
90. Becke, A. Phys. Rev. A 1988, 38, 3098–3100. 
91. J. P. Perdew, Phys. Rev. B 1986, 33, 8822–8824. 
92. A. Schaefer, H. Horn, R. Ahlrichs,  J. Chem. Phys. 1992, 97, 2571–2577. 
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  N     -1.749160     0.057660    -0.285887 
  N      0.478201    -2.652385    -1.524640 
  C      1.801574    -2.321720    -1.399981 
  C      2.184235    -0.821100    -1.455439 
  H      3.293316    -0.814996    -1.526116 
  H      1.792887    -0.360053    -2.381564 
  C      2.242416    -0.550781     1.022940 
  H      2.039131    -1.639099     1.072477 
  H      1.625493    -0.049859     1.790689 
  C      3.718556    -0.262636     1.243666 
  C      4.694440    -1.222245     0.913595 
  H      4.375995    -2.192650     0.494848 
  C      6.070856    -0.952661     1.095924 
  C      6.444252     0.302245     1.613299 
  H      7.516065     0.523492     1.759596 
  C      5.487094     1.286014     1.953657 
  C      4.124972     0.988464     1.760896 
  H      3.355886     1.735741     2.017726 
  C      7.106348    -2.002462     0.755116 
  H      8.135018    -1.590589     0.786188 
  H      6.935458    -2.428628    -0.255739 
  H      7.064356    -2.853346     1.469653 
  C      5.926253     2.617731     2.524042 
  H      5.069081     3.307279     2.657529 
  H      6.668012     3.118206     1.865430 
  H      6.413459     2.491997     3.515391 
  C      1.090544     1.154860    -0.307138 
  C      0.658645     1.742757    -1.681917 
  H      0.404089     0.948761    -2.411196 
  C      1.764143     2.682220    -2.236305 
  H      1.637058     2.786418    -3.335291 
  H      2.786414     2.297018    -2.047012 
  C      1.468793     4.013290    -1.517683 
  H      1.882314     3.983343    -0.490240 
  H      1.905231     4.887447    -2.040499 
  C     -0.067735     4.068340    -1.459559 
  H     -0.458471     4.537709    -0.534059 
  H     -0.513236     4.620629    -2.316957 
  C     -1.801318     2.321826    -1.399685 
  C     -2.184044     0.821227    -1.455314 
  H     -3.293118     0.815155    -1.526125 
  H     -1.792566     0.360192    -2.381387 
  C     -2.242587     0.550779     1.023066 
  H     -2.039387     1.639105     1.072636 
  H     -1.625720     0.049874     1.790870 
  C     -3.718740     0.262575     1.243616 
  C     -4.694588     1.222223     0.913528 
  H     -4.376068     2.192648     0.494894 
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  C     -6.071018     0.952645     1.095722 
  C     -6.444472    -0.302300     1.612969 
  H     -7.516300    -0.523539     1.759166 
  C     -5.487357    -1.286108     1.953322 
  C     -4.125210    -0.988561     1.760711 
  H     -3.356153    -1.735859     2.017556 
  C     -7.106476     2.002467     0.754888 
  H     -6.935740     2.428407    -0.256097 
  H     -7.064269     2.853508     1.469225 
  H     -8.135180     1.590698     0.786225 
  C     -5.926588    -2.617882     2.523525 
  H     -5.069393    -3.307339     2.657318 
  H     -6.668040    -3.118424     1.864615 
  H     -6.414194    -2.492222     3.514687 
  C     -1.090589    -1.154822    -0.306933 
  C     -0.658496    -1.742727    -1.681641 
  H     -0.403912    -0.948759    -2.410937 
  C     -1.763883    -2.682275    -2.236129 
  H     -2.786197    -2.297148    -2.046906 
  H     -1.636706    -2.786444    -3.335107 
  C     -1.468482    -4.013334    -1.517516 
  H     -1.904851    -4.887519    -2.040341 
  H     -1.882015    -3.983404    -0.490078 
  C      0.068042    -4.068281    -1.459371 
  H      0.458785    -4.537795    -0.533946 
  H      0.513611    -4.620379    -2.316856 
 
2.7.9 General procedure for enantioselective catalytic alkylation of N-
(diphenylmethylene)glycine t-butyl ester under phase-transfer conditions 
(benzylation) with chiral cyclopeptoids. 
 
To a solution of N-(diphenylmethylene)glycine t-butyl ester 55 (23.6 mg, 0.08 
mmol) and chiral catalyst 80 (3.3 mg, 0.004 mmol) in toluene (0.8 mL) under inert 
athmosphere, benzyl bromide (11.4 µL, 0.096 mmol) was added. The mixture was 
degassed under vacuo at low temperature (-78° C) and then left at 0° C. Then 
degassed 50% aqueous NaOH (0.5 mL) was added. The reaction mixture was 
stirred at 0° C until disappearance of the starting material was observed by TLC. 
The suspension was diluted with DCM (4 mL) and water (2.5 mL), and the organic 
layer was taken. The aqueous layer was extracted other two times with DCM (4 mL 
× 2) and the combined organic phases were dried over Na2SO4, filtered, and 
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concentrated in vacuo. Purification of the residue by flash column chromatography 
on silica gel (petroleum ether–EtOAc: 98:2 → 9:1) afforded the desired product 
56a (17.0 mg, 54% yield) as a colorless oil. 
 
t-Butyl (R)-N-(Diphenylmethylene)-3,5-dimethylphenylalaninate (56f) 
 
  
20.2 mg, yield 60%, colorless oil; ee 73%, [α]D 30: 20.2 (c = 1.0, CHCl3, 73% ee); 
1H NMR (400 MHz, CDCl3) δ: 7.55 (d, J = 7.9 Hz, 2 H), 7.39-7.23 (m, 6 H), 6.78 (s, 1 
H), 6.69- 6.54 (m, 4 H), 4.09 (dd, J = 9.3, 4.3 Hz, 1 H), 3.15 (dd, J = 13.3, 4.3 Hz, 1 H), 
3.07 (dd, J = 13.3, 9.3 Hz, 1 H), 2.18 (s, 6 H), 1.45 (s, 9 H); 13C NMR (100 MHz, 
CDCl3) δ: 171.0, 170.2, 139.7, 138.1, 137.4, 136.5, 130.0, 128.7, 128.2, 127.9, 127.8, 
127.8, 127.7, 127.6, 81.0, 67.9, 39.4, 28.1, 21.1. 
 
2.7.10 General procedure for enantioselective catalytic alkylation of N-
(diphenylmethylene)glycine cumyl ester under phase-transfer conditions 
(benzylation) with chiral cyclopeptoids. 
 
To a solution of N-(diphenylmethylene)glycine 1-methyl-1-phenylethyl ester 99c 
(178 mg, 0.50 mmol) and cyclopeptoid 80 (9.2 mg, 0.012 mmol) in toluene (5.0 
mL) under nitrogen, the alkyl bromide (1.2−3.0 equiv) was added. The mixture 
was degassed and then cooled to −20 °C. Degassed 50% aqueous KOH (3.0 mL) 
was then added. The reaction mixture was stirred at −20 °C for 20 h. Then the 
suspension was diluted with CH2Cl2 (25 mL) and H2O (15 mL), and the organic 
layer was taken. The aqueous layer was extracted twice with CH2Cl2 (25 mL × 2) 
and the combined organic phases were dried over Na2SO4, filtered, and 
concentrated in vacuo. Purification of the residue by flash column chromatography 
on silica gel (petroleum ether−ethyl acetate: 98:2 to 90:10) afforded the pure 
alkylated products. 
2. Alkylation reactions 
 






168 mg, yield 75%, colorless oil; ee 93%; the spectroscopic data were in good 
agreement with the literature.71 [α]22 D + 13.4 (c = 1.0, CHCl3, 93% ee); 
HPLC analysis: Chiralcel OD-H, i-PrOH/hexane = 1/99, 0.5 mL/min, 260 nm, tr 
(major) = 19.8 min, tr (minor) = 24.7 min; 1H NMR (400 MHz, CDCl3) δ 7.61 (m, 
2H), 7.46−7.13 (m, 14H), 7.07 (m, 2H), 6.60 (bd, J = 6.6 Hz, 2H), 4.20 (dd, J = 9.3, 4.2 
Hz, 1H), 3.28 (dd, J = 13.4, 4.2 Hz, 1H), 3.18 (dd, J = 13.4, 9.3 Hz, 1H), 2.30 (s, 3H), 
1.80 (s, 3H), 1.75 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.4, 170.0, 145.6, 139.4, 
138.3, 136.2, 130.2, 129.9, 128.7, 128.2, 128.2, 128.1, 128.1, 128.0, 127.6, 126.9, 
126.2, 124.3, 82.4, 67.9, 39.3, 28.9, 28.3; MS (ESI) [M + H]+ 462.3, [M + Na]+ 484.2; 




methylphenyl)propanoate (102a).  
 
  
173 mg, yield 75%, yellow oil; ee 94%; [α]25 D + 101.5 (c = 1.0, CHCl3, 94% ee);  
HPLC analysis: Chiralcel OD-H, i-PrOH/hexane = 1/99, 0.5 mL/min, 260 nm, tr 
(minor) = 13.9 min, tr (major) = 17.0 min; 1H NMR (400 MHz, CDCl3) δ 7.61 (m, 
2H), 7.44−7.17 (m, 11H), 7.01 (d, J = 7.9, 2H), 6.94 (d, J = 7.9 Hz, 2H), 6.63 (bd, J = 
6.8 Hz, 2H), 4.18 (dd, J = 9.2, 4.3 Hz, 1H), 3.24 (dd, J = 13.4, 4.3 Hz, 1H), 3.13 (dd, J = 
13.4, 9.2 Hz, 1H), 2.30 (s, 3H), 1.80 (s, 3H), 1.74 (s, 3H); 13C NMR (100 MHz, CDCl3) 
δ 170.2, 170.0, 145.7, 139.5, 136.3, 135.6, 135.1, 130.1, 129.7, 128.7, 128.7, 128.2, 
128.2, 128.1, 127.9, 127.7, 126.9, 124.3, 82.3, 68.0, 38.9, 28.9, 28.3, 21.0; MS (ESI) 
[M + H]+ 462.3, [M + Na]+ 484.2; HRMS (FTICR) [M + H]+ calcd for C32H32NO2 
462.2433, found 462.2440. 
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(R)-2-Phenylpropan-2-yl 2-((diphenylmethylene)amino)-3-(3,5-
dimethylphenyl)propanoate (102b).  
 
 
195 mg, yield 82%, colorless oil; ee 89%; [α]20 D + 97.9 (c = 0.9, CHCl3, 89% ee);  
HPLC analysis: Chiralcel OD-H, i-PrOH/hexane = 1/99, 0.5 mL/min, 260 nm, tr 
(minor) = 14.2 min, tr (major) = 19.5 min; 1H NMR (400 MHz, CDCl3) δ 7.59 (m, 
2H), 7.42−7.14 (m, 11H), 6.80 (s, 1H), 6.66 (s, 2H), 6.61 (bd, J = 6.8 Hz, 2H), 4.18 
(dd, J = 9.2, 4.2 Hz, 1H), 3.21 (dd, J = 13.3, 4.2 Hz, 1H), 3.09 (dd, J = 13.3, 9.2 Hz, 1H), 
2.19 (s, 6H), 1.80 (s, 3H), 1.76 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.3, 170.1, 
145.7, 139.6, 137.9, 137.4, 136.3, 130.0, 128.7, 128.2, 128.2, 127.9, 127.9, 127.8, 
127.7, 127.7, 126.9, 124.3, 82.3, 67.8, 39.1, 28.9, 28.3, 21.1; MS (ESI) [M + H]+ 
476.4; HRMS (FTICR) [M + H]+ calcd for C33H34NO2 476.2590, found 476.2580. 
 
(R)-2-Phenylpropan-2-yl 2-((diphenylmethylene)amino)-3-(2-
methylphenyl)propanoate (102c).  
 
 
205 mg, yield 89%, yellow oil; ee 96%; [α]22 D + 111.4 (c = 1.0, CHCl3, 96% ee);  
HPLC analysis: Chiralcel OD-H, i-PrOH/hexane = 1/99, 0.5 mL/min, 260 nm, tr 
(major) = 20.8 min, tr (minor) = 24.1 min; 1H NMR (400 MHz, CDCl3) δ 7.63 (m, 
2H), 7.43−7.19 (m, 11H), 7.14−6.98 (m, 4H), 6.49 (m, 2H), 4.23 (m, 1H), 3.32 (m, 
1H), 3.20 (m, 1H), 2.08 (s, 3H), 1.83 (s, 3H), 1.77 (s, 3H); 13C NMR (100 MHz, CDCl3) 
δ 170.2, 170.2, 145.7, 139.2, 136.9, 136.3, 136.1, 131.0, 130.1, 130.0, 128.7, 128.2, 
128.1, 128.0, 127.9, 127.7, 127.0, 126.4, 125.6, 124.3, 82.4, 66.5, 36.4, 29.0, 28.3, 
19.3; MS (ESI) [M + H]+ 462.1, [M + Na]+ 484.1; HRMS (FTICR) [M + H]+ calcd for 
C32H32NO2 462.2433, found 462.2431. 
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(R)-2-Phenylpropan-2-yl 2-((diphenylmethylene)amino)-3-(4-t-butyl-
phenyl)propanoate (102d).  
 
 
86 mg, yield 74%, yellow oil; ee 88%; [α]22 D + 38.2 (c = 1.0, CHCl3, 88% ee);  
HPLC analysis: Chiralcel OD-H, i-PrOH/hexane = 1/99, 0.5 mL/min, 260 nm, tr 
(minor) = 11.3 min, tr (major) = 14.1 min; 1H NMR (400 MHz, CDCl3) δ 7.63 (m, 
2H), 7.44−7.17 (m, 13H), 6.98 (d, J = 8.1 Hz, 2H), 6.52 (m, 2H), 4.16 (dd, J = 9.3, 4.0 
Hz, 1H), 3.25 (dd, J = 13.4, 4.0 Hz, 1H), 3.13 (dd, J = 13.4, 9.3 Hz, 1H), 1.80 (s, 3H), 
1.75 (s, 3H), 1.31 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 170.2, 170.1, 149.1, 145.7, 
139.5, 136.2, 135.2, 130.1, 129.5, 128.7, 128.2, 128.2, 128.0, 128.0, 127.6, 126.9, 
125.0, 124.3, 82.3, 68.1, 38.7, 34.4, 31.4, 28.9, 28.3; MS (ESI) [M + H]+ 504.2, [M + 




nitrophenyl)propanoate (102e).  
 
 
219 mg, yield 89%, yellow oil; ee 89%; [α]25 D + 170.7 (c = 1.0, CHCl3, 89% ee); 
HPLC analysis: Chiralcel OD-H, i-PrOH/hexane = 1/99, 1.0 mL/min, 260 nm, tr 
(minor) = 16.6 min, tr (major) = 35.4 min; 1H NMR (400 MHz, CDCl3) δ 8.07(m, 
2H), 7.61 (m, 2H), 7.45−7.21 (m, 13H), 6.70 (bd, J = 7.0 Hz, 2H), 4.26 (dd, J = 8.7, 4.5 
Hz, 1H), 3.35 (dd, J = 13.4, 4.5 Hz, 1H), 3.29 (dd, J = 13.4, 8.7 Hz, 1H), 1.80 (s, 3H), 
1.76 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 171.0, 169.2, 146.6, 146.3, 145.2, 138.9, 
135.8, 130.6, 130.5, 128.6, 128.6, 128.3, 128.2, 128.1, 127.4, 127.1, 124.2, 123.2, 
82.8, 66.9, 39.1, 28.8, 28.2; MS (ESI) [M + H]+ 493.1, [M + Na]+ 515.0; HRMS 
(FTICR) [M + H]+ calcd for C31H29N2O4 493.2127, found 493.2138. 
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(R)-2-Phenylpropan-2-yl 2-((diphenylmethylene)amino)-3-(4-
cyanophenyl)propanoate (102f).  
 
 
189 mg, yield 80%, yellow oil; ee 93%; [α]20D + 50.8 (c = 0.9, CHCl3, 93% ee);  
HPLC analysis: Chiralcel OD-H, i-PrOH/hexane = 1/99, 1.0 mL/min, 260 nm, tr 
(minor) = 18.4 min, tr (major) = 30.7 min; 1H NMR (400 MHz, CDCl3) δ 7.60 (m, 
2H), 7.49 (m, 2H), 7.45−7.21 (m, 11H), 7.18 (m, 2H), 6.66 (bd, J = 6.8 Hz, 2H), 4.21 
(dd, J = 8.9, 4.4 Hz, 1H), 3.30 (dd, J = 13.4, 4.4 Hz, 1H), 3.23 (dd, J = 13.4, 8.9 Hz, 1H), 
1.79 (s, 3H), 1.75 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.9, 169.3, 145.3, 144.2, 
139.0, 135.9, 131.8, 130.7, 130.5, 128.7, 128.6, 128.3, 128.2, 128.1, 127.5, 127.1, 
124.2, 119.0, 110.1, 82.8, 67.0, 39.3, 28.8, 28.2; MS (ESI) [M + H]+ 473.2, [M + Na]+ 
495.2; HRMS (FTICR) [M + H]+ calcd for C32H29N2O2 473.2229, found 473.2240. 
 
(R)-2-Phenylpropan-2-yl 2-((diphenylmethylene)amino)-3-(4-




175 mg, yield 75%, yellow oil; ee 91%; [α]25 D + 170.9 (c = 0.8, CHCl3, 91% ee);  
HPLC analysis: Chiralcel OD-H, i-PrOH/hexane = 1/99, 0.5 mL/min, 260 nm, tr 
(minor) = 13.9 min, tr (major) = 20.5 min; 1H NMR (400 MHz, CDCl3) δ 7.61 (m, 
2H), 7.43−7.19 (m, 11H), 7.02 (m, 2H), 6.89 (m, 2H), 6.65 (bd, J = 6.6 Hz, 2H), 4.17 
(dd, J = 9.2, 4.2 Hz, 1H), 3.24 (dd, J = 13.5, 4.2 Hz, 1H), 3.15 (dd, J = 13.5, 9.2 Hz, 1H), 
1.79 (s, 3H), 1.75 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.5, 170.0, 161.5 (d, J = 
244 Hz), 145.5, 139.3, 136.1, 134.0 (d, J = 2 Hz), 131.3 (d, J = 8 Hz), 130.3, 128.7, 
128.3, 128.2, 128.2, 128.0, 127.6, 127.0, 124.3, 114.8 (d, J = 21 Hz), 82.5, 67.8, 38.4, 
28.8, 28.3; MS (ESI) [M + H]+ 466.2, [M + Na]+ 488.2; HRMS (FTICR) [M + H]+ calcd 
for C31H29FNO2 466.2182, found 466.2174. 
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(R)-2-Phenylpropan-2-yl 2-((diphenylmethylene)amino)-3-(4-




210 mg, yield 87%, yellow oil; ee 94%; [α]22 D + 109.2 (c = 1.0, CHCl3, 94% ee);  
HPLC analysis: Chiralcel OD-H, i-PrOH/hexane = 1/99, 0.5 mL/min, 260 nm, tr 
(minor) = 14.8 min, tr (major) = 23.6 min; 1H NMR (400 MHz, CDCl3) δ 7.62 (m, 
2H), 7.44−7.21 (m, 11H), 7.18 (d, J = 8.3 Hz, 2H), 7.01 (d, J = 8.3 Hz, 2H), 6.67 (bd, J 
= 6.5 Hz, 2H), 4.19 (dd, J = 9.2, 4.2 Hz, 1H), 3.24 (dd, J = 13.4, 4.2 Hz, 1H), 3.15 (dd, J 
= 13.4, 9.2 Hz, 1H), 1.80 (s, 3H), 1.76 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.6, 
169.7, 145.5, 139.2, 136.8, 136.1, 132.0, 131.2, 130.3, 128.7, 128.4, 128.2, 128.2, 
128.2, 128.0, 127.6, 127.0, 124.3, 82.5, 67.6, 38.6, 28.9, 28.3; MS (ESI) [M + Na]+ 








241 mg, yield 97%, colorless oil; ee 95%; [α]22 D + 50.7 (c = 1.0, CHCl3, 95% ee);  
HPLC analysis: Chiralcel OD-H, i-PrOH/hexane = 1/99, 0.5 mL/min, 260 nm, tr 
(minor) = 20.1 min, tr (major) = 29.8 min; 1H NMR (400 MHz, CDCl3) δ 7.78 (m, 
1H), 7.67 (m, 2H), 7.59 (m, 2H), 7.52 (s, 1H), 7.46−7.12 (m, 14H), 6.53 (m, 2H), 4.33 
(dd, J = 9.2, 4.3 Hz, 1H), 3.45 (dd, J = 13.5, 4.3 Hz, 1H), 3.33 (dd, J = 13.5, 9.2 Hz, 1H), 
1.80 (s, 3H), 1.76 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.5, 170.0, 145.6, 139.4, 
136.1, 135.8, 133.4, 132.1, 130.1, 128.7, 128.3, 128.2, 128.2, 128.0, 127.9, 127.6, 
127.5, 127.5, 126.9, 125.8, 125.2, 124.3, 82.4, 67.8, 39.4, 28.9, 28.3; MS (ESI) [M + 
H]+ 498.2; HRMS (FTICR) [M + H]+ calcd for C35H32NO2 498.2433, found 498.2423. 
2. Alkylation reactions 
 






179 mg, yield 90%, yellow oil; ee 93%; the spectroscopic data were in good 
agreement with the literature.67 [α]22 D + 5.7 (c = 0.9, CHCl3, 93% ee);  
HPLC analysis: Chiralcel OD-H, i-PrOH/hexane = 1/99, 0.5 mL/min, 260 nm, tr 
(minor) = 11.1 min, tr (major) = 12.7 min; 1H NMR (400 MHz, CDCl3) δ 7.67 (m, 
2H), 7.48−7.20 (m, 11H), 7.16 (m, 2H), 5.74 (m, 1H), 5.09 (m, 1H), 5.04 (m, 1H), 
4.10 (dd, J = 7.8, 5.1 Hz, 1H), 2.78−2.60 (m, 2H), 1.80 (s, 3H), 1.75 (s, 3H); 13C NMR 
(100 MHz, CDCl3) δ 170.2, 170.0, 145.7, 139.6, 136.5, 134.6, 130.2, 128.8, 128.5, 
128.4, 128.2, 128.0, 127.9, 126.9, 124.3, 117.4, 82.3, 65.8, 37.8, 28.9, 28.3; MS (ESI) 








191 mg, yield 93%, colorless oil; ee 86%; [α]22 D + 66.9 (c = 1.0, CHCl3, 86% ee);  
HPLC analysis: Chiralcel OD-H, i-PrOH/hexane = 1/99, 0.5 mL/min, 260 nm, tr 
(minor) = 10.2 min, tr (major) = 14.2 min; 1H NMR (400 MHz, CDCl3) δ 7.67 (m, 
2H), 7.48−7.20 (m, 11H), 7.16 (m, 2H), 4.77 (m, 1H), 4.74 (m, 1H), 4.18 (dd, J = 8.5, 
4.9 Hz, 1H), 2.70 (dd, J = 13.5, 4.9 Hz, 1H), 2.62 (dd, J = 13.5, 8.5 Hz, 1H), 1.81 (s, 
3H), 1.77 (s, 3H), 1.54 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.3, 170.0, 145.7, 
141.8, 139.7, 136.3, 130.2, 128.8, 128.5, 128.3, 128.2, 128.1, 128.0, 126.9, 124.3, 
113.4, 82.3, 64.8, 41.5, 28.9, 28.3, 22.7; MS (ESI) [M + Na]+ 434.3; HRMS (FTICR) [M 
+ H]+ calcd for C28H30NO2 412.2277, found 412.2288. 
 
2. Alkylation reactions 
 






180 mg, yield 91%, colorless oil; ee 83%; the spectroscopic data were in good 
agreement with the literature.67 [α]22 D + 25.4 (c = 1.0, CHCl3, 83% ee); 
HPLC analysis: Chiralcel OD-H, i-PrOH/hexane = 1/99, 0.5 mL/min, 260 nm, tr 
(minor) = 17.3 min, tr (major) = 18.6 min; 1H NMR (400 MHz, CDCl3) δ 7.69 (m, 
2H), 7.48−7.19 (m, 13H), 4.27 (dd, J = 8.1, 5.1 Hz, 1H), 2.90−2.72 (m, 2H), 1.97 (t, J 
= 2.4 Hz, 1H), 1.79 (s, 3H), 1.75 (s, 3H); 13C NMR (100 MHz, CDCl3) δ: 171.6, 168.8, 
145.4, 139.5, 136.1, 130.4, 128.9, 128.7, 128.4, 128.2, 128.2, 128.0, 127.0, 124.3, 
82.8, 81.2, 70.2, 64.7, 28.8, 28.2, 23.2; MS (ESI) [M + Na]+ 418.3; HRMS (FTICR) [M 
+ H]+ calcd for C27H26NO2 396.1964, found 396.1955. 
 
 




166 mg, yield 86%, colorless oil; ee 86%; the spectroscopic data were in good 
agreement with the literature.71 [α]22 D + 33.1 (c = 1.0, CHCl3, 86% ee);  
HPLC analysis: Chiralcel OD-H, i-PrOH/hexane = 1/99, 0.5 mL/min, 260 nm, tr 
(minor) = 11.5 min, tr (major) = 12.9 min; 1H NMR (400 MHz, CDCl3) δ 7.67 (m, 
2H), 7.47−7.19 (m, 11H), 7.15 (m, 2H), 3.94 (dd, J = 7.9, 5.0 Hz, 1H), 2.03−1.86 (m, 
2H), 1.79 (s, 3H), 1.75 (s, 3H), 0.87 (t, J = 7.5 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 
170.9, 170.3, 146.1, 139.9, 136.9, 130.4, 129.0, 128.7, 128.7, 128.4, 128.3, 128.2, 
127.2, 124.6, 82.3, 67.6, 29.1, 28.6, 26.9, 10.9; MS (ESI) [M + H]+ 386.3; HRMS 
(FTICR) [M + H]+ calcd for C26H28NO2 386.2120, found 386.2114. 
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(R)-2-Phenylpropan-2-yl 3-(carbo-t-butoxy) - 2 -
((diphenylmethylene)amino)propanoate (102n).  
 
 
196 mg, yield 86%, colorless oil; ee 92%; [α]19 D + 40.4 (c = 1.0, CHCl3, 92% ee);  
HPLC analysis: Chiralcel OD-H, i-PrOH/hexane = 1/99, 0.5 mL/min, 260 nm, tr 
(minor) = 18.7 min, tr (major) = 21.9 min; 1H NMR (600 MHz, CDCl3) δ 7.63 (m, 
2H), 7.48−7.12 (m, 13H), 4.47 (dd, J = 7.7, 5.8 Hz, 1H), 2.98 (dd, J = 15.8, 5.8 Hz, 
1H), 2.78 (dd, J = 15.8, 7.7 Hz, 1H), 1.78 (s, 3H), 1.72 (s, 3H), 1.39 (s, 9H); 13C NMR 
(150 MHz, CDCl3) δ 171.3, 170.3, 169.3, 145.5, 139.6, 136.2, 130.3, 128.8, 128.7, 
128.3, 128.2, 128.0, 127.9, 126.9, 124.3, 82.6, 80.6, 62.8, 39.4, 28.9, 28.1, 28.0; MS 
(ESI) [M + Na]+ 494.5; HRMS (FTICR) [M + H]+ calcd for C26H28NO2 472.2482, 
found 472.2501. 
 
2.7.11 General procedure for enantioselective catalytic alkylation of N-
(diphenylmethylene)glycine t-butyl ester under phase-transfer conditions 
(benzylation) with chiral calixarenes. 
 
To a solution of N-(diphenylmethylene)glycine t-butyl ester (55) (23.6 mg, 0.08 
mmol) and chiral catalyst (107) (4.6 mg, 0.004 mmol) in mesytilene (0.8 mL) 
under inert athmosphere, benzyl bromide (11.4 µL, 0.096 mmol) was added. The 
mixture was degassed under vacuo at low temperature (-78° C) and then left at 0° 
C. Then degassed 50% aqueous NaOH (0.5 mL) was added. The reaction mixture 
was stirred at 0° C until disappearance of the starting material was observed by 
TLC. The suspension was diluted with DCM (4 mL) and water (2.5 mL), and the 
organic layer was taken. The aqueous layer was extracted other two time with 
DCM (4 mL × 2) and the combined organic phases were dried over Na2SO4, filtered, 
and concentrated in vacuo. Purification of the residue by flash column 
chromatography on silica gel (petroleum ether–EtOAc: 98:2 → 9:1) afforded the 
desired product (56a) (26.4 mg, 86% yield) as a colorless oil. 
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2.8 Synthesis of 2-aryl-2-oxazoline-4-carboxylic acid esters 
 
2-Aryl-2-oxazoline-4-carboxylic acid esters 115,81a 116,93117,94 131,84 132,84 and 
13384 were synthetized as described in literature. Previously undescribed 
substrates 118, 119, 129 and 130 were prepared as described below. 
 
2.8.1 Synthesis of (S)-2-Phenyl-2-oxazoline-4-carboxylic acid cumyl ester 
(118) 
 
To a solution of (S)-2-phenyl-2-oxazoline-4-carboxylic acid (112 mg, 0.59 mmol) in 
dry DCM (2.5 mL) under nitrogen atmosphere 1-methyl-1-phenylethyl 2,2,2-
trichloro acetimidate (0.17 mg, 0.59 mmol) was added. The reaction mixture was 
stirred for 65 h, diluted with DCM (2 mL), and centrifuged for two times. The 
recovered organic phase was concentrated in vacuo. The residue was purified by 
column chromatography (silica gel, petroleum ether−ethyl acetate: 100:0 to 98:2); 
to afford 118. 
2.8.2 Synthesis of (S)-2-Phenyl-2-oxazoline-4-carboxylic acid benzhydryl 
ester (119) 
To a solution of (S)-2-Phenyl-2-oxazoline-4-carboxylic acid (212  mg, 1.11 mmol) 
and benzophenone hydrazone (327 mg, 1.67 mmol) in DCM (3.4 mL) a solution of 
iodine in DCM [0.15 mL, 1% (w/v)] was added. The mixture was cooled to -10 °C 
and PhI(OAc)2 (536 mg, 1.66 mmol) was added portionwise over a period of 30 
min. Then the reaction mixture was warmed to room temperature and stirred for 
22 h. The solvent was evaporated under reduced pressure and the residue was 
dissolved in EtOAc (20 mL). The organic phase was washed with H2O (1 x 10 mL), 
5% NaHCO3-solution (3 x 10 mL), H2O (1 x 20 mL) and brine (1 x 10 mL), dried 
over Na2SO4 and concentrated in vacuo. The residue was purified by column 
chromatography (silica gel, petroleum ether−ethyl acetate: 98:2 to 80:20); to 
afford 119. 
                                                          
93. A. Laaziri, J. Uziel, S. Jugé, Tetrahedron: Asymmetry 1998, 9, 437. 
94. F. Meyer, A. Laaziri, A. M. Papini, J. Uziel, S. Jugé,Tetrahedron: Asymmetry 2003, 14, 2229. 
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(S)-2-Phenyl-2-oxazoline-4-carboxylic acid cumyl ester (118) 
 
66 mg, 40% yield, white solid: mp = 117-120 °C. Rf = 0.41 (petroleum ether−ethyl 
acetate: 8:2); [α]D25: +8.7 (c = 1.0, CHCl3); 
1H-NMR (400 MHz, CDCl3) δ: 8.00 (m, 2H, PhH), 7.50 (m, 1H, PhH), 7.42-7.40 (m, 
4H, PhH), 7.32 (m, 2H, PhH), 7.25-7.23 (m, 1H, PhH), 4.92 (dd, J = 10.4, 7.7 Hz, 1H, 
CHN), 4.63 (br t, J = 8.0 Hz, 1H, CHHO), 4.55 (dd, J = 10.4, 9.1 Hz, 1H, CHHO), 1.85 (s, 
3H, OC(CH3)2Ph), 1.84 (s, 3H, OC(CH3)2Ph); 13C NMR (100 MHz, CDCl3) δ: 169.5, 
166.1, 145.2, 131.7, 128.6 (× 2), 128.3 (× 4), 127.2, 127.1, 124.3 (× 2), 83.2, 69.5, 
69.3, 28.7, 28.5; HRMS (MALDI) m/z [M + H]+  310.1438 calcd for C19H20NO3+; found 
310.1435.  
 
(S)-2-Phenyl-2-oxazoline-4-carboxylic acid benzhydryl ester (119) 
 
 
113 mg, 29% yield, yellow solid: mp = 124-126 °C. Rf = 0.32 (petroleum 
ether−ethyl acetate: 9:1); [α]D25: +43.8 (c =1.0, CHCl3).  
1H-NMR (400 MHz, CDCl3) δ: 8.00 (m, 2H, PhH), 7.51 (m, 1H, PhH), 7.45-7.26 (m, 
12H, PhH), 6.98 (s, 1H, OCHPh2), 5.06 (dd, J = 10.4, 7.7 Hz, 1H, CHCO), 4.67 (br t, J = 
8.6 Hz, 1H, CHHO), 4.60 (dd, J = 10.4, 8.6 Hz, 1H, CHHO); 13C-NMR (100 MHz, 
CDCl3) δ: 170.1, 166.4, 139.6 (× 2), 131.8 (× 2), 128.6 (× 4), 128.5 (× 2), 128.3 (× 
2), 128.1 , 127.9, 127.3 (× 2), 126.9 (× 2), 77.9, 69.5, 68.8; HRMS (MALDI) m/z [M + 
Na]+ calcd for C23H19NNaO3+ 380.1257; found 380.1256.  
 
2.8.3 Synthesis of 2-(4-Trifluoromethylphenyl)-2-oxazoline-4-carboxylic acid 
t-butyl ester (129) 
 
To a solution of 4-(trifluoromethyl)benzoic acid (200 mg, 1.01 mmol) in DCM (7 
mL) serine-t-butyl ester hydrochloride (200 mg 1.01 mmol), EDC (232 mg, 1.21 
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mmol), HOBT (163 mg, 1.21 mmol) and triethylamine (307 mg, 3.04 mmol) were 
added. The mixture was stirred at room temperature overnight, then diluted with 
DCM (20 mL) and washed with water (10 mL X 2). The organic layer was dried 
over MgSO4 filtered and concentrated in vacuo to afford 2-((4-
trifluoromethyl)benzoyl)-amino)-3-hydroxypropionic acid t-butyl ester (793.5 mg, 
89% yield) as a yellow amorphous solid; Rf = 0.44 petroleum ether−ethyl acetate: 
7:3). This compound was used without further purification. The 2-((4-
trifluoromethyl)benzoyl)-amino]-3-hydroxypropionic acid t-butyl ester (286 mg, 
0.85 mmol) was dissolved in dry DCM (4 mL), and cooled to –78°C. DAST (208 mg, 
1.28 mmol) was added and the solution was stirred overnight. The reaction 
mixture was diluted with 20 mL of DCM, poured into 5 mL of saturated NaHCO3 
aqueous solution and the resulting mixture was stirred at room temperature for 
0.5 h. The organic layer was recovered and washed with water (10 mL), dried over 
MgSO4, filtered and concentrated in vacuo. The residue was purified by column 
chromatography (silica gel, petroleum ether−ethyl acetate: 95:5 to 80:20); to 
afford 129. 
 





210.6 mg, 78% yield in two steps; white solid; mp= 80-81 °C; Rf = 0.57 (petroleum 
ether−ethyl acetate: 8:2); [α]D26: +70.7 (c = 1.0, CHCl3); 1H-NMR (400 MHz, CDCl3) 
δ: 8.06 (d, J = 8.2 Hz, 2H, ArH), 7.63 (d, J = 8.2 Hz, 2H, ArH), 4.83 (dd, J = 10.4, 8.0 
Hz, 1H, CHCO), 4.58 (m, 2H, CH2O), 1.47 (s, 9H, COOC(CH3)3); 13C-NMR (100 MHz, 
CDCl3) δ: 170.0, 164.7, 133.2 (q, J = 32.3 Hz), 130.4, 128.9 (× 2), 125.2, 125.1, 123.6 
(q, J = 270.7 Hz), 82.3, 70.0, 69.4, 27.8 (× 3); HRMS (MALDI): m/z [M + H]+ calcd for 
C15H17F3NO3+ 316.1155; found 316.1154. 
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2.8.4 Synthesis of (S)-2-(4-Methoxyphenyl)-2-oxazoline-4-carboxylic acid t-
butyl ester (130) 
 
The synthetic strategy was the same described for compound 129, starting from a 
solution of 4-methoxybenzoic acid to afford (S)-2-((4-methoxybenzoyl)-amino))-3-
hydroxypropionic acid t-butyl ester (198.5 mg, 66% yield) as a yellow oil. This 
compound was used without further purification as described above, affording 
130. 
 
(S)-2-(4-Methoxyphenyl)-2-oxazoline-4-carboxylic acid t-butyl ester (130) 
 
134 mg, 72% yield, white solid; mp= 70-71 °C. Rf = 0.35 (petroleum ether−ethyl 
acetate: 8:2); [α]D26: +82.3 (c =1.0, CHCl3). 
1H-NMR (400 MHz, CDCl3) δ: 7.91 (d, J = 8.8 Hz, 2H, ArH), 6.89 (d, J = 8.8 Hz, 2H, 
ArH), 4.78 (dd, J = 10.0, 8.2 Hz, 1H, CHCO), 4.53 (m, 2H, CH2O), 3.82 (s, 3H, ArOCH3), 
1.49 (s, 9H, COOC(CH3)3); 13C-NMR (100 MHz, CDCl3) δ: 170.6, 165.8, 162.3, 130.3 
(x 2), 119.6, 113.6 (x 2), 82.0, 69.6, 63.3, 55.3, 27.9 (x 3); HRMS (MALDI) m/z [M + 
H]+ calcd for C15H20NO4+ 278.1387; found 278.1386. 
 
2.8.5 General procedure for the Phase-Transfer Enantioselective Catalytic 
Alkylation of 2-aryl-2 oxazoline-4-carboxylic acid esters 
 
To a solution of 2-(4-Trifluoromethylphenyl)-2-oxazoline-4-carboxylic acid t-butyl 
ester (129) (158 mg, 0.50 mmol) and cyclopeptoid (84) (20.6 mg, 0.025 mmol) in 
toluene (5.0 mL) the benzyl bromide (103 mg, 0.60 mmol) was added. The reaction 
mixture was stirred at 0 °C and then the 50% aqueous NaOH (3.0 mL) was added. 
After completion, the reaction mixture was diluted with water (15 mL), washed 
with DCM (2 x 25 mL), dried over Na2SO4, filtered, and concentrated in vacuo. 
Purification of the residue by flash column chromatography on silica gel 
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(petroleum ether−ethyl acetate: 98:2 to 90:10) for 135, 140-145 or (DCM 100%) 
for 146 afforded the pure alkylated products. 
 
2.8.6 Determination of absolute configuration of alkylated compounds: 
Synthesis of (S)-α-Benzyl serine t-butyl ester (147). 
 
To a solution of NaBH3CN (19.9 mg, 0.06 mmol) in AcOH (0.35 mL) at 0°C 
oxazoline 135 or 120 was added. The mixture was stirred at room temperature for 
17h; after this time the solvent was removed and the residue was partitioned 
between AcOEt (3mL) and a saturated solution of Na2CO3 (5mL). The organic layer 
was treated with 10% NaOH until pH>12 and then recovered. The aqueous layer 
was washed with AcOEt (2 x 10mL). The combined organic layers were dried with 
Na2SO4 and concentrated in vacuo. The crude, used in the next step without 
purification, was dissolved in EtOH (1.5 mL) and 10% Pd/C (21.1 mg) was added. 
The mixture was stirred at rt for 24h under hydrogen athmosphere. The 
suspension was filtered through Celite, washed with EtOH and concentrated in 
vacuo. Purification by silica gel chromatography (DCM : MeOH + 0.1% NH4OH = 95 
: 5) afforded 147. 
 




2.6 mg, 11% yield, white solid, mp= 96-97 °C; ee 18%; [α]D21: +0.4 (c = 0.9, CHCl3).  
HPLC analysis: Chiralcel OD-H, i-PrOH/hexane = 1/99, 1.0 mL/min, 260 nm, tR 
(minor) = 22.2 min, tR (major) = 14.0 min; 1H-NMR (400 MHz, CDCl3) δ: 7.93 (m, 
2H, PhH), 7.48 (m, 1H, PhH), 7.39 (m, 3H, PhH), 7.22-7.17 (m, 4H, PhH), 4.72 (d, J = 
8.9 Hz, 1H, CHHO), 4.36 (d, J = 8.9 Hz, 1H, CHHO), 4.27 (m, 2H, OCH2CH3), 3.27 (br s, 
2H, CH2Ph), 1.28 (m, 3H, OCH2CH3); 13C-NMR (100 MHz, CDCl3) δ: 172.5, 164.8, 
135.5, 131.7, 130.3 (x 2), 128.6 (x 3), 128.2 (x 4), 127.0, 78.5, 72.6, 61.8, 43.5, 14.2; 
HRMS (MALDI) m/z [M + H]+ calcd for C19H20NO3+ 310.1438, found 310.1437. 
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15.0 mg, 50% yield, white solid, mp= 99-100 °C; ee 47%; [α]D21: +1.4 (c = 0.6, 
CHCl3).  
HPLC analysis: Chiralcel OD-H, i-PrOH/hexane = 1/99, 0.5 mL/min, 260 nm, tR 
(minor) = 42.1 min, tR (major) = 24.8 min; 1H-NMR (400 MHz, CDCl3) δ: 7.93 (m, 
2H, PhH), 7.48 (m, 1H, PhH), 7.39-7.33 (m, 7H, PhH), 7.19-7.14 (m, 5H, PhH), 5.28 
(d, J = 12.2 Hz, 1H, OCHHPh), 5.21 (d, J = 12.2 Hz, 1H, OCHHPh), 4.71 (d, J = 9.0 Hz, 
1H, CHHO), 4.35 (d, J = 9.0 Hz, 1H, CHHO), 3.30 (d, J = 13.8 Hz, CHHPh), 3.26 (d, J = 
13.8 Hz, CHHPh); 13C-NMR (100 MHz, CDCl3) δ: 172.2, 165.0, 135.4, 135.0, 131.7, 
130.3 (x 2), 128.5 (x 4), 128.4 (x 3), 128.3 (x 4), 127.1, 127.0, 78.6, 72.5, 67.3, 43.4;  
HRMS (MALDI) m/z [M + H]+ calcd for C24H22NO3+ 372.1594, found 372.1593. 
 
 
 (S)-2-Phenyl-4-benzyl-2-oxazoline-4-carboxylic acid cumyl ester (123) 
 
 
21.6 mg, 68% yield, colorless liquid; ee 45%; [α]D20: -1.1 (c = 1.0, CHCl3). 
HPLC analysis: Chiralcel OD-H, i-PrOH/hexane = 1/99, 1.0 mL/min, 260 nm, tR 
(minor) = 24.4 min, tR (major) = 34.4 min; 1H NMR (400 MHz, CDCl3) δ: 7.96 (m, 
2H, PhH), 7.50 (m, 1H, PhH), 7.42 (m, 2H, PhH), 7.35 (m, 2H, PhH), 7.28-7.22 (m, 
8H, PhH), 4.72 (d, J = 8.9 Hz, 1H, CHHO), 4.29 (d, J = 8.9 Hz, 1H, CHHO), 3.37 (d, J = 
13.9 Hz, 1H, CHHPh), 3.30 (d, J = 13.9 Hz, 1H, CHHPh), 1.82 (s, 3H, O(CH3)2Ph), 1.79 
(s, 3H, O(CH3)2Ph); 13C NMR (100 MHz, CDCl3) δ: 170.6, 164.8, 145.3, 135.6, 131.6, 
130.3 (x 2), 128.5 (x 2), 128.2 (x 6), 127.3, 127.1, 126.8, 124.2 (x 2),  83.2, 78.8, 
72.6, 42.8, 28.9, 27.9; HRMS (MALDI) m/z [M + H]+ calcd for C26H26NO3+ 400.1907, 
found 400.1905. 
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17.8 mg, 50% yield, white solid, mp= 124-127 °C; ee 61%; [α]D20: +9.7 (c = 0.8, 
CHCl3). HPLC analysis: Chiralcel OD-H, i-PrOH/hexane = 1/99, 0.5 mL/min, 260 
nm, tR (minor) = 29.5 min, tR (major) = 24.7 min; 1H NMR (400 MHz, CDCl3) δ: 7.93 
(m, 2H, PhH), 7.40-7.10 (m, 18H, PhH), 6.96 (s, 1H, OCHPh2), 4.73 (d, J = 9.0 Hz, 1H, 
CHHO), 4.33 (d, J = 9.0 Hz, 1H, CHHO), 3.37 (d, J = 13.9 Hz, 1H, CHHPh), 3.27 (d, J = 
13.9 Hz, 1H, CHHPh); 13C NMR (100 MHz, CDCl3) δ: 171.2, 165.0, 143.8 (x 2), 139.7, 
135.1, 131.7, 130.3 (x 2), 128.5 (x 4), 128.3, 128.1 (x 2), 127.9, 127.6, 127.4, 127.2, 
126.9 (x 2), 126.5 (x 4), 78.7, 77.9, 72.5, 42.9; HRMS (MALDI) m/z [M + H]+ calcd 
for C30H26NO3+  448.1907, found 448.1906. 
 
2-((4-Trifluoromethyl)benzoyl)-amino)-3-hydroxypropionic acid t-butyl 
ester (134a) 
 
794 mg, 89% yield; yellow amorphous solid; 
 1H-NMR (300 MHz, CDCl3) δ: 7.95 (d, J = 8.1 Hz, 2H, ArH), 7.71 (d, J = 8.2 Hz, 2H, 
ArH), 7.19 (br d, J = 6.5 Hz, 1H, NH), 4.74 (m, 1H, CHCO), 4.07 (m, 2H, CH2OH), 1.52 
(s, 9H, COOC(CH3)3). 
 
2-((4-Methoxy)benzoyl)-amino)-3-hydroxypropionic acid t-butyl ester 
(134b) 
 
199 mg, 66% yield; yellow amorphous solid; 
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1H-NMR (300 MHz, CDCl3) δ: 7.80 (m, 2H, ArH), 7.04 (br d,  J = 6.5 Hz, 1H, NH), 6.93 
(d, J = 8.8 Hz, 2H, ArH), 4.72 (m, 1H, CHCO), 4.07 (dd, J = 11.2, 3.4 Hz, 2H, CHHOH), 
3.98 (dd, J = 11.2, 4.6 Hz, 2H, CHHOH), 3.86 (s, 3H, ArOCH3), 1.52 (s, 9H, 
COOC(CH3)3). 
 
2-[(1-Naphtyl-2-carbonyl)-amino]-3-hydroxy-propionic acid t-butyl ester 
(134c) 
 
316 mg, 99% yield; yellow amorphous solid; 
1H-NMR (400 MHz, CDCl3) δ: 8.39 (d, J = 8.2 Hz, 1H, ArH), 7.95 (d, J = 8.2 Hz, 1H, 
ArH), 7.88 (d, J = 7.5 Hz, 1H, ArH), 7.72 (d, J = 7.1 Hz, 1H, ArH), 7.59-7.46 (m, 2H, 
ArH), 6.93 (br s, 1H, NH), 4.88 (m, 1H, CHCO), 4.11 (br s, 2H, CH2OH), 2.60 (br s, 1H, 
CH2OH), 1.54 (s, 9H, COOC(CH3)3). 
 




322 mg, 99% yield; yellow amorphous solid; 
1H-NMR (400 MHz, CDCl3) δ: 8.37 (br s, 1H, ArH), 7.92-7.88 (m, 3H, ArH), 7.57 (m, 
2H, ArH), 4.80 (m, 1H, CHCO), 4.14 (dd, J = 11.0, 3.0 Hz, 1H, CHHOH), 4.06 (dd, J = 
11.0, 4.2 Hz, 1H, CHHOH), 2.59 (br s, 1H, CH2OH), 1.54 (s, 9H, COOC(CH3)3). 
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1373 mg, 93% yield; yellow amorphous solid; 
1H-NMR (300 MHz, CDCl3) δ: 7.67 (m, 1H, ArH), 7.46-7.40 (m, 8H, ArH), 6.14 (br d, J 
= 5.7 Hz, 1H, NH), 4.48 (m, 1H, CHCO), 3.67 (br s, 2H, CH2OH), 2.62 (br s, 1H, 
CH2OH), 1.40 (s, 9H, COOC(CH3)3). 
(S)-2-(4-Trifluoromethylphenyl)-4-benzyl-2-oxazoline-4-carboxylic acid t-
butyl ester (135) 
 
 
151 mg, 75% yield; white solid; mp= 89-91 °C; ee 72%; Rf = 0.71 (petroleum 
ether−ethyl acetate: 8:2); ee 72%; [α]D30: +89.0 (c = 1.0, CHCl3, 72% ee);  
HPLC analysis: Chiralcel OD-H, i-PrOH/hexane = 1/99, 1.0 mL/min, 260 nm, tR 
(minor) =  9.5 min, tR (major) =  6.4 min; 1H-NMR (400 MHz, CDCl3) δ: 8.04 (d, J = 
8.2 Hz, 2H, ArH), 7.65 (d,  J = 8.2 Hz, 2H, ArH), 7.26-7.21 (m, 5H, PhH), 4.68 (d, J = 
9.0 Hz, 1H, CHHO), 4.34 (d, J = 9.0 Hz, 1H, CHHO), 3.24 (br s, 2H, CH2Ph), 1.48 (s, 
9H, COOC(CH3)3); 13C-NMR (100 MHz, CDCl3) δ: 171.2, 163.4, 135.4, 133.0 (q, J = 
32.3 Hz), 130.7, 130.4 (× 2), 128.9 (× 2), 128.2 (× 2), 127.0, 125.2 (× 2), 123.6 (q, J = 
271.9 Hz), 82.4, 79.0, 73.1, 43.1, 27.9 (× 3); HRMS (MALDI): m/z [M + H]+ calcd for 
C22H23F3NO3+ 406.1625; found: 406.1623. 
 




19.6 mg, 67% yield, white solid, mp= 75-77 °C; ee 62%; [α]D30: +69.4 (c = 1.0, 
CHCl3, 62% ee); HPLC analysis: Chiralcel OD-H, i-PrOH/hexane = 1/99, 0.5 
mL/min, 260 nm, tR (minor) = 24.8 min, tR (major) = 12.2 min. 1H NMR (400 MHz, 
CDCl3) δ: 7.88 (d, J = 8.9 Hz, 2H, ArH), 7.25-7.18 (m, 5H, PhH), 6.88 (d,  J = 8.9 Hz, 
2H, ArH), 4.62 (d, J = 8.8 Hz, 1H, CHHO), 4.28 (d, J = 8.8 Hz, 1H, CHHO), 3.84 (s, 3H, 
OCH3), 3.26 (d, J = 13.8 Hz, 2H, CHHPh), 3.20 (d, J = 13.8 Hz, 2H, CHHPh), 1.46 (s, 
9H, COOC(CH3)3); 13C NMR (100 MHz, CDCl3) δ: 171.6, 164.4, 162.2, 135.8, 130.4 (x 
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2), 130.3 (x 2), 128.1 (x 2), 126.8, 119.8, 113.6 (x 2), 82.1, 78.8, 72.8, 55.3, 43.3, 
28.0 (x 3); HRMS (MALDI) m/z [M + H]+ calcd for C22H26NO4+  368.1856, found 
368.1854. 
 




16 mg, 52% yield, white amorphous solid; ee 46%; HPLC analysis: Chiralcel OD-H, 
i-PrOH/hexane = 1/99, 0.5 mL/min, 260 nm, tR (minor) = 11.8 min, tR (major) = 
10.3 min.1H-NMR (400 MHz, CDCl3) δ: 8.84 (d, J = 8.3 Hz, 1H, ArH), 7.94 (d, J = 8.2 
Hz, 1H, ArH), 7.90-7.85 (m, 2H, ArH), 7.56-7.45 (m, 4H, ArH), 7.32-7.22 (m, 4H, 
PhH), 4.72 (d, J = 8.8 Hz, 1H, CHHO), 4.37 (d, J = 8.8 Hz, 1H, CHHO), 3.34 (m, 2H, 
CH2Ph), 1.53 (s, 9H, COOC(CH3)3); 
 
 
2-(2-Naphtyl)-2-oxazoline-4-carboxylic acid t-butyl ester (138) 
 
 
19.7 mg, 64% yield, white amorphous solid; ee 62%; HPLC analysis: Chiralcel OD-
H, i-PrOH/hexane = 1/99, 0.5 mL/min, 260 nm, tR (minor) = 68.4 min, tR (major) = 
30.8 min. 1H-NMR (400 MHz, CDCl3) δ: 8.42 (s, 1H, ArH), 8.05 (d, J = 8.4 Hz, 1H, 
ArH), 7.90-7.84 (m, 3H, ArH), 7.53 (m, 2H, ArH), 7.30-7.18 (m, 5H, PhH), 4.72 (d, J = 
8.8 Hz, 1H, CHHO), 4.38 (d, J = 8.8 Hz, 1H, CHHO), 3.30-3.29 (m, 2H, CH2Ph), 1.49 (s, 
9H, COOC(CH3)3); 
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20.6 mg, 62% yield, white amorphous solid; ee 73%; HPLC analysis: Chiralcel OD-
H, i-PrOH/hexane = 1/99, 0.5 mL/min, 260 nm, tR (minor) = 26.3 min, tR (major) = 
12.1 min. 1H-NMR (400 MHz, CDCl3) δ: 7.74 (d, J = 7.6 Hz, 1H, ArH), 7.49 (m, 1H, 
ArH), 7.37-7.21 (m, 12H, ArH + PhH), 4.37 (d, J = 8.9 Hz, 1H, CHHO), 3.99 (d, J = 8.9 
Hz, 1H, CHHO), 3.31 (d, J = 13.9 Hz, 1H, CHHPh), 3.12 (d, J = 13.9 Hz, 1H, CHHPh), 
1.48 (s, 9H, COOC(CH3)3); 
 
(S)-2-(4-Trifluoromethylphenyl)-4-o-tolyl-2-oxazoline-4-carboxylic acid t-




152 mg, 73% yield; colorless liquid; ee 67%; Rf = 0.54 (petroleum ether−ethyl 
acetate: 9:1); [α]D28: +61.7 (c = 0.7, CHCl3 67% ee);  
HPLC analysis: Chiralcel AD-H, i-PrOH/hexane = 1/99, 0.5 mL/min, 260 nm, tR 
(minor) =  13.6 min, tR (major) =  15.8 min; 1H-NMR (400 MHz, CDCl3) δ: 8.05 (d, J = 
8.5 Hz, 2H, ArH), 7.65 (d, J = 8.2 Hz, 2H, ArH), 7.19-7.04 (m, 4H, ArH + PhH), 4.77 (d, 
J = 8.9 Hz, 1H, CHHO), 4.29 (d, J = 8.9 Hz, 1H, CHHO), 3.34-3.27 (br s, 2H, CH2Ar), 
2.35 (s, 3H, CH3Ph), 1.46 (s, 9H, COOC(CH3)3); 13C-NMR (100 MHz, CDCl3) δ: 171.5, 
163.2, 137.3, 134.1, 133.1 (q, J = 32.4 Hz), 130.7, 130.4, 130.0, 128.9 (× 2), 126.9, 
125.7, 125.2 (× 2), 123.5 (q, J = 270.9 Hz), 82.4, 79.2, 73.5, 39.4, 27.9 (× 3), 20.3; 
HRMS (MALDI): m/z [M + H]+ calcd for C23H25F3NO3+ 420.1781; found: 420.1789. 
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(S)-2-(4-Trifluoromethylphenyl)-4-p-tolyl-2-oxazoline-4-carboxylic acid t-
butyl ester (141) 
 
 
129 mg, 61% yield; white solid; mp= 121-123 °C; ee 68%; Rf = 0.78 (petroleum 
ether−ethyl acetate: 8:2); [α]D28: +62.8 (c = 1.0, CHCl3, 68% ee);  
HPLC analysis: Chiralcel AD-H, i-PrOH/hexane = 1/99, 0.5 mL/min, 260 nm, tR 
(minor) =  17.1 min, tR (major) = 26.3 min; 1H-NMR (400 MHz, CDCl3) δ: 8.05 (d, J = 
7.6 Hz, 2H, ArH), 7.65 (d, J = 7.6 Hz, 2H, ArH), 7.12 (d, J = 7.2 Hz, 2H, ArH), 7.04 (d, J 
= 7.2 Hz, 2H, ArH), 4.68 (d, J = 8.9 Hz, 1H, CHHO), 4.33 (d, J = 8.9 Hz, 1H, CHHO), 
3.21 (br s, 2H, CH2Ph), 2.28 (s, 3H, CH3Ph), 1.49 (s, 9H, COOC(CH3)3); 13C-NMR (100 
MHz, CDCl3) δ:171.2, 163.3, 136.5, 133.1 (q, J = 32.4 Hz), 132.9, 132.2, 130.8, 130.2 
(× 2), 128.9 (× 3), 125.2 (× 2), 123.6 (q, J = 270.4 Hz),  82.4, 79.1, 73.1, 42.7, 27.9 (× 




acid t-butyl ester (142) 
 
 
135 mg, 58% yield; white solid; mp= 105-107 °C; ee 74%; Rf = 0.88 (petroleum 
ether−ethyl acetate: 9:1); [α]D30: +53.2 (c = 1.0, CHCl3 , 74% ee);  
HPLC analysis: Chiralcel AD-H, i-PrOH/hexane = 1/99, 0.5 mL/min, 260 nm, tR 
(minor) =  12.7 min, tR (major) =  13.9 min; 1H-NMR (400 MHz, CDCl3) δ:8.05 (d, J = 
8.2 Hz, 2H, ArH), 7.65 (d, J = 8.2 Hz, 2H, ArH), 7.25 (d, J = 8.2 Hz, 2H, ArH), 7.17 (d, J 
= 8.2 Hz, 1H, ArH), 4.70 (d, J = 8.9 Hz, 1H, CHHO), 4.35 (d, J = 8.9 Hz, 1H, CHHO), 
3.26 (d, J = 13.9 Hz, 1H CHHAr), 3.18 (d, J = 13.9 Hz, 1H CHHAr), 1.47 (s, 9H, 
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COOC(CH3)3), 1.26 (s, 9H, PhC(CH3)3); 13C-NMR (100 MHz, CDCl3) δ: 171.2, 163.3, 
149.8, 133.1 (q, J = 32.8 Hz), 132.3, 130.8, 130.0 (× 2), 128.9 (× 2), 125.2 (× 2), 
125.1 (× 2), 123.5 (q, J = 270.4 Hz), 82.4, 79.1, 73.3, 42.8, 34.4, 31.3 (× 3), 27.9 (× 




acid t-butyl ester (143) 
 
 
175 mg, 83% yield; white solid; mp= 99-100 °C; ee 70%; Rf = 0.89 (petroleum 
ether−ethyl acetate: 7:3); [α]D27: +76.4 (c = 1.0, CHCl3, 70% ee); 
 HPLC analysis: Chiralcel OD-H, i-PrOH/hexane = 1/99, 1.0 mL/min, 260 nm, tR 
(minor) =  6.5 min, tR (major) =  5.6 min; 1H-NMR (400 MHz, CDCl3) δ: 8.04 (d, J = 
8.2 Hz, 2H, ArH), 7.66 (d, J = 8.2 Hz, 2H, ArH), 7.22 (m, 2H, ArH), 6.92 (m, 2H, ArH), 
4.67 (d, J = 9.0 Hz, 1H, CHHO), 4.31 (d, J = 9.0 Hz, 1H, CHHO), 3.25 (d, J = 13.9 Hz, 
1H, CH2Ar), 3.15 (d, J = 13.9 Hz, 1H, CH2Ar), 1.47 (s, 9H, COOC(CH3)3); 13C-NMR 
(100 MHz, CDCl3) δ: 171.1, 163.5, 162.0 (d, J = 250.0 Hz), 133.2 (q, J = 32.4 Hz), 
131.9 (d, J = 7.8 Hz) (× 2), 131.1, 130.6, 128.8 (× 2), 125.2 (× 2), 123.6 (q, J = 272.5 
Hz), 115.0 (d, J = 21.1 Hz) (× 2), 82.5, 78.9, 73.2, 42.3, 27.9 (× 3); HRMS (MALDI): 
m/z [M + H]+ calcd for C22H22F4NO3+ 424.1530; found: 424.1529. 
 
(S)-2-(4-Trifluoromethylphenyl)-4-chloro-phenyl-2-oxazoline-4-carboxylic 
acid t-butyl ester (144) 
 
 
163 mg, 74% yield; white solid; mp= 110-111 °C ; ee 62%; Rf = 0.74 (petroleum 
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ether−ethyl acetate: 7:3); [α]D27: +66.7 (c = 1.0, CHCl3, 62% ee);  
HPLC analysis: Chiralcel OD-H, i-PrOH/hexane = 1/99, 1.0 mL/min, 260 nm, tR 
(minor) =  6.6 min, tR (major) =  5.6 min; 1H-NMR (400 MHz, CDCl3) δ: 8.04 (d, J = 
7.6 Hz, 2H, ArH), 7.66 (d, J = 7.6 Hz, 2H, ArH), 7.20 (m, 4H, PhH), 4.67 (d, J = 8.9, 1.7 
Hz, 1H, CHHO), 4.29 (d, J = 8.9, 1.7 Hz, 1H, CHHO), .25 (d, J = 13.9 Hz, 1H, CH2Ar), 
3.15 (d, J = 13.9 Hz, 1H, CH2Ar), 1.47 (s, 9H, COOC(CH3)3); 13C-NMR (100 MHz, 
CDCl3) δ: 171.0, 163.5, 133.9, 133.2 (q, J = 32.4 Hz), 132.8, 131.7 (× 2), 130.5, 128.9 
(× 2), 128.3 (× 2), 125.3 (× 2), 123.6 (q, J = 271.8 Hz), 82.6, 78.8, 73.3, 42.2, 27.9 (× 




carboxylic acid t-butyl ester (145) 
 
 
167 mg, 74% yield; white solid; mp= 126-128 °C; ee 75%; Rf = 0.82 (petroleum 
ether−ethyl acetate: 9:1); [α]D30: +79.8 (c = 1.0, CHCl3, 75% ee);  
HPLC analysis: Chiralcel OD-H, i-PrOH/hexane = 1/99, 0.5 mL/min, 260 nm, tR 
(minor) =  18.8 min, tR (major) =  24.8 min; 1H-NMR (400 MHz, CDCl3) δ: 8.04 (d, J = 
8.0 Hz, 2H, ArH), 7.78-7.64 (m, 6H, ArH + NpH), 7.42 (m, 3H, NpH), 4.72 (d, J = 8.9 
Hz, 1H, CHHO), 4.41 (d, J = 8.9 Hz, 1H, CHHO), 3.43 (bs, 2H, CH2O), 1.49 (s, 9H, 
COOC(CH3)3); 13C-NMR (100 MHz, CDCl3) δ: 171.2, 163.5, 133.2, 133.1 (q, J = 32.3 
Hz), 133.0 132.4, 130.7, 129.1, 128.9 (× 2), 128.6, 127.7, 127.6 (× 2), 126.0, 125.7, 
125.2 (× 2), 123.6 (q, J = 270.2 Hz), 82.5, 79.2, 73.1, 43.2, 27.3 (× 3); HRMS 
(MALDI): m/z [M + H]+ calcd for C26H25F3NO3+ 456.1781; found: 456.1777. 
 
(S)-2-(4-Trifluoromethylphenyl)-4-allyl)-2-oxazoline-4-carboxylic acid t-
butyl ester (146) 
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97 mg, 55% yield; coloress liquid; ee 48%; Rf = 0.87 (petroleum ether−ethyl 
acetate: 9:1); [α]D27: +8.9 (c = 1.0, CHCl3, 48% ee);  
HPLC analysis: Chiralcel AS-H, i-PrOH/hexane = 1/99, 0.5 mL/min, 260 nm, tR 
(minor) =  7.6 min, tR (major) =  8.2 min; 1H-NMR (400 MHz, CDCl3) δ: 8.09 (d, J = 
8.0 Hz, 2H, ArH), 7.67 (d, J = 8.0 Hz, 2H, ArH), 5.70 (m, 1H, CCH2CHCH2), 5.17 (m, 
2H, CCH2CHCH2), 4.73 (d, J = 8.9 Hz, CHHO), 4.29 (d, J = 8.9 Hz, CHHO), 2.74-2.61 
(m, 2H, CCH2CHCH2), 1.50 (s, 9H, COOC(CH3)3); 13C-NMR (100 MHz, CDCl3) δ: 171.0, 
163.4, 133.3 (q, J = 32.4 Hz), 131.7, 129.0 (× 3), 125.2 (× 2), 123.5 (q, J = 270.4 Hz), 
119.7, 82.3, 78.1, 73.4, 42.1, 28.0 (× 3); HRMS (MALDI): m/z [M + H]+ calcd for 
C18H21F3NO3+ 356.1468; found: 356.1464. 
 
(S)-α-Benzyl serine t-butyl ester (147) 
 
Starting from 135: 11.5 mg, 70% yield; coloress liquid; [α]D27: +1.3 (c = 0.9, CHCl3).  
Starting from 120: 9.8 mg, 80% yield; coloress liquid; [α]D27:  +1.4 (c = 0.8, CHCl3). 
1H NMR (400 MHz, CDCl3) δ: 7.37-7.33 (m, 3H, PhH), 7.27 (m, 2H, PhH), 3.83 (d, J = 
10.6 Hz, 1H, CHHOH), 3.62 (d, J = 10.6 Hz, 1H, CHHOH), 3.16 (d, J = 13.5 Hz, 1H, 
CHHPh), 2.89 (d, J = 13.5 Hz, 1H, CHHPh), 2.06 (br s, 3H, NH2, OH), 1.54 (s, 9H, 
O(CH3)3); 13C NMR (100 MHz, CDCl3) δ: 174.2, 135.7, 130.1 (× 2), 128.4 (× 2),  
127.0, 82.0, 68.1, 63.1, 41.7, 28.0 (× 3); HRMS (MALDI): m/z [M + H]+ calcd for 
C14H22NO3+ 252.1594; found: 252.1590. 
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3. DIASTEROSELECTIVE SYNTHESIS OF γ-BUTENOLIDES  
3.1 Synthesis of γ-butenolides 
Butenolides are unsaturated γ-lactones, widely diffused as natural biologically 
active compounds, present in terrestrial, marine and microbial sources. For 
example, butenolide frameworks are incorporated in naturally occurring steroids 
from plants and microorganisms.95 Other representative examples of butenolide-
containing natural products are the Securinega alkaloids such as securinine (151), 




Figure 3.1 Representative examples of Securinega alkaloids 
 
The family of Securinega alkaloids is composed of 60 different metabolites and the 
the most abundant is securinine (151) that is able to induce apoptosis of several 
cancer cell lines. 96 
Construction of -butenolides received considerable attention in total synthesis of 
natural products. Some examples of biologically active -butenolides are indicated 
in figure 3.2. These compounds showed unique biologically features such as anti-




Figure 3.2 Examples of biologically active -butenolides (154-157) 
                                                          
95 Y. S. Rao, Chem. Rev., 1964, 353-388. 
96 E. Chirkin, S. Michel, F. H. Porée, J. Org, Chem., 2015, 80, 6525-6528. 
97 L. Vasamsetty, F. A. Khan, G. Mehta, Tetrahedro Lett., 2015, 71, 3209-3215. 
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The presence of a lactone moiety characterized the family of cardenolides which 
contain a five-membered unsaturated butyrolactone ring. Cardenolides are cardiac 
glycosides also able to inhibit the growth of cancer cell lines. One of the cardiac 
glycosides, digitoxin (158), has been used for treatment of heart diseases.98 
Another important bioactive compund is giganin (159),99 a member of the 
annonaceous acetogenins, characterized by a long aliphatic chain with a terminal 
methyl-substituted α,β-unsaturated γ-lactone. 
 
Figure 3.3 Structures of digitoxin and giganin 
 
Furthermore, γ-butenolides are versatile chiral building blocks or intermediates, 
useful in synthetic strategies for the construction of natural products, that can be 
subjected to various transformations involving the carbon-carbon double bond or 




Scheme 3.1 Possible transformation of γ-butenolide rings 
                                                          
98 I. Prassas, E. P. Diamandis, Nature Reviews Drug Discovery, 2008, 7, 926-935. 
99 C. J. Fletcher, K. M. P. Wheelhouse, V. K. Aggarwal, Angew. Chem. Int. Ed., 2013, 52, 2503-
2506. 
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Hydrogenation reactions are widely used for the generation of saturated lactones, 
synthetic intermediates in the synthesis of natural products such as alkaloids and 
terpenoids,100 or biologically active compounds such as anti-tumor, anti-
depressants and antiviral compounds.101 Interesting derivatives are also obtained 
by cycloaddition reactions, dihydroxylations or reduction of the ester group. For 
example the cycloaddition reactions have been used by Fukuyama in order to 
obtain mitomycins (figure 3.4) potent anti-tumor agents.102 Examples of reactions 
involving the 1,4-addition to the double bond and opening of the lactone have been 
reported by Hanessian for the synthesis of ionomicine (figure 3.5).103  The 
prominent attention towards butenolides as target molecules or key synthetic 
intermediates has led to the development of new stereoselective methods of 
synthesis based on the vinylogous reactivity of γ-butenolides. The idea is to 
generate a new tertiary stereocenter in the γ-position of butenolide, by reaction of 
a 2-(5H)-furanone derivative (direct vinylogous reaction) with an electrophilic 
species. Alternatively, a 2-silyloxyfuran, an activated form of 2-(5H)-furanone, can 
be employed (Mukaiyama-type vinylogous reaction). 
 
 
Figure 3.4 Synthesis of mytomicin C 
                                                          
100. For examples see: a) M. T. Davis-Coleman, D. E. A. Rivett, Prog. Chem. Nat. Prod., 1989, 
55, 1–35; b) C. W. Jefford, D. Jaggi, A. W. Sledeski, Boukouvalas, J. In Studies in Natural 
Products Chemistry, 1989, 3, 157-171; c) L. A. Paquette, T. Z. Wang, E. Pinard, J. Am. Chem. 
Soc., 1995, 117, 1455–1456; d) H. Nemoto, T. Tanabe, K. Fukumoto, J. Org. Chem., 1995, 60, 
6785–6790.  
101. For examples see: a) H. Fukui, Y. Tsuchiya, K. Fujita, T. Nakagawa, H. Koshino, T. Nakata, 
Bioorg. Med. Chem. Lett., 1997, 7, 2081–2086; b) J. W. Hilborn, Z. H. Lu, A. R. Jurgens, Q. K. 
Fang, P. Byers, S. A. Wald, C. H. Senanayake, Tetrahedron Lett., 2001, 42, 8919–8921. 
102. For examples see: a) T. Fukuyama, L. Yang, Tetrahedron Lett., 1986, 27, 6299-6300; b) T. 
Fukuyama, L. Yang, J. Am. Chem. Soc., 1987, 109, 7881-7882; c) T. Fukuyama, L. Yang, J. Am. 
Chem. Soc., 1989, 111, 8303-8304. 
103. For examples see: a) S. Hanessian, P. J. Murray, Can. J. Chem.,1986, 64, 2231-2234; b) S. 
Hanessian, N. G. Cooke, B. DeHoff, Y. Sakito, J. Am. Chem. Soc., 1990, 112, 5276-5290. 
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Figure 3.5 Synthesis of ionomicin 
 
Reactions are possible with aldehydes, imines and electron–poor alkenes, to give 
aldol reactions, Mannich reactions or Michael reactions respectively (scheme 3.2). 
The following is a brief overview of the stereoselective synthesis of γ-butenolides 




Scheme 3.2 Vinylogous reactions of 2-(5H)-furanone or 2-silyloxyfuran  
 
3.2 Asymmetric vinylogous synthesis of γ-monosubstituted butenolides by 
Michael-type addition. 
 
The enantioselective Michael-type addition of 2-furanones and 2-silyloxyfurans to 
electron-poor alkenes is a much studied and widely used process. In this section it 
will be discussed only the protocols for the synthesis of -monosubstituted γ-
butenolides, starting from 5-unsubstituted substrates, that are most relevant to 
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our work. In 2003 it was reported the first example of asymmetric addition of 2-
silyloxyfuran with various α,β-unsaturated aldehydes by MacMillan and co-
workers (scheme 3.3). The catalytic system used, a chiral imidazolidinone, 
activates the electrophile with an iminium ion mechanism. The reaction takes 
place with complete regioselectivity towards the 1,4-addition while the steric 
constrains imposed by the catalyst prevent the 1,2-addition.104 An investigation on 
the Mukaiyama-Michael reaction between (E)-3-crotonyl-1,3-oxazolidin-2-one and 
2-trimethylsilyloxyfuran was conducted by Desimoni and collaborators (scheme 
3.4).105,106 In particular, lanthanide salts in the presence of pyridine-2,6-
bis(oxazoline) ligands was able to promote the highly stereoselective formation of 
the product with the anti configuration (R,R).  
 
 
Scheme 3.3 Organocatalyzed addition of silyloxy furan to α,β-unsaturated aldehydes 
 
 
Scheme 3.4 Mukayama-Michael reaction of 2-trimethylsilyloxyfuran to (E)-3-crotonyl-1,3-
oxazolin-2-one 
                                                          
104 S. P. Brown, N. C. Goodwin, D. W. C. MacMillan, J. Am. Chem. Soc., 2003, 125, 1192-1194. 
105 For examples see: a) G. Desimoni, G. Faita, M. Guala, A. Laurenti, M. Mella, Chem., Eur. J., 
2005, 11, 3816-3824; b) G. Desimoni, G. Faita, S. Filippone, M. Mella, M. G. Zampori, M. Zema, 
Tetrahedron, 2001, 57, 10203-10212. 
106. For other examples of Michael addition to α,β-unsaturated oxazolidin-2-ones see: a) H. 
Kitajima, T. Katsuki, Synlett, 1997, 568-569; b) H. Suga, T. Kitamura, A. Kakehi, T. Baba, 
Chem. Commun, 2004,1414-1415. 
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Trost and co-workers in 2009 developed the first direct asymmetric Michael 
addition of 2-trimethylsilyloxyfuran to nitroalkenes (scheme 3.5). The use of a 
dinuclear zinc complex allowed the synthesis of γ-butenolide nitro-derivatives 
with high enantiomeric excesses and diastereomeric ratios up to 20: 1.107 
 
  
Scheme 3.5 Direct asymmetric Michael addition of 2-trimethylsilyloxyfuran to nitroalkenes 
The asymmetric vinylogous Michael reaction of γ-butenolides to trans-chalcones 
has been extensively studied. This reaction has been described by Ge, Li and 
coworkers in the presence of chiral 1,2-diaminocyclohexane (scheme 3.6).108 A 
wide variety of 3,4-diarylated 2-(5H)-furanones and chalcones reacted with high 
diastereo- and enantio- selectivities. An high enantioselectivity was obtained by 
using unsubstituted  furan-2(5H)-one as well, although only a 1:1 syn/anti ratio 
was obtained in this case. An example of asymmetric vinylogous Mukaiyama-
Michael reaction of 2-silyloxyfuran with trans-chalcones was conducted by Feng 
and co-workers (scheme 3.7). The use of Sc(OTf)3 in the presence of a N,N'-dioxide 
chiral ligand containing L-proline residues has been particularly effective to obtain 
exclusively the anti adduct with high ee’s.109 However, from the atom economy 
point of view, the employment of commercially available unmodified γ-butenolides 
instead of 2-silyloxyfurans is more attractive. Ji, Wang and co-workers in 2010 
obtained good diastereoselectivities and enantiomeric excesses in the Michael 
addition reaction between 2-(5H)-furanone and trans-chalcone derivatives 
                                                          
107 B. M. Trost, J. Hitee, J. Am. Chem. Soc., 2009, 131, 4572-4573. 
108 J. Wang, C. Qi, Z. Ge, T. Cheng, R. Li, Chem. Commun., 2010, 46, 2124-2126. 
109 Q. Zhang, X. Xiao, L. Lin, X. Liu, X. Feng, Org. Biomol. Chem., 2011, 9, 5748-5754. 
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promoted by Takemoto catalyst (scheme 3.8).110 This catalytic approach proved to 
be ineffective with aliphatic enones. Liang, Ye and coworkers  developed a triamine 
catalyst, characterized by a chiral spatial pocket, which afforded Michael adducts 
with excellent enantioselectivities (scheme 3.9).111 However, the anti product was 
obtained with high diastereoselectivities only with methyl-,-unsaturated 
ketones (R2=Me in scheme 3.9); with more hindered Michael acceptor (e.g. R2=Ph 
or Bu) the anti-diastereoselectivities proved to be moderate. 
 
 









Scheme 3.8 Organocatalytic direct conjugate addition of γ -Butenolide to chalcones  
 
                                                          
110 Y. Zhang, C. Yu, Y. Ji, W. Wang, Chem. Asian J., 2010, 5, 1303-1306. 
111 H. Huang, F. Yu, Z. Jin, W. Li, W. Wu, X. Liang, J. Ye, Chem. Commu., 2010, 46, 5957-5959. 
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Scheme 3.9 Organocatalytic asymmetric vinylogous Michael reaction 
 
 
3.3 Diasteroselective vinylogous synthesis of γ-monosubstituted butenolides 
by Michael-type addition.  
 
As previously seen, to date the research has been primarily aimed to the enantio- 
and diastereoselective vinylogous Michael addition of 2-silyloxyfuran or 2-(5H)-
furanone promoted by chiral organocatalysts or transition metal complexes which 
are generally expensive or not commercially available. The latter may require a 
tedious laboratory synthesis starting from relatively expensive chiral building 
blocks. The use of chiral catalysts is unnecessary for the development of purely 
diastereoselective vinylogous Michael addition. This issue has recently encouraged 
the invention of novel methods based on simple and off-the-shelf catalysts. Yadav 
and co-workers reported in 2009 a metal-free synthesis of γ-substituted 
butenolides promoted by iodine, that is characterized by a mild Lewis acidity. The 
addition of 2-trimethylsilyloxyfuran to different α,β-unsaturated compounds at 
low temperatures afforded the syn diasteroisomer with moderate to high 
diastereoselectivity (scheme 3.10).112 
 
 
Scheme 3.10 Iodine-catalyzed synthesis of butenolides 
                                                          
112 J. S. Yadav, S. B. V. Reddy, G. Narasimhulu, S. N. Reddy, J. P. Reddy, Tetrahedron Lett., 
2009, 50, 3760-3762. 
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In other studies the syn/anti diastereoselectivity in the Mukaiyama-Michael 
addition of 2-trimethylsilyloxyfuran to ,-unsaturated ketones was disappointing 
or limited in scope. 
Du, He and co-workers, in 2015, employed N-heterocyclic carbenes (NHCs) in a 
diasteroselective reaction of 2-trimethylsilyloxyfuran and enones. High anti-
diastereoselectivities and excellent yields were achieved with various chalcone 
derivatives. This system was also applicable to aliphatic enones but moderate 
yields and moderate anti-diasteroselectivities were obtained (scheme 3.11).113  
 
Scheme 3.11 N-Heterocyclic-Carbene-Catalysed Diastereoselective Vinylogous 
Mukaiyama/Michael Reaction of 2-(Trimethylsilyloxy)furan and Enones 
 
Taguchi and co-workers explored the effect of a Brønsted acid catalyst, 1,1,3,3-
tetrakis(trifluoromethanesulfonyl)propane in this reaction (scheme 3.12).114 
Although this proved to be an efficient regioselective method for the 1,4 addition, 
only moderate diastereoselectivities were obtained with 2-triethylsilyloxyfuran. 
Good anti-diastereoselectivities were achieved only with 3-bromo-derivative of 2-
silyloxyfuran. 
In 2012 Fraile and collaborators developed the Mukayama-Michael addition of 2-
trimethylsilyloxyfuran to α,β unsaturated carbonyl derivatives, using a Lewis acid 
catalyst.115 They employed Cu(OTf)2 as homogeneous catalyst or copper-
exchanged laponite as heterogeneous catalyst. However low anti-
diastereoselectivities were obtained with ,-unsaturated ketones as Michael 
acceptors (scheme 3.13). 
                                                          
113. Y. Wang, G. Du, F. Xing, K. Huang,B. Dai, L. He, Asian J. Org. Chem., 2015, 4, 1362–1365. 
114. A. Takahashi, H. Yanai, M. Zhang, T. Sonoda, M. Mishima, T. Taguchi, J. Org. Chem., 2010, 
75, 1259-1265. 
115 J. M. Fraile, N. Garcià, C. I. Herrerìas, M. Martin, J. A. Mayoral, ACS Catal., 2012, 2, 56-64. 
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Scheme 3.12 Vinylogous Mukayama-Michael reaction catalyzed with 
 1,1,3,3-tetrakis(trifluoromethanesulfonyl) propane  
 
 
Scheme 3.13 Vinylogous Mukayama-Michael reaction promoted by copper catalysts 
 
3.4 Novel synthetic strategies for the synthesis of γ- butenolides using a 
diastereoselective Mukayama-Michael addition  
The interest in the developing convenient and stereoselective methodologies to 
obtain γ-butenolides, has been demonstrated by numerous studies reported in 
literature as discussed above. On the other hand, the diastereoselective vinylogous 
Mukaiyama-Michael addition of 2-silyloxyfuran catalyzed by achiral, cheap and 
easily available compounds, has been rarely reported. Furthermore, it would be 
intriguing to develop an efficient and convenient methodology that would afford 
both the syn and the anti diastereomer. Therefore, one of the aim of this PhD 
project was to test commercially available macrocyclic phase-transfer catalysts in 
fluoride-promoted Mukayama-Michael addition of silyloxyfurans to ,-
unsaturated ketones. While it is well-established the application of organic fluoride 
as promoters of Mukaiyama-Michael addition with silyl enol ethers, this strategy 
has never been applied to silyloxyfurans to date.116 To the best of our knowledge a 
unique example of vinylogous Michael addition of 2-trimethylsilyloxyfuran 
promoted by a fluoride, the tetra-n-butylammonium fluoride (TBAF), was reported 
as a step in the synthesis of mytomicins.91a However, in this article the 
diasteroisomeric ratio obtained is not reported.  
                                                          
116 a) R. Noyori, K. Yokoyama, J. Sakata, J. Am. Chem. Soc., 1977, 1265-1266; b) T. V. 
RajanBabu,  J. Am. Chem. Soc., 1984, 49, 2083-2089. 
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3.5 Mukayama-Michael addition of trans-chalcone with 2-
trimethylsilyloxyfuran catalyzed by TBAF 
 
Considering the few data reported in the literature, the use of organic fluoride, 
such as TBAF, was first investigated in the vinylogous Mukayama-Michael reaction 
of 2-trimethylsilyloxyfuran with trans-chalcone. The experiments were carried out 
using TBAF as catalyst in different solvents in order to evaluate differences 
between apolar solvent such as toluene, aprotic polar solvents (DMF and THF) and 
medium polar solvents (CHCl3 and DCM). In all cases the adducts 168 and 169 
were formed in mixture with their respective trimethylsilyl enol ethers. Therefore, 
once the reaction was complete, it followed a treatment with HCl in order to 
desilylate the adducts. The reaction in DMF and DCM led to a complex mixture of 
products (Table 3.1, entries 3,5), while in all the other solvents TBAF efficiently led 
to products with a preference for the anti diasteroselectivity. Interestingly in CHCl3 
an high diasteroisomeric ratio was achieved (98/2 anti/syn, Table 3.1, entry 2). 
 
Table 3.1 Vinylogous Mukayama-Michael reaction of trans-chalcone catalyzed by TBAFa  
 
Entry Solvent T(°C) Time(h) syn/antib Yieldc,d(%) 
1 Toluene -78 40 7/93 57 
2 CHCl3 -55 4 2/98 84 
3 DMF -60 5 - - 
4 THF -78 15 17/83 79 
5 DCM -78 24 - - 
aAll reactions were carried out in liquid-liquid system at 0.218 mmol scale using 167 (1.0 eq.), 2-
trimethylsilyloxyfuran (1.2 eq.) and catalyst TBAF (10 mol%) in the appriopriate solvent (1.1 mL). 
bsyn/anti ratio was determined by 1H NMR spectroscopy of the crude products. cIsolated yields. 
dMixture of products. 
 
 
3.6 Mukayama-Michael addition of trimethylsilyloxyfuran to trans-chalcone 
catalyzed by dicyclohexane-18-crown-6 
Afterwards, the Mukayama-Michael reaction was carried out with inorganic 
fluoride, KF, in presence of dicyclohexane-18-crown-6 as a phase-transfer catalyst. 
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A screening of solvents was performed using toluene, halogenated solvents (DCE, 
CHCl3, DCM), aprotic polar solvents (THF, DMF, ACN). The temperature for each 
entry was choosen compatibly with the melting point of the solvent. Surprisingly, 
an extraordinary dependence of the diastereoselectivity on the solvent used, was 
observed. In toluene, differently from what observed with TBAF, a high syn-
diastereoselectivity was achieved (93/7 syn/anti, Table 3.2, entry 1). However, 
when we move from toluene to CHCl3, DCM, DMF and ACN (Table 3.2, entries 5, 6, 
7, 8) an inversion of diasteroselectivity was observed, and the anti product 169 
prevailed again. This catalytic system showed a better solvent tolerability than 
TBAF. In addition, the same high anti-diastereoselectivity was obtained in CHCl3, 
DCM, DMF and ACN (98/2 anti/syn). This interesting result has led to further 
investigations on the combination of different commercially available macrocyclic 
phase transfer-catalysts with inorganic fluorides, as silyloxyfurans activating 
agents. In order to assess the effect of the inorganic salts in diasteroisomeric ratio, 
a screening study was conducted. In toluene, the syn product 168 was favoured 
with all the inorganic salts tested. However, the best result was achieved 
performing the reaction with KF (Table 3.3, entry 1).  
 
Table 3.2 Vinylogous Mukayama-Michael reaction of 2-trimethylsilyloxyfuran and trans-
chalcone catalyzed by DCH-18-crown-6a 
 
Entry Solvent T(°C) Time(h) syn/antib Yieldc(%) 
1 Toluene -78 22 93/7 83 
2 Et2O -78 21 57/43 32 
3 THF -78 23 12/88 12 
4 DCE -30 2 12/88 86 
5 CHCl3 -55 21 2/98 87 
6 DCM -78 4 2/98 98 
7 DMF -60 2 2/98 74 
8 ACN -40 21 2/98 72 
aAll reactions were carried out in liquid-liquid system at 0.218 mmol scale using 167 (1.0 eq.), 
2-trimethylsilyloxyfuran (1.2 eq.), KF (1.0 eq.) and catalyst DCH-18-crown-6 (10 mol%) in the 
appriopriate solvent (1.1 mL). bsyn/anti ratio was determined by 1H NMR spectroscopy of the 
crude products. cIsolated yields.  
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Table 3.3 Screening of inorganic salts in Mukayama-Michael reaction catalyzed by DCH-18-
crown-6a,b 
 
Entry Inorganic Salt Time(h) syn/antib Yieldc(%) 
1 KF 22 93/7 83 
2 KOPh 43 83/17 63 
3 KOAc 43 88/12 40 
4 KOH 19 88/12 83 
5 CsF 41 82/18 67 
aAll reactions were carried out in liquid-liquid system at 0.218 mmol scale using 167 
(1.0 eq.), 2-trimethylsilyloxyfuran (1.2 eq.), KF (1.0 eq.) and catalyst DCH-18-crown-6 
(10 mol%) in toluene (1.1 mL) at -78°C. bsyn/anti ratio was determined by 1H NMR 





Figure 3.6 18-crown-6 and 15-crown-5 derivatives tested in the fluoride promoted 
Mukaiyama-Michael reaction 
 
The effect of the catalyst’s structure was then evaluated, using different crown 
ethers. 18-crown-6 derivatives and 15-crown-5 analogues were screened (figure 
3.6, Table 3.4) in order to clarify the possible correlation between the cavity size of 
the macrocycle and the diasteroisomeric ratio.  Most of the different catalytic 
systems showed good diastereoselectivities with the only exception of compound 
172. All the 18-crown-6 derivatives favored the syn isomer in toluene. Moreover 
with compound 5, the presence of molecular sieves in the reaction medium and the 
use of different catalyst loadings showed negligible effect on the diastereomeric 
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ratio. Unexpectedly, 15-crown-5 analogues, even in toluene, favored the anti 
isomer, with the exception of compound 171 (Table 3.4, entry 6). In particular, 
compound 173 afford the anti product with a very high diasteroselectivity (97/3 
anti/syn, entry 11). 
Taking into account that both 15-crown-5 ether derivatives and halogenated 
solvents promote mainly the anti products, we studied the performance of the best 
catalyst 173 in CHCl3 and DCM (Table 3.5, entries 1 and 2). To our delight, the 
structure of the macrocycle and type of solvents exerted a synergistic effect, and 
the anti product was obtained exclusively. 
Table 3.4 Screening of catalysts in Mukayama-Michael reaction of 2-trimethylsilyloxyfuran 
and trans-chalconea  
 
Entry Catalyst Time(h) syn/antib Yieldc(%) 
1 5 22 93/7 83 
2 4 44 88/12 80 
3 6 46 92/8 90 
4 170 43 88/12 93 
5d 5 20 90/10 74 
6e 5 20 88/12 70 
7f 5 20 95/5 86 
8 3 44 38/62 53 
9 171 41 92/8 54 
10 172 43 50/50 57 
11 173 40 3/97 76 
12 174 44 17/83 46 
aAll reactions were carried out in liquid-liquid system at 0.218 mmol scale using 167 (1.0 eq.), 
trimethylsilyloxyfuran (1.2 eq.), KF (1.0 eq.) and catalyst (10 mol%) in toluene (1.1 mL)at -78°C. 
bsyn/anti ratio was determined by 1H NMR spectroscopy of the crude products. cIsolated yields. dThe 
reaction was carried out with molecular sieves (4Å). eWith 2 mol% of 5. fWith 1.0 eq. of 5. 
 




Entry Catalyst Solvent T(°C) Time(h) syn/antib Yieldc(%) 
1 173 CHCl3 -55 21 <1/99 94 
2 173 DCM -78 6 <1/99 99 
aAll reactions were carried out in liquid-liquid system at 0.218 mmol scale using 167 (1.0 eq.), 
trimethylsilyloxyfuran (1.2 eq.), KF (1.0 eq.) and catalyst 173 (10 mol%) in the appropriate solvent 
(1.1 mL). bsyn and anti ratio was determined by 1H NMR spectroscopy of the crude products. 
cIsolated yields.  
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Having optimized the anti-diastereoselective vinylogous addition, further efforts 
were made to improve the yield of the syn product 168 with the reaction catalyzed 
by dicyclohexane-18-crown-6 (5) in toluene, at different temperatures. The best 
result was observed at -50°C (94/6 anti/syn, Table 3.6, entry 3) while different 
values afforded a little decrease in diastereoselectivity. Finally, using the best 
solvents (toluene and DCM) the [2,2,2]-cryptand, known for his very good 
complexation ability for the potassium,1 was used as catalyst (Table 3.7). In this 
case the behavior was very similar to TBAF, with a strong preference for the anti 
product both in toluene and DCM (anti/syn 98/2). 
 




Entry T(°C) Time(h) syn/antib Yieldc(%) 
1 0 20 89/11 44 
2 -20 2 91/9 79 
3 -50 4 94/6 96 
4 -78 22 93/7 83 
aAll reactions were carried out in liquid-liquid system at 0.218 mmol scale using 167 (1.0 eq.), 2-
trimethylsilyloxyfuran (1.2 eq.), KF (1.0 eq.) and catalyst 5 (10 mol%) in toluene (1.1 mL). bsyn/anti 
ratio was determined by 1H NMR spectroscopy of the crude products. cIsolated yields. 
 
 





Solvent T(°C) Time(h) syn/antib Yieldc(%) 
1 KF Toluene -78°C 40 2/98 82 
2 KF DCM -78°C 5 2/98 83 
aAll reactions were carried out in liquid-liquid system at 0.218 mmol scale using 167 (1.0 eq.), 
trimethylsilyloxyfuran (1.2 eq.), KF (1.0 eq.) and catalyst 7 (10 mol%) in the appropriate solvent (1.1 
mL). bsyn and anti ratio was determined by 1H NMR spectroscopy of the crude products. cIsolated 
yields. 
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In summary our premilinary results have shown that the vinylogous Mukayama-
Michael addition of 2-trimethylsilyloxyfuran to trans-chalcone is promoted by 
TBAF or KF in presence of crown ethers of different sizes. TBAF promoted the 
formation of anti diastereoisomer with high selectivity. On the other hand, in 
apolar solvent such as toluene, KF/18-crown-6 ethers favour the syn product, 
while in aprotic polar or halogentated solvents, KF/15-crown-5 ethers afford 
exclusively to the anti diastereoisomer. KF/crown system definitely proved to be a 
more efficient and flexible promoter than TBAF, ensuring better yield and anti-
diastereoselectivity, and giving the opportunity to switch the diastereoselectivity 
towards the syn diastereoisomer, by simply changing solvent or cavity size of 
macrocyclic catalyst (figure 3.7). The strenght of this work is represented by the 
possibility to control the diasteroselectivity. On the basis of these promising 
results we decided to investigate the reaction, in the optimized conditions, on 
different α,β-unsaturated carbonyl substrates. 
 
 
Figure 3.7 Switchable diastereoselectivity in the vinylogous Mukayama-Michael addition of 
2-trimethylsilyloxyfuran by changing reaction conditions  
 
 
3.7 Synthesis of α,β-unsaturated carbonyl compounds 
 
To extend the scope of conjugate addition of 2-trimethylsilyloxyfuran, different not 
commercially available α,β-unsaturated ketones were synthetized (compounds 
177a, 177e, 177g-l). For most of them the classical aldol condensation was used, 
as shown in Table 3.8, between aldehydes 175a-d and ketones 176a-d.117 The 
synthesis of trans-1-phenyl-2-octen-1-one (180) required a different strategy 
                                                          
117 E. P. Kohler, H. M. Chadwell, H. T. Clarke, R. P. Leavitt, Organic Syntheses, 1941, 1, 78. 
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(scheme 3.14) which was realized by a modified literature procedure.118 
 




Entry Aldehyde Ketone Time(h) Yieldb(%) Product 
1 
  
3 81 177a 
2 
  
3,5 75 177e 
3 
  
20 91 177g 
4 
  
5,5 57 177h 
5 
  
4 79 177i 
6 
  
4 50 177l 
aAll reactions were carried out at 4.2 mmol scale using the aldehydes 175 (1.0 eq.), ketones 176 (1.0 




Scheme 3.14 Synthesis of trans-1-phenyl-2-octen-1-one (180) 
                                                          
118 C. Ni, L. Zhang, J. Hu, J. Org. Chem., 2008, 73, 5699-5713. 
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3.8 Mukayama-Michael addition of 2-trimethylsilyloxyfuran to chalcones 
catalyzed by dicyclohexane-18-crown-6 
 
With the new substrates in our hands the investigation started with dicyclohexane-
18-crown-6 as catalyst, in toluene at -50°C. A correlation between the substition on 
the aromatic ring of the chalcones and the diastereoisomeric ratio (Table 3.9) was 
observed. 
The presence of electron-withdrawing groups on the aromatic ring generally 
favoured the conjugate addition (Table 3.9, entries 3, 4, 5, 10) while electron-
donating groups required longer reaction times (Table 3.9, entries 1, 2, 8, 9). As a 
consequence, moderate yields were obtained with electron-rich aromatic and 
heteroaromatic substrates 177b, 177g and 177i. Indeed, the presence of an 
electron-poor β-aromatic ring probably increase the electrophile nature of C-β. 
Similarly, electron-poor aromatic groups attached to carbonyl group accelerate the 
reaction by polarizing the C=C bond and stabilizing the developing negative charge 
on C-. As expected, the syn isomer, under those conditions, was the preferred 
product with all the chalcone derivatives, with syn/anti ranging from 80/20 to 
94/6 in most cases. A lower diastereoisomeric ratio was just observed with the 
NO2-substituted Michael acceptor 177c (73/27 syn/anti, entry 3). At any rate, at 
lower temperature, an even worse diastereoselectivity resulted. 
 
3.9 Mukayama-Michael addition of 2-trimethylsilyloxyfuran to chalcones 
catalyzed by benzo-15-crown-5 
The scope of conjugate addition was also studied using benzo-15-crown-5 as 
catalyst. The electron properties of substituents on the aromatic rings influenced 
the reaction rate, as well as before. In fact, longer reaction times were needed with 
electron-rich substrates (Table 3.10, entries 1-2 and 7-10). As expected, the anti 
isomer 182 could be obtained as a sole product with nearly all the substrates at -
78°C. A small amount of syn byproduct was only observed with heteroaromatic 
substrate 177g (anti/syn 97/3, entry 7). Under optimized conditions, yields were 
good with all the substrates. With methoxy-derivatives 177b and 177i, improved 
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yields were achieved by increasing the temperature up to -50°C, without affecting 
the anti-diastereoselectivity (Table 3.10, entries 2 and 10).  
Table 3.9 Syn-diastereoselective vinylogous Mukayama-Michael reaction of 2-
trimethylsilyloxyfuran with chalcones catalyzed by DCH-18-crown-6a  
 
Entry Substrate Time(h) syn/antib Yieldc(%) 
1 
 
85 92/8 72 
2 
 
110 85/15 50 
3 
 
20 73/27 90 
4 
 
20 87/13 81 
5 
 
65 80/20 75 
6 
 
20 88/12 80 
7d 
 
40 95/5 50 
8 
 
110 94/6 72 
9 
 
85 84/16 58 
10e 
 
20 89/11 99 
aAll reactions were carried out in liquid-liquid system at 0.218 mmol scale using 177 (1.0 eq.), 
trimethylsilyloxyfuran (1.2 eq.), KF (1.0 eq.) and catalyst 5 (10 mol%) in the appropriate solvent 
(1.1 mL). bsyn/anti ratio was determined by 1H NMR spectroscopy of the crude products. 
cIsolated yields. dReaction carried out at -78°C. eReaction carried out at -20°C. 
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Table 3.10 Anti-diastereoselective vinylogous Mukayama-Michael addition of 2-
trimethylsilyloxyfuran to chalcones catalyzed by benzo-15-crown-5a 
 
 
Entry Substrate Time(h) syn/antib Yieldc(%) 
1 
 
40 1/99 87 
2d 
 
110 <1/99 75 
3 
 
20 <1/99 99 
4 
 
20 <1/99 88 
5 
 
20 <1/99 74 
6 
 
20 <1/99 90 
7 
 
40 3/97 78 
8 
 
40  <1/99 87 
 
 
   
9d 40  <1/99 70 
10 
 
20 <1/99 90 
aAll reactions were carried out in liquid-liquid system at 0.218 mmol scale using 177 (1.0 eq.), 
trimethylsilyloxyfuran (1.2 eq.), KF (1.0 eq.) and catalyst 148 (10 mol%) in the appropriate 
solvent (1.1 mL) bsyn/anti ratio was determined by 1H NMR spectroscopy of the crude products. 
cIsolated yields. dReaction carried out at -50°C.  
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3.10 KF/crown ether promoted Mukayama-Michael addition of 2-
trimethylsilyloxyfuran to different ketones. 
In order to extend the scope of the methodology we decided to study the reaction 
with substrates different from chalcones. α,β-Unsaturated ketones 180, 183, 184, 
with aliphatic substituents were first examined (figure 3.8). 
 
Figure 3.8 Structures of aliphatic enones 
With compound 180 the reaction resulted slower in comparison with trans-
chalcones but here again, the anti diasteroisomer was favoured with 
dicyclohexane-18-crown-6 in toluene (Table 3.11, entries 1-2) and the syn product 
with the benzo-15-crown-5 in CH2Cl2 (Table 3.11, entries 3-5). The best results 
were obtained at -20°C both with KF/dicyclohexane-18-crown-6 in toluene 
(syn/anti 84/16, 42% yield, Table 3.11, entry 2) and with with KF/benzo-15-
crown-5 in CH2Cl2 (anti/syn 93/7, 62% yield, Table 3.11, entry 4). The latter 
catalyst, once again, has proved more efficient than TBAF (Table 3.11, entry 5). 
With substrate 183, the yields were generally lower than the trans-chalcones, too.  
 
Table 3.11 Vinylogous Mukayama-Michael reaction of 2-trimethylsilyloxyfuran with trans-
1-phenyl-2-octen-1-one catalyzed by crown ethersa  
 
Entry Catalyst Solvent T(°C) syn/antib Yieldc(%) 
1 5 Toluene -78 79/21 10 
2 5 Toluene -20 84/16 42 
3 168 DCM -78 43/57 23 
4 168 DCM -20 7/93 62 
5 TBAF DCM -20 25/75 60 
aAll reactions were carried out in liquid-liquid system at 0.218 mmol scale using 180 
(1.0 eq.), trimethylsilyloxyfuran (1.2 eq.), KF (1.0 eq.) and the appropiate catalyst 
(10 mol%) in the appropiate solvent (1.1 mL). bsyn/anti ratio was determined by 1H 
NMR spectroscopy of the crude products. cIsolated yields.  
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Entry Catalyst Solvent T(°C) syn/antib Yieldc(%) 
1 5 Toluene -78 93/7 17 
2 5 Toluene -30 96/4 46 
3 5 Toluene -20 95/5 60 
4 5 Toluene 0 94/6 56 
5 174 DCM -78 19/81 16 
6 174 DCM -30 8/92 20 
7 174 DCM -20 16/84 37 
8d 174 DCM -20 13/87 33 
9e 174 DCM -20 12/88 34 
10 174 DCM 0 21/79 35 
11 174 CHCl3 0 17/83 37 
12 174 Toluene -20 81/19 21 
13 5 DCM -20 34/66 43 
14 6 DCM -20 87/13 51 
15 6 CHCl3 -20 89/11 64 
16 TBAF DCM -20 26/74 30 
aAll reactions were carried out in liquid-liquid system at 0.218 mmol scale using 183 
(1.0 eq.), 2-trimethylsilyloxyfuran (1.2 eq.), KF (1.0 eq.) and the appropiate catalyst 
(10 mol%) in the appropiate solvent (1.1 mL). bsyn/anti ratio was determined by 1H 
NMR spectroscopy of the crude products. cIsolated yields. d3.0 eq. of KF were used. 
e2.0 eq. of 2-trimethylsilyloxyfuran were used. 
 
However moderate yields and good diastereoselectivities were achieved, after an 
extensive screening of temperature, catalyst and solvent (Table 3.12): the best 
results were observed with KF/dicyclohexane-18-crown-6 in toluene at -30°C 
(syn/anti 96/4, 46% yield, Table 3.12, entry 2) for the syn isomer, and with 
KF/benzo-15-crown-5 in CH2Cl2 at -20°C (anti/syn 88/12, 34% yield, Table 3.12, 
entry 9) for the anti isomer. A slightly higher anti-diastereoselectivity was 
obtained at -30°C but the yield was disappointing (anti/syn 92/8, 20% yield, Table 
3.12, entry 6). Finally, the aliphatic substrate (E)-3-octen-2-one 184 did not afford 
any product with different catalysts (Table 3.13, entries 1, 2, 3): this result 
demonstrates the crucial role of aromatic residues in the reactivity of the 
substrate. 
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Entry Catalyst Solvent T(°C) Tempo(h) syn/antib Yieldc(%) 
1 5 Toluene -78 17 - - 
2 175 DCM -78 17 - - 
3 175 DCM -30 44 - - 
aAll reactions were carried out in liquid-liquid system at 0.218 mmol scale using 175 (1.0 eq.), 
trimethylsilyloxyfuran (1.2 eq.), KF (1.0 eq.) and the appropiate catalyst (10 mol%) in the 
appropiate solvent (1.1 mL). bsyn and anti ratio was determined by 1H NMR spectroscopy of the 
crude products. cIsolated yields.  
 
As mentioned before, the presence of an electron-withdrawing group attached to 
the -carbon is expected to improve the reactivity of the Michael acceptor. With 
this in mind, we considered the ethyl ester of the β-benzoyl acrilic acid 194, as a 
possible candidate for our Mukaiyama-Michael addition. The synthesis of β-
benzoyl acrilic acid was performed, as reported in literature, by Friedel-Crafts 
acylation of benzene with maleic anhydride.119 Then, the esterification reaction 
with H2SO4 in presence of EtOH, led to 194 as reported in scheme 3.15. The 
substrate 194, was used in the Mukayama-Michael reactions, under the usual 
conditions previously described. The reaction carried out with KF/DCH-18-crown-
6, as expected, afforded preferentially the syn product with good yield, albeit with 
moderate diastereoselectivity (syn/anti 76/24, Table 3.14, entry 1). The reaction 
with benzo-15-crown-5 gave an high anti-diastereoselectivity with good yield 
(anti/syn 92/8, Table 3.14, entry 2). It should be noted that the syn and the anti 
products could be easily separated by column chromatography. 
                                                          
119 a) Organic Syntheses, Coll. Vol. 3, p.109 (1955); Vol. 29, p.11 (1949); b) B. J. Drakulić, T. 
P. Stanojković, Z. S. Žižak, M. M. Dabović, European Journal of Medicinal Chemistry, 2011, 46, 
3265-3273. 
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Scheme 3.15 Synthesis of ethyl 3-benzoylacrylate (192) 
 




Entry Catalyst Solvent T(°C) Time(h) syn/antib Yieldc(%) 
1 5 Toluene -50 17 76/24 83 
2 168 DCM -78 15 8/92 86 
aAll reactions were carried out in liquid-liquid system at 0.218 mmol scale using 194 (1.0 
eq.), trimethylsilyloxyfuran (1.2 eq.), KF (1.0 eq.) and the appropiate catalyst (10 mol%) in 
the appropiate solvent (1.1 mL). bsyn/anti ratio was determined by 1H NMR spectroscopy of 
the crude products. cIsolated yields.  
 
 
3.11 Mechanistic hypothesis of fluoride-promoted Mukayama-Michael 
addition of 2-trimethylsilyloxyfuran to α,β-unsaturated carbonyl compounds 
catalyzed by crown ethers 
Basing on the examples previously reported in literature,116a the fluoride 
promoted Mukayama-Michael addition of a silyl enol ether involves the formation 
of the corresponding enolate that after addition to the Michael acceptor, lead to an 
enolate adduct. The enolate adduct can desilylate the substrate and restart the 
catalytic cycle. From this point of view, the fluoride can be considered as an 
initiator. Analogously, in this case, a dienolate intermediate, generated by 
desilylation of 2-trimethylsilyloxyfuran can be supposed. The complexation of 
potassium cation with crown ethers, and formation of host-guest complex, with 
fluoride as counterion can be assumed. Then, through a phase-transfer process, the 
fuoride comes into contact with 2-trimethylsilyloxy furan, generating the ion pair 
dienolate/K+-crown ether (Scheme 3.16, step A). This nucleophilic species reacts 
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diasteroselectively with the α,β-unsaturated carbonyl compound (Scheme 3.16, 
step B). As a following step, the silylation of the product (Scheme 3.16, step C) with 
2-trimethylsilyloxyfuran regenerate the dienolate. In support of this scenario, the 
product was recovered as a mixture of adduct and the corresponding silyl enol 
ether. The latter was usually cleaved in the following acidic work-up procedure 
(see the experimental section). In order to confirm the hypothetical involvement of 
a dienolate intermediate, some experiments were carried out. The reactions was 
performed with 2-(5H)-furanone in place of the 2-trimethylsilyloxyfuran and using 
KOH as a base in place of KF. In agreement with the results reported with KF/2-
trimethylsilyloxyfuran, the conjugate addition with dicyclohexane-18-crown-6 led 
to the formation of the syn product (scheme 3.17) while the reaction with benzo-
15-crown-5 afforded the anti product (scheme 3.18). 
 
Scheme 3.16 Mechanicistic hypothesis of Mukayama-Michael addition of 2-
trimethylsilyloxyfuran catalyzed by crown ethers 
 
Despite lower yields and diasteroisomeric ratios were obtained in comparison 
with the previously described protocol with KF and 2-trimethylsilyloxyfuran, these 
results support the involvement of a common dienolate intermediate. The syn/anti 
diastereoselectivity obtained under the different reaction conditions, proved to be 
under kinetic control. Some experiment indeed demonstrated that syn and anti 
adducts did not interconvert in presence of KF, dicyclohexane-18-crown-6, and 2-
trimethylsilyloxyfuran. Diastereomerically enriched 169 (97/3 anti) was treated 
with KF and dicyclohexane-18-crown-6 in toluene for two days. After this time the 
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diastereoisomeric ratio was unchanged. The same experiment was also done in 
presence of 2-trimethylsilyloxyfuran with the same result. In a similar manner, 
diastereomerically enriched 168 (94/6 syn) was treated with benzo-15-crown-5 in 
CH2Cl2 for two days, in presence or not of 2-trimethylsilyloxyfuran. The 
diastereoisomeric ratio did not change in both cases. On the basis of these results a 
retro-Michael process should be ruled out.  
 
Scheme 3.17 Mukayama-Michael addition of trans-chalcone with 2-(5H)-furanone 
catalyzed by DCH-18-crown-6 
 
Scheme 3.18 Mukayama-Michael addition of trans-chalcone with 2-(5H)-furanone 





In conclusion we have developed the first example of vinylogous Mukayama-
Michael addition of 2-trimethylsilyloxyfuran, activated by potassium fluoride, 
catalyzed by crown ethers through a phase-transfer process. The system KF/crown 
ethers proved to be more efficient than TBAF with aromatic α,β-unsaturated 
ketones, affording -butenolides with good yields and high diastereoselectivity. 
The most intriguing aspect is the switchable anti/syn-diastereoselectivity 
controlled by the solvent polarity and the macrocycle catalyst’s cavity size. To the 
best of our knowledge this is the first example reported in literature where the 
diastereoselectivity can be tuned in such an easy way. KF/dicyclohexane-18-
crown-6 in toluene afforded syn products with good yields and good to high 
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diastereoselectivity, while anti products were obtained with good yields and 




Figure 3.9 General scheme of the developed methodology 
 
The figure 3.10 summarize the results obtained under these the two different 
reaction conditions. In general, for aromatic α,β-unsaturated ketones, the present 
methodology proved to be more efficient and flexible than the most 
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Figure 3.10 Best results obtained in Mukayama-Michael reaction of α,β-unsaturated 
carbonyl compounds with 2-trimethylsilyloxy furan, catalyzed by crown ethers 
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3.13 Experimental section 
 
3.13.1 Synthesis of chalcone derivatives 
The synthesis of compunds 177a, 177e, 177g, 177h, 177i, 177l were performed 
with a modified literature procedure.120 To a solution of sodium hydroxide (0.2 g, 
5.4 mmol) in water (2.5 mL) and ethanol (1.25 mL) ketone 176 (1.0 eq, 4.2 mmol) 
and aldehyde 175 (1.0 eq, 4.2 mmol) were added. The mixture was heated at 30°C 
for 4h. After that the stirring was removed and the mixture was left in an ice box 
for 12h. The white precipitate was filtered on a Büchner funnel, washed with water 
and cooled ethanol. Purification by silica gel chromatography (petroleum ether: 




Prepared with acetophenone and p-methyl-benzaldehyde. 
0.8 g, yield 81%, white solid; the spectroscopic data were in good agreement with 
the literature.121 
1H-NMR (400 MHz, CDCl3): δ = 8.02 (dd, J = 8.2, 1.4 Hz, 2H), 7.80 (d, J = 15.7 Hz, 




Prepared with acetophenone and p-bromo-benzaldehyde. 
0.9 g, yield 75%, yellow solid; the spectroscopic data were in good agreement with 
the literature.122 
                                                          
120 E. P. Kohler, H. M. Chadwell, H. T. Clarke, R. P. Leavitt, Organic Syntheses, 1941, 1, 78. 
121 G. Romanelli, G. Pasquale, A. Sathicq, H. Thomas, Journal of Molecular Catalysis A, 2011, 
24-32. 
122 . A. Stroba, F. Schaeffer, V. Hindie, L. Lopez-Garcia, I. Adrian, W. Fröhner, R. W. Hartmann, 
R. M. Biondi, M. Engel, J. Med. Chem. 2009, 52, 4683–4693. 
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1H-NMR (400 MHz, CDCl3): δ = 8.01 (dd, J = 8.2, 1.1, 2H), 7.74 (d, J = 15.7 Hz, 1H), 
7.62-7-50 (m, 8H).  
(E)-3-(Furan-2-yl)-1-phenylprop-2-en-1-one (177g) 
 
Prepared with acetophenone and furaldehyde. 
0.9 g, yield 91%, white solid; the spectroscopic data were in good agreement with 
the literature.112,123 
1H-NMR (400 MHz, CDCl3): δ = 8.03 (m, 2H), 7.54 (m, 6H), 6.73 (d, J = 3.4 Hz, 1H), 
6.52 (dd, J = 3.4, 1.8 Hz, 1H).  
(E)-3-Phenyl-1-(p-tolyl)prop-2-en-1-one (177h) 
 
Prepared with p-methyl-acetophenone and benzaldehyde. 
0.4 g, yield 50%, yellow solid; the spectroscopic data were in good agreement with 
the literature.124 
1H-NMR (400 MHz, CDCl3): δ = 7.94 (d, J = 8.0 Hz, 2H), 7.81 (d, J = 15.7 Hz, 1H), 7.65 
(m, 2H), 7.54 (d, J = 15.7 Hz, 1H), 7.42 (m, 3H), 7.31 (d, J = 8.0, 2H), 2.44 (s, 3H).  
(E)-1-(4-Methoxyphenyl)-3-phelylprop-2-en-1-one (177i) 
 
Prepared with p-methoxy-acetophenone and benzaldehyde. 
0.4 g, yield 57%, yellow solid; the spectroscopic data were in good agreement with 
the literature.124 
1H-NMR (300 MHz, CDCl3): δ = 8.05 (d, J = 8.7 Hz, 2H), 7.81 (d, J = 15.7 Hz, 1H), 7.65 
(m, 2H), 7.55 (d, J = 15.7 Hz, 1H), 7.42 (m, 3H), 6.99 (d, J = 8.7, 2H), 3.90 (s, 3H).  
                                                          
123 H. Lebel, M. Davi, Adv. Synth. Catal., 2008, 350, 2352-2358. 
124 X. F. Wu, H. Neumann, A. Spennenberg, T. Schulz, H. Jiao, M. Beller, J. Am. Chem. Soc., 
2010, 132, 14596-14602. 
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Prepared with p-chloro-acetophenone and benzaldehyde. 
0.6 g, yield 79%, white solid; the spectroscopic data were in good agreement with 
the literature.124 
1H-NMR (400 MHz, CDCl3): δ = 7.96 (d, J = 8.6 Hz, 2H), 7.82 (d, J = 15.7 Hz, 1H), 7.64 
(m, 2H), 7.49 (m, 3H), 7.43 (m, 3H). 
3.13.2 Synthesis of trans-1-Phenyl-2-octen-1-one (180) 
The synthesis of compound 180 was performed as previously described in 
literature.125 To a solution of diisopropylamine (1.7 mL, 12.5 mmol) in 42 mL of dry 
THF at -78°C n-butyllithium (2.5 M in hexanes, 5.0 mL, 12.5 mmol) was added and 
the mixture was stirred for 30 min. The acetophenone (0.97 mL, 8.3 mmol) was 
added. After 30 min the hexanal (2.2 mL, 18.3 mmol) was added. After 120 min, the 
reaction was quenched with a solution of HOAc/H2O (1:1 v/v) at -78°C. The flask 
was warmed to room temperature, and  water (42 mL) was added. The aqueous 
layer was extracted with Et2O (3 x 50 mL). The collected organic layers were 
washed with saturated solution of NaHCO3 (50 mL) and brine (50 mL), dried over 
Na2SO4 and concentrated in vacuo. Purification by silica gel chromatography 
(petroleum ether : Et2O 90:10 – 70:30) afforded the desidered hydroxyl keton 179 
(0.6 g, yield 60%). The aldol product was dissolved in 8.3 mL dry Et3N at 0°C and 
methansulfonyl chloride (0.11 mL, 1.46 mmol) was added. The reactiom was 
warmed to room temperature for 16h. Then water (6 mL) was added and the 
aqueous layer was extracted with Et2O (3 x 9 mL). The combined organic layers 
were washed with 1M HCl aqueous solution (13 mL) and a saturated solution of 
NaHCO3 (9 mL), dried over Na2SO4 and concentrated in vacuo. Purification by silica 
gel chromatography (petroleum ether : Et2O 95:5 – 90:10) afforded the desidered 
product 180. 
 
                                                          
125 R. Shintani, G. Fu, Organic Letters, 2002, 4, 3699-3702. 
3. Diasteroselective synthesis of γ-butenolides 
 




170 mg, yield 75%, colorless liquid; the spectroscopic data were in good 
agreement with the literature. 126 
1H-NMR (400 MHz, CDCl3): δ = 7.91 (d, J = 7.9 Hz, 2H), 7.50 (m, 3H), 7.06 (m, 1H), 
6.87 (dd, J = 15.4, 1,3 Hz, 1H), 2.30 (m, 2H), 1.52 (m, 2H), 1.33 (m, 4H), 0.90 (t, J = 
7.0 Hz, 3H). 
 
3.13.3 Synthesis of ethyl 3-Benzoylacrylate (194). 
The synthesis of compound 192 was performed as previously described in 
literature.107 To a stirred solution of maleic anhydride (3.0 g, 30 mmol) in 
anhydrous benzene (18 mL),  anhydrous AlCl3  (8.8 g, 66 mmol) was added in 
portions in 30 minutes.  The reaction mixture was warmed at reflux for 1 h, then 
cooled at 0°C and water (18 mL) was added. Concentrated HCl (5 mL) was added 
and the mixture was stirred for further 40 minutes, concentrated in vacuo. The 
residue was worked up with a solution of Na2CO3 until pH=8, warming at 40–50°C 
for 15 minutes, and washed with DCM (2 x 30mL). To the aqueous layer 
concentrated HCl was added dropwise until pH=2 and the resulting solid was 
filtered and crystallized from toluene. Finally the product was warmed at reflux in 
a solution of concentrated H2SO4 (8 µL) and EtOH (50µL). The mixture was treated 
with water (0.3 mL) and extracted with EtOH (2 x 1 mL). The collected organic 
layers were washed with saturated solution of NaHCO3 to pH=7 and then with 
water (2 mL), dried over Na2SO4 and concentrated in vacuo.  
 
Ethyl 3-benzoylacrylate (194)  
 
68.0 mg, yield 20%, colorless liquid. The spectroscopic data were in good 
agreement with the literature.  
                                                          
126 R. Shintani, G. Fu, Organic Letters, 2002, 4, 3699-3702. 
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1H-NMR (400 MHz, CDCl3): δ = 7.97 (m, 2H), 7.89 (d, J = 15.5 Hz, 1H), 7.60 (m, 1H), 
7.49 (m, 2H), 6.86 (d, J = 15.5 Hz, 1H), 4.28 (q, J = 7.1 Hz, 2H), 1.33 (t, J = 7.2 Hz, 
3H). 
 
3.13.4 General procedure for diasteroselective vinylogous Mukayama-
Michael addition with KF and 2-trimethylsilyloxyfuan catalyzed by crown 
ethers. 
 
To a stirred solution of α,β-unsaturated carbonyl compound (1.0 eq, 0.218 mmol), 
KF (1.0 eq, 0.218 mmol), and catalyst (0.1 eq, 0.0218 mmol) in the appropriate 
solvent (1.1 mL) under inert athmosphere, the 2-trimethylsilyloxyfuran (1.2 eq, 
0.262 mmol) was added after 15 min. The resulting reaction mixture was allowed 
to stir at the appropriate temperature for the required time. After complete 
conversion, estimate with TLC, the mixture was treated with 1M HCl aqueous 
solution (1 mL) and THF (3 mL). The resulting solution was stirred for 2h. The 
mixture was diluted with water (1.2 mL) and extracted with DCM (3 x 2 mL). The 
collected organic layers were washed with saturated solution of NaHCO3 (1.5 mL), 




61 mg, yield 96%, white solid : mp = 97-100 °C. 
1H-NMR (400 MHz, CDCl3): δ = 7.97 (m, 2H), 7.58 (m, 1H), 7.46 (m, 2H), 7.36 (m, 
1H), 7.30-7.16 (m, 5H), 5.85 (dd, J = 5.7, 1.9 Hz, 1H), 5.45 (m, 1H), 3.96 (m, 1H), 
3.80 (dd, J = 18.0, 8.2 Hz, 1H), 3.46 (dd, J = 18.0, 5.5 Hz, 1H). 13C-NMR (100 MHz, 
CDCl3): δ = 197.7, 172.8, 155.3, 137.1, 136.4, 133.4, 128.6, 128.5, 128.3, 127.9, 
127.5, 121.9, 84.3, 42.8, 40.0. HRMS (MALDI) [M + H]+ calcd for C19H17O3 293.1172, 
found 293.1172. HRMS (MALDI) [M + Na]+ calcd for C19H16NaO3 315.0992, found 
315.0991. 
 
3. Diasteroselective synthesis of γ-butenolides 
 




64.0 mg, yield 99%, white solid : mp = 83-85 °C. 
1H-NMR (400 MHz, CDCl3): δ = 7.87 (m, 2H), 7.53 (m, 1H), 7.42 (m, 2H), 7.36-7.20 
(m, 6H), 6.07 (dd, J = 5.7, 2.0 Hz, 1H), 5.25 (m, 1H), 3.69 (m, 1H), 3.56 (dd, J = 17.7, 
5.0 Hz, 1H), 3.48 (dd, J = 17.7, 8.1 Hz, 1H). 13C-NMR (100 MHz, CDCl3): δ = 197.2, 
172.6, 155.6, 139.5, 136.4, 133.2, 128.8, 128.5, 128.0, 127.8, 127.5, 121.8, 85.7, 




48.2 mg, yield 72%, white solid : mp = 129-131 °C. 
1H-NMR (400 MHz, CDCl3): δ = 7.98 (m, 2H), 7.58 (m, 1H), 7.47 (m, 2H), 7.35 (m, 
1H), 7.11-7.02 (m, 4H), 5.86 (m, 1H), 5.43 (m, 1H), 3.93 (m, 1H), 3.78 (dd, J = 18.0, 
8.3 Hz, 1H), 3.43 (dd, J = 18.0, 5.7 Hz, 1H), 2.28 (s, 3H). 13C-NMR (100 MHz, CDCl3): 
δ = 197.9, 172.9, 155.3, 137.3, 136.6, 134.1, 133.5, 129.3, 128.7, 128.2, 128.0, 





57.1 mg, yield 87%, white solid : mp = 95-98 °C. 
1H-NMR (400 MHz, CDCl3): δ = 7.88 (m, 2H), 7.54 (m, 1H), 7.43 (m, 2H), 7.28 (m, 
1H), 7.22 (d, J = 8.0 Hz, 2H), 7.13 (d, J = 8.0 Hz, 2H), 6.07 (dd, J = 5.8, 2.0 Hz, 1H), 
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5.24 (m, 1H), 3.64 (m, 1H), 3.57 (dd, J = 17.5, 4.8 Hz, 1H), 3.46 (dd, J = 17.5, 8.3 Hz, 
1H), 2.31 (s, 3H). 13C-NMR (100 MHz, CDCl3): δ = 197.4, 172.7, 155.6, 137.3, 136.6, 
136.5, 133.3, 129.6, 128.6, 127.9 (2C), 121.9, 85.9, 44.1, 40.2, 21.0. HRMS (MALDI) 




34.7 mg, yield 50%, yellow liquid. 
1H-NMR (400 MHz, CDCl3): δ = 7.97 (m, 2H), 7.58 (m, 1H), 7.47 (m, 2H), 7.34 (m, 
1H), 7.12 (d, J = 8.4 Hz, 2H), 6.79 (d, J = 8.4 Hz, 2H), 5.86 (m, 1H), 5.41 (m, 1H), 3.91 
(m, 1H) 3.82-3.69 (m, 4H), 3.42 (dd, J = 17.9 Hz, 5.5 Hz, 1H). 13C-NMR (100 MHz, 
CDCl3): δ = 197.9, 172.9, 158.9, 155.4, 136.6, 133.5, 129.1, 129.4, 128.7, 128.0, 
122.1, 113.9, 84.6, 55.2, 42.1, 40.4. HRMS (MALDI) [M + H]+ calcd for C20H19O4 




52.7 mg, yield 75%, yellow liquid. 
1H-NMR (400 MHz, CDCl3): δ = 7.87 (m, 2H), 7.53 (m, 1H), 7.41 (m, 2H), 7.31-7.17 
(m, 3H), 6.84 (d, J = 8.6 Hz, 2H), 6.06 (m, 1H), 5.22 (m, 1H), 3.76 (s, 3H), 3.62 (m, 
1H), 3.53 (dd, J = 17.5 Hz, 5.0 Hz, 1H), 3.43 (dd, J = 17.5, 8.3 Hz, 1H). 13C-NMR (100 
MHz, CDCl3): δ = 197.4, 172.7, 158.9, 155.6, 136.6, 133.3, 131.5, 129.1, 128.6, 127.9, 
121.9, 114.2, 86.0, 55.2, 43.7, 40.3. HRMS (MALDI) [M + H]+ calcd for C20H19O4 
323.1278, found 323.1277. 
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65.9 mg, yield 90%, colorless liquid. 
1H-NMR (400 MHz, CDCl3): δ = 8.14 (m, 2H), 7.97 (m, 2H), 7.61 (m, 1H), 7.49 (m, 
2H), 7.42-7.36 (m, 3H), 5.90 (m, 1H), 5.47 (m, 1H), 4.08 (m, 1H),  3.84 (dd, J = 18.3, 
7.7 Hz, 1H), 3.56 (dd, J = 18.3, 6.1 Hz, 1H). 13C-NMR (100 MHz, CDCl3): δ = 196.9, 
172.1, 154.4, 147.4, 144.7, 136.2, 133.9, 129.5, 128.8, 128.0, 123.8, 122.8, 83.6, 
42.9, 40.3. HRMS (MALDI) [M + H]+ calcd for C19H16NO5 338.1023, found 338.1017. 
(S*,S*)-5-(3-Oxo-3-phenyl-1-(4-nitrophenyl)propyl)furan-2(5H)-one (182c) 
 
73.8 mg, yield 99%, white solid : mp = 163-165 °C. 
1H-NMR (400 MHz, CDCl3): δ = 8.18 (d, J = 8.3 Hz, 2H), 7.87 (d, J = 7.9 Hz, 2H), 7.63-
7.52 (m, 3H), 7.44 (m, 2H), 7.34 (d, J = 5.6 Hz,  1H), 6.14 (m, 1H), 5.30 (m, 1H), 3.93 
(m, 1H),  3.56-3.38 (m, 2H). 13C-NMR (100 MHz, CDCl3): δ = 196.5, 172.1, 154.6, 
147.4, 147.3, 136.0, 133.7, 129.3, 128.7, 127.9, 124.0, 122.7, 84.7, 43.5, 38.8. HRMS 
(MALDI) [M + H]+ calcd for C19H16NO5 338.1023, found 338.1024. 
(R*,S*)-5-(3-Oxo-3-phenyl-1-(4-fluorophenyl)propyl)furan-2(5H)-one (181d) 
 
54.8 mg, yield 81%, white solid : mp = 106-109 °C. 
1H-NMR (400 MHz, CDCl3): δ = 7.96 (m, 2H), 7.57 (m, 1H), 7.46 (m, 2H), 7.34 (m, 
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1H), 7.17 (m, 2H), 6.94 (m, 2H), 5.86 (m, 1H), 5.41 (m, 1H), 3.95 (m, 1H), 3.77 (dd, J 
= 18.1, 8.0 Hz, 1H), 3.45 (dd, J = 18.1, 5.0 Hz, 1H). 13C-NMR (100 MHz, CDCl3): δ = 
197.5, 172.6, 162.0 (d, J = 246 Hz), 155.1, 136.4, 133.5, 132.8, 129.9 (d, J = 8 Hz), 
128.7, 127.9, 122.2, 115.4 (d, J = 21 Hz), 84.2, 42.1, 40.4. HRMS (MALDI) [M + H]+ 
calcd for C19H16FO3 311.1078, found 311.1073. 
(S*,S*)-5-(3-Oxo-3-phenyl-1-(4-fluorophenyl)propyl)furan-2(5H)-one (182d) 
 
58.8 mg, yield 88%, white solid : mp = 102-105 °C. 
1H-NMR (CDCl3, 400 MHz): δ = 7.86 (m, 2H), 7.54 (m, 1H), 7.42 (m, 2H), 7.36-7.25 
(m, 3H), 7.0 (m, 2H), 6.08 (dd, J = 5.7, 1.9 Hz, 1H), 5.23 (m, 1H), 3.71 (m, 1H), 3.51 
(dd, J = 17.8, 5.0 Hz, 1H), 3.42 (dd, J = 17.8, 8.0 Hz, 1H). 13C-NMR (100 MHz, CDCl3): 
δ = 197.1, 172.4, 161.9 (d, J = 246 Hz), 155.2, 136.3, 135.3 (d, J = 2 Hz), 133.4, 129.7 
(d, J = 8 Hz), 128.6, 127.8, 122.1, 115.7 (d, J = 21 Hz), 85.5, 43.3, 39.8. HRMS 
(MALDI) [M + H]+ calcd for C19H16FO3 311.1078, found 311.1079.  
(R*,S*)-5-(3-Oxo-3-phenyl-1-(4-bromophenyl)propyl)furan-2(5H)-one(181e) 
 
61.0 mg, yield 75%, colorless liquid. 
1H-NMR (400 MHz, CDCl3): δ = 7.95 (m, 2H), 7.58 (m, 1H), 7.46 (m, 2H), 7.38 (m, 
2H), 7.34 (m, 1H), 7.08 (d, J = 8.3 Hz, 2H), 5.87 (m, 1H), 5.41 (m, 1H), 3.92 (m, 1H), 
3.76 (dd, J = 18.0, 8.1 Hz, 1H), 3.45 (dd, J = 18.0, 5.8 Hz, 1H). 13C-NMR (100 MHz, 
CDCl3): δ = 197.4, 172.6, 155.0, 136.4, 136.2, 133.6, 131.7, 130.1, 128.7, 128.0, 
122.4, 121.6, 84.0, 42.4, 40.2. HRMS (MALDI) [M + Na]+ calcd for C19H15BrNaO3 
393.0098, found 393.0096. 
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60.1 mg, yield 74%, white solid : mp = 138-141 °C. 
1H-NMR (400 MHz, CDCl3): δ = 7.87 (m, 2H), 7.56 (m, 1H), 7.49-7.36 (m, 4H), 7.32-
7.18 (m, 3H), 6.10 (dd, J = 5.8, 2.0 Hz, 1H), 5.24 (m, 1H), 3.70 (m, 1H), 3.51 (dd, J = 
17.8, 5.1 Hz, 1H), 3.41 (dd, J = 17.7, 8.2 Hz, 1H). 13C-NMR (100 MHz, CDCl3): δ = 
197.0, 172.4, 155.1, 138.7, 136.3, 133.5, 132.0, 129.9, 128.7, 127.9, 122.3, 121.6, 




57.3 mg, yield 80%, white solid : mp = 115-118 °C. 
1H-NMR (400 MHz, CDCl3): δ = 7.97 (m, 2H), 7.59 (m, 1H), 7.48 (m, 2H), 7.34 (m, 
1H), 7.24 (m, 2H), 7.15 (m, 2H), 5.88 (dd, J = 5.7, 1.9 Hz, 1H), 5.43 (m, 1H), 3.94 (m, 
1H), 3.78 (dd, J = 18.0, 8.0 Hz, 1H), 3.46 (dd, J = 18.0, 5.7 Hz, 1H). 13C-NMR (100 
MHz, CDCl3): δ = 197.5, 172.6, 154.9, 136.4, 135.6, 133.6, 133.5, 129.7, 128.8, 128.7, 
128.0, 122.4, 84.1, 42.3, 40.3. HRMS (MALDI) [M + H]+ calcd for C19H16ClO3 
327.0783, found 327.0783. 
(S*,S*)-5-(3-Oxo-3-phenyl-1-(4-chlorophenyl)propyl)furan-2(5H)-one (182f) 
 
64.2 mg, yield 90%, white solid : mp = 111-113 °C. 
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1H-NMR (400 MHz, CDCl3): δ = 7.86 (m, 2H), 7.54 (m, 1H), 7.42 (m, 2H), 7.34-7.24 
(m, 5H), 6.08 (dd, J = 5.6, 1.5 Hz, 1H), 5.23 (d, J = 6.7 Hz, 1H), 3.71 (m, 1H), 3.51 (dd, 
J = 17.8, 5.0 Hz, 1H), 3.42 (dd, J = 17.8, 8.2 Hz, 1H). 13C-NMR (100 MHz, CDCl3): δ = 
197.0, 172.4, 155.2, 138.2, 136.3, 133.5, 133.4, 129.5, 129.0, 128.7, 127.9, 122.2, 




30.5 mg, yield 50%, yellow solid : mp = 91-93 °C. 
1H-NMR (400 MHz, CDCl3): δ = 7.96 (m, 2H), 7.58 (m, 1H), 7.51-7.40 (m, 4H), 6.25 
(m, 1H), 6.15 (d, J = 3,0 Hz, 1H), 5.99 (dd, J = 5.7, 1.9 Hz, 1H), 5.38 (m, 1H), 4.16 (m, 
1H), 3.57 (dd, J = 18.0, 7.3 Hz, 1H), 3.41 (dd, J = 18.0, 6.6 Hz, 1H). 13C-NMR (100 
MHz, CDCl3): δ = 197.1, 172.6, 154.8, 151.3, 141.8, 136.3, 133.5, 128.7, 128.0, 122.1, 
110.4, 107.8, 83.3, 38.0, 36.8. HRMS (MALDI) [M + Na]+ calcd for C17H14NaO4 
305.0784, found 305.0784. 
(S*,S*)-5-(3-Oxo-3-phenyl-1-(2-furanyl)propyl)furan-2(5H)-one (182g) 
 
47.9 mg, yield 78%, yellow solid : mp = 80-83 °C. 
1H-NMR (400 MHz, CDCl3): δ = 7.92 (m, 2H), 7.56 (m, 1H), 7.44 (m, 2H), 7.40 (m, 
1H), 7.32 (m, 1H), 6.29 (m, 1H), 6.21 (d, J = 3.3 Hz, 1H), 6.07 (dd, J = 5.7, 1.9 Hz, 1H), 
5.34 (m, 1H), 3.88 (m, 1H), 3.54 (dd, J = 17.7, 7.8 Hz, 1H,), 3.44 (dd, J = 17.7, 5.4 Hz, 
1H). 13C-NMR (100 MHz, CDCl3): δ = 196.9, 172.4, 155.1, 152.2, 142.0, 136.4, 133.4, 
128.7, 128.0, 122.0, 110.5, 107.6, 83.7, 38.0, 37.8. HRMS (MALDI) [M + H]+ calcd for 
C17H15NaO4 283.0965, found 283.0965. 
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48.2 mg, yield 72%, white solid : mp = 110-113 °C. 
1H-NMR (400 MHz, CDCl3): δ = 7.88 (d, J = 8.2 Hz, 2H), 7.36 (m, 1H), 7.30-7.13 (m, 
7H), 5.85 (dd, J = 5.7, 2.0, 1H), 5.45 (m, 1H), 3.96 (m, 1H), 3.79 (dd, J = 18.0, 8.4 Hz, 
1H), 3.43 (dd, J = 18.0, 5.5 Hz, 1H), 2.41 (s, 3H). 13C-NMR (100 MHz, CDCl3): δ = 
197.4, 172.9, 155.3, 144.4, 137.3, 134.1, 129.4, 128.6, 128.4, 128.2, 127.6, 122.0, 




57.1 mg, yield 87%, white solid : mp = 104-106 °C. 
1H-NMR (400 MHz, CDCl3): δ = 7.78 (d, J = 8.1 Hz, 2H), 7.38-7.11 (m, 8 H), 6.06 (m, 
1H), 5.26 (d, J = 7.1 Hz, 1H), 3.71 (m, 1H), 3.53 (dd, J = 17.6, 5.1 Hz, 1H), 3.43 (dd, J 
= 17.6, 8.0 Hz, 1H), 2.39 (s, 3H). 13C-NMR (100 MHz, CDCl3): δ = 196.9, 172.7, 155.6, 
144.2, 139.7, 134.1, 129.3, 128.9, 128.1, 128.0, 127.6, 121.9, 85.8, 44.3, 39.8, 21.6. 
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41.0 mg, yield 58%, white solid : mp = 149-152 °C. 
1H-NMR (400 MHz, CDCl3): δ = 7.97 (m, 2H), 7.35 (m, 1H), 7.27-7.17 (m, 5H), 6.94 
(m, 2H), 5.84 (dd, J = 5.7, 2.0 Hz, 1H), 5.45 (m, 1H), 3.95 (m, 1H), 3.87 (s, 3H), 3.77 
(dd, J = 17.7, 8.5 Hz, 1H), 3.39 (dd, J = 17.7, 5.3 Hz, 1H). 13C-NMR (100 MHz, CDCl3): 
δ = 196.3, 172.9, 163.8, 155.3, 137.3, 130.4, 129.7, 128.6, 128.4, 127.5, 122.0, 





49.0 mg, yield 70%, white solid : mp = 139-141 °C. 
1H-NMR (400 MHz, CDCl3): δ = 7.86 (d, J = 8,6 Hz, 2H), 7.37-7.20 (m, 6H), 6.89 (d, J 
= 8.6 Hz, 2H), 6.05 (m, 1H), 5.26 (d, J = 6.8 Hz, 2H), 3.84 (s, 3H) 3.70 (m, 1H), 3.50 
(dd, J = 17.4, 5.1 Hz, 1H), 3.40 (dd, J = 17.4, 8.0 Hz, 1H). 13C-NMR (100 MHz, CDCl3): 
δ = 195.7, 172.7, 163.6, 155.6, 139.8, 130.2, 129.7, 128.8, 128.1, 127.6, 121.9, 




71.0 mg, yield 99%, white solid : mp = 100-102 °C. 
1H-NMR (400 MHz, CDCl3): δ = 7.91 (m, 2H), 7.44 (m, 2H), 7.34 (m, 1H), 7.30-7.15 
(m, 5H), 5.85 (dd, J = 5.7, 1.9 Hz, 1H), 5.44 (m, 1H), 3.95 (m, 1H), 3.76 (dd, J = 18.0, 
8.3 Hz, 1H), 3.43 (dd, J = 18.0, 5.6 Hz, 1H). 13C-NMR (100 MHz, CDCl3): δ = 196.6, 
172.7, 155.1, 140.0, 137.0, 134.8, 129.4, 129.0, 128.6, 128.3, 127.7, 122.1, 84.2, 
42.9, 40.1. HRMS (MALDI) [M + Na]+ calcd for C19H15ClNaO3 349.0602, found 
349.0602. 
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63.6 mg, yield 90%, white solid : mp = 102-105 °C. 
1H-NMR (400 MHz, CDCl3): δ = 7.80 (m, 2H), 7.44-7.18 (m, 8H), 6.07 (m, 1H), 5.24 
(m, 1H), 3.64 (m, 1H), 3.53 (dd, J = 17.6, 4.8 Hz, 1H), 3.44 (dd, J = 17.6, 8.3 Hz, 1H). 
13C-NMR (100 MHz, CDCl3): δ = 196.1, 172.6, 155.5, 139.7, 139.4, 134.9, 129.4, 
128.9 (x 2), 128.0, 127.7, 122.0, 85.7, 44.5, 40.2. HRMS (ESI) [M + Na]+ calcd for 
C19H15ClNaO3 349.0602, found 349.0603. 
(R*,S*)-5-(3-Oxo-1-phenylhexyl)furan-2(5H)-one (185) 
 
26.2 mg, yield 42%, yellow liquid. 
1H-NMR (400 MHz, CDCl3): δ = 7.96 (m, 2H), 7.58 (m, 1H), 7.52-7.39 (m, 3H),  6.15 
(m, 1H), 5.25 (m, 1H), 3.24 (dd, J = 17.7, 7.9 Hz, 1H), 2.96 (dd, J = 17.7, 5.1 Hz, 1H), 
2.65 (m, 1H), 1.42-1.11 (m, 8H), 0.85 (m, 3H). 13C-NMR (100 MHz, CDCl3): δ = 
199.0, 173.1, 155.4, 136.7, 133.4, 128.7, 128.0, 122.2, 85.2, 39.1, 36.3, 31.7, 28.0, 




38.9 mg, yield 62%, white solid : mp = 56-59 °C. 
1H-NMR (400 MHz, CDCl3): δ = 7.89 (m, 2H), 7.55 (m, 1H), 7.50-7.37 (m, 3H), 6.01 
(dd, J = 5.7, 1.6 Hz, 1H), 5.23 (m, 1H), 2.93-2.77 (m, 2H), 2.70 (m, 1H), 1.70-1.19 (m, 
8H), 0.87 (m, 3H). 13C-NMR (100 MHz, CDCl3): δ = 198.7, 173.1, 156.2, 136.6, 133.3, 
128.7, 127.9, 121.6, 84.8, 36.8, 36.2, 32.1, 31.7, 26.8, 22.5, 14.0. HRMS (MALDI) [M 
+ H]+ calcd for C18H23O3 287.1642, found 287.1642. 
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84.5 mg, yield 46%, colorless liquid. 
1H-NMR (400 MHz, CDCl3): δ = 7.36-7.18 (m, 4H), 7.12 (m, 2H), 5.84 (m, 1H), 5.34 
(m, 1H), 3.74 (m, 1H), 3.24 (dd, J = 18.2, 8.3 Hz, 1H), 2.92 (dd, J = 18.2, 5.8 Hz, 1H), 
2.17 (s, 3H). 13C-NMR (100 MHz, CDCl3): δ = 206.5, 172.8, 155.1, 137.0, 128.6, 
128.2, 127.6, 122.0, 84.1, 44.7, 42.5, 30.5. HRMS (ESI) [M + Na]+ calcd for 
C14H14NaO3 253.0835, found 253.0834.  
(S*,S*)-5-(3-Oxo-1-phenylbutyl)furan-2(5H)-one (188) 
 
18.8 mg, yield 37%, white solid : mp = 77-78 °C. 
1H-NMR (400 MHz, CDCl3): δ = 7.37-7.33 (m, 2H), 7.31-7.25 (m, 3H), 7.22 (m, 1H), 
6.10 (m, 1H), 5.15 (m, 1H) 3.45 (m, 1H), 3.04 (dd, J = 17.6, 5.2 Hz, 1H), 2.91 (dd, J = 
17.5, 8.2 Hz, 1H), 2.07 (s, 3H). 13C-NMR (100 MHz, CDCl3): δ = 205.9, 172.7, 155.5, 
139.3, 129.0, 128.0, 127.8, 121.9, 85.7, 45.0, 44.2, 30.6 ppm. HRMS (MALDI) [M + 
Na]+ calcd for C14H14NaO3 253.0835, found 253.0835. 
 
 (R*,S*)-5-(3-Oxo-3-ethylbutanoate-1-phenyl)furan-2(5H)-one (195)  
 
52.0 mg, yield 83%, colorless liquid. 
1H-NMR (400 MHz, CDCl3): δ = 7.92 (m, 2H), 7.61-7.54 (m, 2H), 7.46 (m, 2H), 6.14 
(dd, J = 5.8, 2.0 Hz, 1H), 5.44 (m, 1H), 4.17 (q, J = 7.1 Hz, 2H), 3.67 (m, 1H), 3.44 (dd, 
J = 18.2 Hz, 7.7 Hz, 1H), 3.21 (dd, J = 18.2, 5.1 Hz, 1H), 1.22 (t, J = 7.1 Hz, 3H,).13C-
NMR (100 MHz, CDCl3): δ =197.0, 172.1, 170.2, 154.7, 136.0, 133.6, 128.7, 128.0, 
122.0, 81.6, 61.5, 42.9, 35.2, 14.1. HRMS (MALDI) [M + H]+ calcd for C16H17O5 
289.1070, found 289.1070. 
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1H-13C HMBC NMR of compound 195 (400 MHz, CDCl3) 
 
 
(S*,S*)-5-(3-Oxo-3-ethylbutanoate-1-phenyl)furan-2(5H)-one (196)  
 
27.1 mg, yield 86%, colorless liquid. 
1H-NMR (400 MHz, CDCl3): δ =7.94 (m, 2H), 7.62-7.54 (m, 2H), 7.46 (m, 2H), 6.13 
(m, 1H), 5.57 (m, 1H), 4.22 (q, J = 7.1 Hz, 2H), 3.63 (dd, J = 18.2 Hz, 6.8 Hz 1H), 3.41 
(m, 1H), 3.10 (dd, J = 18.1, 4.9 Hz, 1H), 1.26 (t, J = 7.1 Hz, 3H). 13C-NMR (100 MHz, 
CDCl3): δ = 197.1, 172.1, 170.6, 155.1, 136.0, 133.6, 128.7, 128.0, 122.2, 81.9, 61.7, 
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